



POLYVALENT IMMUNOGLOBULINS – PART 1: A RAPID REVIEW

SUPPLEMENT 1: SEARCH STRATEGY



POLYVALENT IMMUNOGLOBULINS – PART 1: A RAPID REVIEW

SUPPLEMENT 1: SEARCH STRATEGY

JOLYCE BOURGEOIS, NICOLAS FAIRON, LORENA SAN MIGUEL



COLOPHON

Title:	Polyvalent immunoglobulins – Part 1: a rapid review – Supplement 1
Authors:	Jolyce Bourgeois (KCE), Nicolas Fairon (KCE), Lorena San Miguel (KCE)
Information specialist:	Nicolas Fairon (KCE)
Project facilitator:	Els Van Bruystegem (KCE)
Senior supervisor:	Leen Verleye (KCE)
Reviewers:	Dominique Roberfroid (KCE), Charline Maertens (KCE)
External experts:	Marc Van De Castele (RIZIV – INAMI - Rijksinstituut voor ziekte- en invaliditeitsverzekering – Institut national d'assurance maladie-invalidité), Martine De Witte (RIZIV-INAMI), Joël Daems, (RIZIV – INAMI), Laure Geslin ((FAGG – AFMPS – Federaal agentschap voor geneesmiddelen en gezondheidsproducten – Agence fédérale des medicaments et des produits de santé), Margaretha Haelterman (FOD Volksgezondheid – SPF Santé Publique), Marlène Jagut (Sciensano), Nicolas Mavroudakis (ULB – Université libre de Bruxelles, Hôpital Erasme), Rik Schrijvers (UZ Leuven), Peter Van den Bergh (Cliniques universitaires Saint-Luc, Bruxelles), Jeroen Van der Hilst (Jessa ziekenhuis, U Hasselt)
International experts:	Jo Cameron (Immunoglobulin Governance National Blood Authority, Australia), Gaelle Guyader (National Agency for the Safety of Medicines and Health Products, France), Brian O'Rourke (CADTH – Canadian Agency for Drugs and Technologies in Health), Brent Fraser (CADTH – Canadian Agency for Drugs and Technologies in Health), Sylvain Grenier (Plasma Protein Products Formulary Program with the Canadian Blood Services), Rob Coster (National Programme of Care Manager-Blood and Infection, NHS England)
External validators:	Michel Delforge (Hematology, Universitair ziekenhuis Leuven), Sara Khangura (CADTH – Canadian Agency for Drugs and Technologies in Health), Wim Penninckx (FAGG – AFMPS – Federaal agentschap voor geneesmiddelen en gezondheidsproducten – Agence fédérale des medicaments et des produits de santé)
Acknowledgements:	We would like to thank Luc Hourlay (KCE), Irina Cleemput (KCE) and Jutte van der Werff (UZ Brussel, ZNA Paola kinderziekenhuis) for their input in this study.
Reported interests:	'All experts and stakeholders consulted within this report were selected because of their involvement in the topic of Immunoglobulines. Therefore, by definition, each of them might have a certain degree of conflict of interest to the main topic of this report'
	Participation in scientific or experimental research as an initiator, principal investigator or researcher: Michel Delforge (Comparative study administration IV Immunoglobulins)



Payments to speak, training remuneration, subsidised travel or payment for participation at a conference: Rik Schrijvers (Travel support CSL Behring CIS meeting 2019)

Layout:

Ine Verhulst

Disclaimer:

- The external experts were consulted about a (preliminary) version of the scientific report. Their comments were discussed during meetings. They did not co-author the scientific report and did not necessarily agree with its content.
- Subsequently, a (final) version was submitted to the validators. The validation of the report results from a consensus or a voting process between the validators. The validators did not co-author the scientific report and did not necessarily all three agree with its content.
- Finally, this report has been approved by a majority of votes by the Executive Board.
- Only the KCE is responsible for errors or omissions that could persist. The policy recommendations are also under the full responsibility of the KCE.

Publication date:

13 February 2020

Domain:

Health Technology Assessment (HTA)

MeSH:

Immunoglobulins, Intravenous, Immune System Diseases, Technology Assessment, Biomedical

NLM Classification:

QW 601

Language:

English

Format:

Adobe® PDF™ (A4)

Legal depot:

D/2019/10.273/83

ISSN:

2466-6459

Copyright:

KCE reports are published under a "by/nc/nd" Creative Commons Licence
<http://kce.fgov.be/content/about-copyrights-for-kce-publications>.





How to refer to this document?

Bourgeois J, Fairon F, San Miguel L. Polyvalent immunoglobulins – Part 1: a rapid review. Supplement 1. Health Technology Assessment (HTA) Brussels: Belgian Health Care Knowledge Centre (KCE). 2019. KCE Reports 327S1. D/2019/10.273/83.

This document is available on the website of the Belgian Health Care Knowledge Centre.



■ APPENDIX REPORT

TABLE OF CONTENTS

1	SEARCH STRATEGY	3
1.1	MEDLINE, EMBASE AND COCHRANE FOR SYSTEMATIC REVIEWS.....	3
1.1.1	Cochrane	3
1.1.2	Embase	5
1.1.3	MEDLINE	7
1.2	DARE-CRD DATABASE FOR SYSTEMATIC REVIEWS.....	12
1.3	MEDLINE, EMBASE AND COCHRANE SEARCH PER INDICATION.....	13
1.3.1	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)	13
1.3.2	Dermatomyositis and Polymyositis	24
1.3.3	Fetomaternal thrombocytopenia (FMAIT)	40
1.3.4	Guillain-Barre	47
1.3.5	Idiopathic thrombocytopenic purpura	58
1.3.6	Kawasaki disease	66
1.3.7	Multifocal Motor Neuropathy	75
1.3.8	Myasthenia Gravis	83
1.3.9	Pemphigus (Immunobullous disease).....	90
1.3.10	Post transfusion purpura	98
1.3.11	Primary Immunodeficiency.....	108
1.3.12	Pure red cell aplasia (Erythroblastopenia)	124
1.3.13	Secondary Immunodeficiency	131
1.3.14	Solid Organ Transplantation	147



1.3.15	Streptococcal toxic shock syndrome.....	155
1.4	ONGOING STUDIES.....	166
1.5	ECONOMIC SEARCHES	167
1.5.1	MEDLINE	167
1.5.2	EconLit (via Ovid).....	170
1.5.3	CRD Databases – NHS EED; NHS HTA	170
2	PRISMA'S PER INDICATION	171
3	EXCLUSION LIST.....	186
3.1	EXCLUSION LIST OF SYSTEMATIC REVIEW WITH REASONS FOR EXCLUSION	186
3.2	EXCLUSION LIST OF PRIMARY STUDIES (RCTS) WITH REASONS FOR EXCLUSION	191



1 SEARCH STRATEGY

1.1 Medline, Embase and Cochrane for Systematic Reviews

1.1.1 Cochrane

Date	13/11/2018 11:47:59	
Database	Cochrane@Wiley.com	
Search strategy		
#1	[mh ^"immunoglobulins, intravenous"]	738
#2	IVIG:ti	223
#3	scig:ti	9
#4	intraglobin*:ti	1
#5	(intravenous AND antibod*):ti	91
#6	(intravenous AND immunoglob*):ti	736
#7	(subcutaneous AND antibod*):ti	73
#8	(subcutaneous AND immunoglob*):ti	54
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	1386
#10	[mh "Immunoglobulins"]	21277
#11	[mh "Administration, Intravenous"]	17581
#12	[mh "Injections, Subcutaneous"]	4138
#13	#11 OR #12	21234
#14	#10 AND #13	1406
#15	intravenous:ti	15709
#16	subcutaneous:ti	3780
#17	intradermal:ti	646
#18	iv:ti	4985
#19	inject*:ti	14766
#20	perfus*:ti	2699



#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	40541
#22	#10 AND #21	1480
#23	immunoglob*:ti	1716
#24	immune glob*:ti	382
#25	Ig:ti	1655
#26	#23 OR #24 or #25	3649
#27	#21 AND #26	981
#28	#13 AND #26	151
#29	alphaglobin:ti	0
#30	endobulin:ti	0
#31	flebogamma:ti	2
#32	gamimmune:ti	0
#33	gammagard:ti	9
#34	gammonativ:ti	0
#35	gamunex:ti	6
#36	"globulin n":ti	0
#37	iveegam:ti	0
#38	privigen:ti	0
#39	sandoglobulin:ti	6
#40	venimmune:ti	0
#41	venoglobulin:ti	3
#42	HyQvia:ti	3
#43	Octagam:ti	9
#44	Hizentra:ti	1
#45	Gamunex-C:ti	1
#46	Gammaked:ti	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	37



#48	#9 OR #14 OR #22 OR #27 OR #28 OR #47	3327
#49	#48 with Cochrane Library publication date Between Jan 2008 and Jan 2018	1492

Comments**1.1.2 Embase**

Date	6 Nov 2018	
Database	Embase.com	
Search strategy		
#1	intravenous:ti AND immunoglob*:ti	6317
#2	subcutaneous:ti AND immunoglob*:ti	570
#3	intravenous:ti AND antibod*:ti	822
#4	subcutaneous:ti AND antibod*:ti	326
#5	ivig:ti	1644
#6	scig:ti	98
#7	intraglobin*:ti	7
#8	'subcutaneous immunotherapy'/exp	1491
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	10229
#10	'immunoglobulin'/exp	468248
#11	'intravenous drug administration'/exp	376623
#12	'subcutaneous drug administration'/exp	97686
#13	#11 OR #12	457719
#14	#10 AND #13	12040
#15	intravenous:ti	80753
#16	subcutaneous:ti	30749
#17	intradermal:ti	4097
#18	iv:ti	59130
#19	inject*:ti	122410
#20	perfus*:ti	70516



#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	356203
#22	#10 AND #21	11557
#23	immunoglob*:ti	52732
#24	immune AND (globu*:ti OR globi*:ti)	3079
#25	ig:ti	4034
#26	#23 OR #24 OR #25	59482
#27	#21 AND #26	8018
#28	#13 AND #26	3215
#29	alphaglobin:ti	2
#30	endobulin:ti	2
#31	flebogamma:ti	18
#32	gamimmune:ti	0
#33	gammagard:ti	19
#34	gammonativ:ti	1
#35	gamunex:ti	8
#36	'globulin n':ti	4
#37	iveegam:ti	0
#38	privigen:ti	38
#39	sandoglobulin:ti	15
#40	venimmune:ti	0
#41	venoglobulin:ti	4
#42	hyqvia:ti	16
#43	octagam:ti	27
#44	hizentra:ti	50
#45	'gamunex c':ti	2
#46	gammaked:ti	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	200



#48	#9 OR #14 OR #22 OR #27 OR #28 OR #47	24282
#49	#48 AND ('meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review')	420
#50	#49 NOT [medline]/lim	144
#51	#50 AND [2008-2019]/py	125

Comments**1.1.3 MEDLINE**

Date	November 05, 2018
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to November 05, 2018>
Search strategy	
1	Immunoglobulins, intravenous/ 12050
2	IVIG.ti,kf. 1093
3	scig.ti,kf. 44
4	intraglobin*.ti,kf. 3
5	(intravenous and antibod*).ti,kf. 784
6	(intravenous and immunoglob*).ti,kf. 5152
7	(subcutaneous and antibod*).ti,kf. 322
8	(subcutaneous and immunoglob*).ti,kf. 305
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 14385
10	exp Immunoglobulins/ 841713
11	exp Administration, Intravenous/ 137745
12	exp Injections, Subcutaneous/ 38776
13	11 or 12 172280
14	10 and 13 11338
15	intravenous.ti,kf. 67354
16	subcutaneous.ti,kf. 25227



17	intradermal.ti,kf.	3833
18	iv.ti,kf.	53370
19	inject*.ti,kf.	107449
20	perfus*.ti,kf.	58058
21	15 or 16 or 17 or 18 or 19 or 20	303253
22	10 and 21	14991
23	immunoglob*.ti,kf.	48369
24	immune glob*.ti,kf.	1516
25	Ig.ti,kf.	3632
26	23 or 24 or 25	53089
27	21 and 26	6340
28	13 and 26	1172
29	alphaglobin.ti,kf.	1
30	endobulin.ti,kf.	2
31	flebogamma.ti,kf.	12
32	gamimmune.ti,kf.	0
33	gammagard.ti,kf.	12
34	gammonativ.ti,kf.	0
35	gamunex.ti,kf.	5
36	globulin n.ti,kf.	3
37	iveegam.ti,kf.	0
38	privigen.ti,kf.	15
39	sandoglobulin.ti,kf.	16
40	venimmune.ti,kf.	0
41	venoglobulin.ti,kf.	2
42	venoglobulin.ti,kf.	2
43	HyQvia.ti,kf.	1
44	Octagam.ti,kf.	9



45	Hizentra.ti,kf.	16
46	Gamunex-C.ti,kf.	1
47	Gammaked.ti,kf.	0
48	or/29-47	89
49	9 or 14 or 22 or 27 or 28 or 48	31846
50	limit 49 to yr="2008-current"	12427
51	limit 50 to systematic reviews	433
52	remove duplicates from 51	419
Comments		

Date	November 05, 2018	
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to November 05, 2018>	
Search strategy		
1	Immunoglobulins, intravenous/	12050
2	IVIG.ti,kf.	1093
3	scig.ti,kf.	44
4	intraglobin*.ti,kf.	3
5	(intravenous and antibod*).ti,kf.	784
6	(intravenous and immunoglob*).ti,kf.	5152
7	(subcutaneous and antibod*).ti,kf.	322
8	(subcutaneous and immunoglob*).ti,kf.	305
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8	14385
10	exp Immunoglobulins/	841713
11	exp Administration, Intravenous/	137745
12	exp Injections, Subcutaneous/	38776
13	11 or 12	172280



14	10 and 13	11338
15	intravenous.ti,kf.	67354
16	subcutaneous.ti,kf.	25227
17	intradermal.ti,kf.	3833
18	iv.ti,kf.	53370
19	inject*.ti,kf.	107449
20	perfus*.ti,kf.	58058
21	15 or 16 or 17 or 18 or 19 or 20	303253
22	10 and 21	14991
23	immunoglob*.ti,kf.	48369
24	immune glob*.ti,kf.	1516
25	Ig.ti,kf.	3632
26	23 or 24 or 25	53089
27	21 and 26	6340
28	alphaglobin.ti,kf.	1
29	endobulin.ti,kf.	2
30	flebogamma.ti,kf.	12
31	gamimmune.ti,kf.	0
32	gammagard.ti,kf.	12
33	gammonativ.ti,kf.	0
34	gamunex.ti,kf.	5
35	globulin n.ti,kf.	3
36	iveegam.ti,kf.	0
37	privigen.ti,kf.	15
38	sandoglobulin.ti,kf.	16
39	venimmune.ti,kf.	0
40	venoglobulin.ti,kf.	2
41	venoglobulin.ti,kf.	2



42	HyQvia.ti,kf.	1
43	Octagam.ti,kf.	9
44	Hizentra.ti,kf.	16
45	Gamunex-C.ti,kf.	1
46	Gammaked.ti,kf.	0
47	or/28-46	89
48	9 or 14 or 22 or 27 or 47	31830
49	limit 48 to yr="2008-current"	12424
50	limit 49 to systematic reviews	433
51	remove duplicates from 50	419
52	from 51 keep 1-419	419
53	exp clinical pathway/	6067
54	exp clinical protocol/	155342
55	exp consensus/	9479
56	exp consensus development conference/	11129
57	exp consensus development conferences as topic/	2631
58	critical pathways/	6067
59	exp guideline/	31129
60	guidelines as topic/	37165
61	exp practice guideline/	24435
62	practice guidelines as topic/	106583
63	health planning guidelines/	4011
64	(guideline or practice guideline or consensus development conference or consensus development conference, NIH).pt.	39876
65	(position statement* or policy statement* or practice parameter* or best practice*).ti,ab,kf,kw.	27416
66	(standards or guideline or guidelines).ti,kf,kw.	97521
67	((practice or treatment* or clinical) adj guideline*).ab.	34143



68	(CPG or CPGs).ti.	5349
69	consensus*.ti,kf,kw.	22332
70	consensus*.ab. /freq=2	21618
71	((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol*).ti,ab,kf,kw.	17591
72	recommendat*.ti,kf,kw.	35976
73	(care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab,kf,kw.	48714
74	(algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab,kf,kw.	6501
75	(algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or therap* or treatment* or intervention*).ti,ab,kf,kw.	8385
76	or/53-75	549272
77	49 and 76	740
78	77 not 52	641
79	limit 78 to yr="2013-Current"	354
80	remove duplicates from 79	354
81	limit 78 to yr="2008-2012"	287

Comments

1.2 DARE-CRD database for Systematic Reviews

Search performed in the DARE-CRD database in October 2018. No update was performed as from 31 March 2018, no new records were added in the HTA database.

Search term: immunoglobulin* (in title), no date limit	141 references
After elimination of Cochrane reviews	106 references
Date limit- 2009-2019	61 references
Exclusion on Title and abstract (n=27)	34 references
No full text available (n= 10)	
Full text analysis	24 references
• Already included via searches in MEDLINE and EMBASE (n=16)	



- Not on assessing effectiveness and safety (n= 1)
- Cost-utility analysis (n= 5)

2 references additional included (INESSS, Samuelsson et al 2014 an HTA on postpolio syndrome)

1.3 Medline, Embase and Cochrane search per indication

1.3.1 Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Date	25/03/2019 05:21:53	
Database	Cochrane@Wiley.com	
Search strategy		
#1	[mh ^"Immunoglobulins, intravenous"]	766
#2	IVIG:ti,kw	228
#3	scig:ti,kw	10
#4	intraglobin*:ti,kw	2
#5	(intravenous NEAR/5 antibod*):ti,kw	207
#6	(intravenous NEAR/5 immunoglob*):ti,kw	1331
#7	(subcutaneous NEAR/5 antibod*):ti,kw	153
#8	(subcutaneous NEAR/5 immunoglob*):ti,kw	101
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	1781
#10	[mh "Immunoglobulins"]	21834
#11	[mh "Administration, Intravenous"]	17766
#12	[mh "Injections, Subcutaneous"]	4209
#13	#11 OR #12	21482
#14	#10 AND #13	1453
#15	intravenous:ti,kw	48965
#16	subcutaneous:ti,kw	11559
#17	intradermal:ti,kw	1526
#18	iv:ti,kw	20229
#19	inject*:ti,kw	41687



#20	perfus*:ti,kw	4808
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	96631
#22	#10 AND #21	4605
#23	immunoglob*:ti,kw	10917
#24	immune glob*:ti,kw	569
#25	Ig:ti,kw	1965
#26	#23 OR #24 OR #25	12080
#27	#21 AND #26	2878
#28	#13 AND #26	498
#29	alphaglobin:ti,kw	0
#30	endobulin:ti,kw	0
#31	flebogamma:ti,kw	2
#32	gamimmune:ti,kw	0
#33	gammagard:ti,kw	9
#34	gammonativ:ti,kw	0
#35	gamunex:ti,kw	6
#36	globulin n:ti,kw	20
#37	iveegam:ti,kw	0
#38	privigen:ti,kw	1
#39	sandoglobulin:ti,kw	6
#40	venimmune:ti,kw	0
#41	venoglobulin:ti,kw	4
#42	HyQvia:ti,kw	3
#43	Octagam:ti,kw	9
#44	Hizentra:ti,kw	2
#45	Gamunex-C:ti,kw	1
#46	Gammaked:ti,kw	0



#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	59
#48	#9 or #14 or #22 or #27 or #28 or #47	6044
#49	#48 with Cochrane Library publication date Between Jan 2008 and Jan 2019	4148
#50	[mh ^"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"]	53
#51	[mh ^"demyelinating diseases"]	80
#52	demyelinat*:ab,ti,kw	813
#53	#51 OR #52	813
#54	[mh "Inflammation"]	9461
#55	inflammat*:ab,ti,kw	58160
#56	#54 OR #55	62250
#57	#53 AND #56	356
#58	[mh ^"polyneuropathies"]	162
#59	[mh ^"Polyradiculoneuropathy"]	71
#60	[mh ^"neuritis"]	73
#61	#58 OR #59 OR #60	303
#62	polyradiculoneur*:ab,ti,kw	190
#63	polyneur*:ab,ti,kw	911
#64	#62 OR #63	1048
#65	#61 OR #64	1117
#66	#57 AND #65	205
#67	[mh "chronic disease"]	12433
#68	chronic:ab,ti,kw	103764
#69	long-term:ab,ti,kw	69728
#70	long-time:ab,ti,kw	827
#71	#68 or #69 or #70	163566
#72	#67 OR #71	163567
#73	#66 AND #72	192



#74	cidp:ab,ti,kw	152
#75	#73 OR #74	214
#76	#50 OR #75	214
#77	#49 AND #76	97
Comments	3 results for Cochrane Systematic Reviews Database 94 Results for CENTRAL	

Date	21 Mar 2019	
Database	Embase.com	
Search strategy		
#1	(intravenous:ab,ti,kw OR subcutaneous:ab,ti,kw) AND (immunoglob*:ab,ti,kw OR 50136 antibod*:ab,ti,kw)	
#2	ivig:ab,ti,kw OR scig:ab,ti,kw	15456
#3	intraglobin*:ab,ti,kw	34
#4	#1 OR #2 OR #3	56350
#5	'subcutaneous immunotherapy'/exp	1561
#6	#4 OR #5	57737
#7	'immunoglobulin'/exp	476978
#8	'intravenous drug administration'/exp	377709
#9	'subcutaneous drug administration'/exp	97741
#10	#8 OR #9	458852
#11	#7 AND #10	12058
#12	intravenous:ab,ti,kw	362573
#13	subcutaneous:ab,ti,kw	170606
#14	intradermal:ab,ti,kw	18470
#15	iv:ab,ti,kw	473297
#16	inject*:ab,ti,kw	922451
#17	perfus*:ab,ti,kw	270086



#18	#12 OR #13 OR #14 OR #15 OR #16 OR #17	1975978
#19	#7 AND #18	56464
#20	immunoglob*:ab,ti,kw	186399
#21	immune AND glob*:ab,ti,kw	31566
#22	ig:ab,ti,kw	46805
#23	#20 OR #21 OR #22	242261
#24	#18 AND #23	40698
#25	#10 AND #23	6050
#26	alphaglobin:ab,ti,kw,tn	11
#27	endobulin:ab,ti,kw,tn	292
#28	flebogamma:ab,ti,kw,tn	277
#29	gamimmune:ab,ti,tn	50
#30	gammagard:ab,ti,tn	760
#31	gammonativ:ab,ti,tn	64
#32	gamunex:ab,ti,tn	318
#33	globulin AND n:ab,ti,tn	6058
#34	iveegam:ab,ti,tn	115
#35	privigen:ab,ti,kw,tn	343
#36	sandoglobulin:ab,ti,kw,tn	1202
#37	venimmune:ab,ti,kw,tn	2
#38	venoglobulin:ab,ti,kw,tn	263
#39	venoglobulin:ab,ti,kw,tn	263
#40	hyqvia:ab,ti,kw,tn	49
#41	octagam:ab,ti,kw,tn	392
#42	hizentra:ab,ti,kw,tn	253
#43	'gamunex c':ab,ti,kw,tn	45
#44	gammaked:ab,ti,kw,tn	13



#45	#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44	9130
#46	#6 OR #11 OR #19 OR #24 OR #25 OR #45	106990
#47	#46 NOT [medline]/lim	43232
#48	#47 AND [2008-2019]/py	38013
#49	#48 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	6323
#50	'polyradiculoneuropathy'/de	2778
#51	'demyelinating disease'/de	14602
#52	demyelinat*:ab,ti,kw	44299
#53	#51 OR #52	50645
#54	'inflammation'/exp	3294492
#55	inflammat*:ab,ti,kw	1214255
#56	#54 OR #55	3753582
#57	#53 AND #56	26954
#58	'polyneuropathy'/de	16335
#59	'neuritis'/de	6788
#60	#58 OR #59	22935
#61	polyradiculoneur*:ab,ti,kw	3290
#62	polyneur*:ab,ti,kw	23368
#63	#61 OR #62	25962
#64	#60 OR #63	37328
#65	#57 AND #64	6042
#66	'chronic disease'/exp	187332
#67	chronic:ab,ti,kw	1530432
#68	'long term':ab,ti,kw	999486
#69	'long time':ab,ti,kw	38615
#70	#67 OR #68 OR #69	2440104
#71	#66 OR #70	2489244



#72	#65 AND #71	4171
#73	cidp:ab,ti,kw	3279
#74	#72 OR #73	4883
#75	#50 OR #74	6766
#76	#49 AND #75	133
#77	#76 AND ('meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review')	3
#78	#76 AND (random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti))	25
#79	#76 NOT (#77 OR #78)	107
Comments	Line 77 exported for SR Line 78 exported for RCT Line 79 exported for All studies except SR or RCT	

Date	March 19, 2019	
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to March 19, 2019>	
Search strategy		
1	Immunoglobulins, intravenous/	12364
2	IVIG.ti,kf.	1118
3	scig.ti,kf.	48
4	intraglobin*.ti,kf.	3
5	(intravenous and antibod*).ti,kf.	796
6	(intravenous and immunoglob*).ti,kf.	5207
7	(subcutaneous and antibod*).ti,kf.	330
8	(subcutaneous and immunoglob*).ti,kf.	309
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8	14721
10	exp Immunoglobulins/	850448



11	exp Administration, Intravenous/	138819
12	exp Injections, Subcutaneous/	39116
13	11 or 12	173669
14	10 and 13	11509
15	intravenous.ti,kf.	68039
16	subcutaneous.ti,kf.	25500
17	intradermal.ti,kf.	3873
18	iv.ti,kf.	53903
19	inject*.ti,kf.	108935
20	perfus*.ti,kf.	58848
21	15 or 16 or 17 or 18 or 19 or 20	306925
22	10 and 21	15184
23	immunoglob*.ti,kf.	48900
24	immune glob*.ti,kf.	1530
25	Ig.ti,kf.	3676
26	23 or 24 or 25	53663
27	21 and 26	6410
28	13 and 26	1187
29	alphaglobin.ti,kf.	1
30	endobulin.ti,kf.	2
31	flebogamma.ti,kf.	13
32	gamimmune.ti,kf.	0
33	gammagard.ti,kf.	12
34	gammonativ.ti,kf.	0
35	gamunex.ti,kf.	5
36	globulin n.ti,kf.	3
37	iveegam.ti,kf.	0
38	privigen.ti,kf.	17



39	sandoglobulin.ti,kf.	16
40	venimmune.ti,kf.	0
41	venoglobulin.ti,kf.	2
42	venoglobulin.ti,kf.	2
43	HyQvia.ti,kf.	1
44	Octagam.ti,kf.	10
45	Hizentra.ti,kf.	19
46	Gamunex-C.ti,kf.	1
47	Gammaked.ti,kf.	0
48	or/29-47	95
49	9 or 14 or 22 or 27 or 28 or 48	32413
50	limit 49 to yr="2008-current"	12898
51	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/	1328
52	demyelinating diseases/	11414
53	demyelinat*.ab,ti,kf.	28919
54	52 or 53	33301
55	exp Inflammation/	308356
56	inflammat*.ab,ti,kf.	840116
57	55 or 56	1011668
58	54 and 57	10838
59	polyneuropathies/	4881
60	Polyradiculoneuropathy/	3792
61	neuritis/	4944
62	59 or 60 or 61	13287
63	polyradiculoneur*.ab,ti,kf.	2126
64	polyneur*.ab,ti,kf.	15709
65	63 or 64	17445
66	58 and 65	3011



67	exp chronic disease/	254135
68	chronic.ab,ti,kf.	1079563
69	long-term.ab,ti,kf.	729394
70	long-time.ab,ti,kf.	29033
71	68 or 69 or 70	1752449
72	67 or 71	1816401
73	66 and 72	2424
74	cidp.ab,ti,kf.	1603
75	73 or 74	2623
76	51 or 75	2806
77	50 and 76	355
78	limit 77 to systematic reviews	26
79	randomized controlled trial.pt.	478099
80	controlled clinical trial.pt.	92974
81	randomized.ti,ab.	472128
82	placebo.ti,ab.	201616
83	clinical trials as topic/	186320
84	randomly.ti,ab.	308370
85	trial?.ti.	261936
86	79 or 80 or 81 or 82 or 83 or 84 or 85	1235412
87	exp animal/ not humans/	4558766
88	86 not 87	1137167
89	77 and 88	77
90	77 not (78 or 89)	266
91	90 not 87	263
92	remove duplicates from 91	263
Comments	Line 78 exported for SR Line 89 exported for RCT	



Line 92 exported for All studies except SR or RCT



1.3.2 Dermatomyositis and Polymyositis

Date	12/07/2019 13:52:29	
Database	Cochrane@Wiley.com	
Search strategy		
#0	[mh ^"Immunoglobulins, intravenous"]	777
#0	IVIG:ti,kw	278
#0	scig:ti,kw	10
#0	intraglobin*:ti,kw	2
#0	(intravenous NEAR/5 antibod*):ti,kw	205
#0	(intravenous NEAR/5 immunoglob*):ti,kw	1481
#0	(subcutaneous NEAR/5 antibod*):ti,kw	151
#0	(subcutaneous NEAR/5 immunoglob*):ti,kw	113
#9	[mh ^"Immunoglobulins, intravenous"] or IVIG:ti,kw or scig:ti,kw or intraglobin*:ti,kw or (intravenous NEAR/5 antibod*):ti,kw or (intravenous NEAR/5 immunoglob*):ti,kw or (subcutaneous NEAR/5 antibod*):ti,kw or (subcutaneous NEAR/5 immunoglob*):ti,kw	2378
#10	[mh "Immunoglobulins"]	22382
#11	[mh "Administration, Intravenous"]	17966
#12	[mh "Injections, Subcutaneous"]	4257
#13	#11 OR #12	21726
#14	#10 AND #13	1482
#15	intravenous:ti,kw	52959
#16	subcutaneous:ti,kw	12723
#17	intradermal:ti,kw	1681
#18	iv:ti,kw	21303
#19	inject*:ti,kw	46767
#20	perfus*:ti,kw	5526
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	108072



#22	#10 AND #21	4703
#23	immunoglob*:ti,kw	11375
#24	immune glob*:ti,kw	637
#25	Ig:ti,kw	2189
#26	#23 OR #24 OR #25	12766
#27	#21 AND #26	3099
#28	#13 AND #26	501
#29	alphaglobin:ti,kw	0
#30	endobulin:ti,kw	0
#31	flebogamma:ti,kw	4
#32	gamimmune:ti,kw	0
#33	gammagard:ti,kw	9
#34	gammonativ:ti,kw	0
#35	gamunex:ti,kw	7
#36	globulin n:ti,kw	20
#37	iveegam:ti,kw	0
#38	privigen:ti,kw	1
#39	sandoglobulin:ti,kw	6
#40	venimmune:ti,kw	0
#41	venoglobulin:ti,kw	4
#42	HyQvia:ti,kw	4
#43	Octagam:ti,kw	14
#44	Hizentra:ti,kw	5
#45	Gamunex-C:ti,kw	2
#46	Gammaked:ti,kw	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	71
#48	#9 OR #14 or #22 or #27 or #28 or #47	6751



#49	[mh ^"Dermatomyositis"]	74
#50	[mh ^"Polymyositis"]	34
#51	#49 OR #50	79
#52	dermatomyosit*:ab,ti,kw	315
#53	dermatopolymyositis:ab,ti,kw	1
#54	(juvenile NEAR/3 myositis).ab,ti,kw	20
#55	(multiple NEAR/3 myositis):ab,ti,kw	5
#56	polymyositis-dermatomyositis:ab,ti,kw	34
#57	polymyosit*:ab,ti,kw	196
#58	#52 OR #53 OR #54 OR #55 OR #56 OR #57	382
#59	#51 OR #58	382
#60	#48 AND #59	39
Comments	1 results for Cochrane Systematic Reviews Database 38 Results for CENTRAL	

Date	12 Jul 2019	
Database	Embase.com	
Search strategy		
#1	intravenous:ti AND immunoglob*:ti	6521
#2	subcutaneous:ti AND immunoglob*:ti	638
#3	intravenous:ti AND antibod*:ti	841
#4	subcutaneous:ti AND antibod*:ti	337
#5	ivig:ti	1719
#6	scig:ti	107
#7	intraglobin*:ti	7
#8	'subcutaneous immunotherapy'/exp	1613
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	10681



#10	'immunoglobulin'/exp	484894
#11	'intravenous drug administration'/exp	378834
#12	'subcutaneous drug administration'/exp	97788
#13	#11 OR #12	460020
#14	#10 AND #13	12091
#15	intravenous:ti	82817
#16	subcutaneous:ti	31915
#17	intradermal:ti	4186
#18	iv:ti	60672
#19	inject*:ti	126602
#20	perfus*:ti	72464
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	366923
#22	#10 AND #21	11939
#23	immunoglob*:ti	53759
#24	immune AND (globu*:ti OR globi*:ti)	3119
#25	ig:ti	4126
#26	#23 OR #24 OR #25	60636
#27	#21 AND #26	8289
#28	#13 AND #26	3228
#29	alphaglobin:ti	2
#30	endobulin:ti	2
#31	flebogamma:ti	19
#32	gamimmune:ti	0
#33	gammagard:ti	19
#34	gammonativ:ti	1
#35	gamunex:ti	8
#36	'globulin n':ti	4
#37	iveegam:ti	0



#38	privigen:ti	39
#39	sandoglobulin:ti	15
#40	venimmune:ti	0
#41	venoglobulin:ti	4
#42	hyqvia:ti	17
#43	octagam:ti	28
#44	hizentra:ti	55
#45	'gamunex c':ti	2
#46	gammaked:ti	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	209
#48	#9 OR #14 OR #22 OR #27 OR #28 OR #47	24887
#49	'dermatomyositis'/exp OR 'polymyositis'/exp	19699
#50	dermatomyosit*:ab,ti,kw	12619
#51	dermatopolymyositis:ab,ti,kw	138
#52	(juvenile NEAR/3 myositis):ab,ti,kw	193
#53	(multiple NEAR/3 myositis):ab,ti,kw	81
#54	'polymyositis dermatomyositis':ab,ti,kw	1077
#55	polymyosit*:ab,ti,kw	8310
#56	#50 OR #51 OR #52 OR #53 OR #54 OR #55	16909
#57	#49 OR #56	22290
#58	#48 AND #57	575
#59	#58 NOT [medline]/lim	179
#60	#59 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	108
#61	#60 AND [2011-2019]/py	27
#62	#61 AND ('meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review')	2
#63	#61 AND (random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti))	3



#64	#61 NOT (#62 OR #63)	23
Comments	Line 62 exported for SR Line 63 exported for RCT Line 64 exported for All studies except SR or RCT	

Date	July 10, 2019
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to July 10, 2019>
Search strategy	
1	Dermatomyositis/ 7544
2	Polymyositis/ 2413
3	1 or 2 8928
4	dermatomyosit*.ab,ti,kf,jw. 8644
5	dermatopolymyositis.ab,ti,kf,jw. 101
6	(juvenile adj3 myositis).ab,ti,kf,jw. 76
7	(multiple adj3 myositis).ab,ti,kf,jw. 52
8	polymyositis-dermatomyositis.ab,ti,kf,jw. 764
9	polymyosit*.ab,ti,kf,jw. 5775
10	4 or 5 or 6 or 7 or 8 or 9 11894
11	3 or 10 13474
12	Immunoglobulins, intravenous/ 12586
13	IVIG.ti,kf. 1169
14	scig.ti,kf. 54
15	intraglobin*.ti,kf. 3
16	(intravenous and antibod*).ti,kf. 815
17	(intravenous and immunoglob*).ti,kf. 5335
18	(subcutaneous and antibod*).ti,kf. 333



19	(subcutaneous and immunoglob*).ti,kf.	331
20	12 or 13 or 14 or 15 or 16 or 17 or 18 or 19	15039
21	exp Immunoglobulins/	859270
22	exp Administration, Intravenous/	139807
23	exp Injections, Subcutaneous/	39396
24	22 or 23	174914
25	21 and 24	11645
26	intravenous.ti,kf.	68924
27	subcutaneous.ti,kf.	26091
28	intradermal.ti,kf.	3934
29	iv.ti,kf.	54554
30	inject*.ti,kf.	110823
31	perfus*.ti,kf.	59663
32	26 or 27 or 28 or 29 or 30 or 31	311674
33	21 and 32	15391
34	immunoglob*.ti,kf.	49486
35	immune glob*.ti,kf.	1538
36	Ig.ti,kf.	3712
37	34 or 35 or 36	54286
38	32 and 37	6561
39	24 and 37	1199
40	alphaglobin.ti,kf.	1
41	endobulin.ti,kf.	2
42	flebogamma.ti,kf.	13
43	gamimmune.ti,kf.	0
44	gammagard.ti,kf.	12
45	gammonativ.ti,kf.	0
46	gamunex.ti,kf.	5



47	globulin n.ti,kf.	3
48	iveegam.ti,kf.	0
49	privigen.ti,kf.	17
50	sandoglobulin.ti,kf.	16
51	venimmune.ti,kf.	0
52	venoglobulin.ti,kf.	2
53	venoglobulin.ti,kf.	2
54	HyQvia.ti,kf.	1
55	Octagam.ti,kf.	11
56	Hizentra.ti,kf.	19
57	Gamunex-C.ti,kf.	1
58	Gammaked.ti,kf.	0
59	or/40-58	96
60	20 or 25 or 33 or 38 or 39 or 59	32943
61	11 and 60	429
62	randomized controlled trial.pt.	485251
63	controlled clinical trial.pt.	93153
64	randomized.ti,ab.	483716
65	placebo.ti,ab.	204507
66	clinical trials as topic/	187601
67	randomly.ti,ab.	315035
68	trial?.ti.	268918
69	62 or 63 or 64 or 65 or 66 or 67 or 68	1257282
70	exp animal/ not humans/	4597467
71	69 not 70	1157230
72	61 and 71	58
73	limit 72 to yr="2011-Current"	18
Comments	Line 72 exported for RCT	



A redo of the search strategy has been performed on 21st of October 2019 to check for SR, 3 were found, already present in the exported set of RCT line 72.

Date	11/10/2019 18:15:45	
Database	Cochrane@Wiley.com	
Search strategy		
#1	[mh ^"Immunoglobulins, intravenous"]	786
#2	IVIG:ti,kw	285
#3	scig:ti,kw	10
#4	intraglobin*:ti,kw	2
#5	(intravenous NEAR/5 antibod*):ti,kw	205
#6	(intravenous NEAR/5 immunoglob*):ti,kw	1474
#7	(subcutaneous NEAR/5 antibod*):ti,kw	151
#8	(subcutaneous NEAR/5 immunoglob*):ti,kw	119
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	1974
#10	[mh "Immunoglobulins"]	22872
#11	[mh "Administration, Intravenous"]	18094
#12	[mh "Injections, Subcutaneous"]	4303
#13	#11 OR #12	21896
#14	#10 AND #13	1515
#15	intravenous:ti,kw	53460
#16	subcutaneous:ti,kw	12875
#17	intradermal:ti,kw	1694
#18	iv:ti,kw	21452
#19	inject*:ti,kw	47819
#20	perfus*:ti,kw	5670
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	109915



#22	#10 AND #21	4808
#23	immunoglob*:ti,kw	11441
#24	immune glob*:ti,kw	649
#25	Ig:ti,kw	2220
#26	#23 OR #24 OR #25	12858
#27	#21 AND #26	3112
#28	#13 AND #26	501
#29	alphaglobin:ti,kw	0
#30	endobulin:ti,kw	0
#31	flebogamma:ti,kw	4
#32	gamimmune:ti,kw	0
#33	gammagard:ti,kw	9
#34	gammonativ:ti,kw	0
#35	gamunex:ti,kw	7
#36	globulin n:ti,kw	20
#37	iveegam:ti,kw	0
#38	privigen:ti,kw	1
#39	sandoglobulin:ti,kw	6
#40	venimmune:ti,kw	0
#41	venoglobulin:ti,kw	4
#42	HyQvia:ti,kw	4
#43	Octagam:ti,kw	14
#44	Hizentra:ti,kw	5
#45	Gamunex-C:ti,kw	2
#46	Gammaked:ti,kw	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	71
#48	#9 or #14 or #22 or #27 or #28 or #47	6484



#49	[mh ^"myositis"]	75
#50	[mh ^"polymyositis"]	35
#51	#49 or #50	108
#52	myositis:ab,ti,kw,so	512
#53	polymyositis:ab,ti,kw,so	210
#54	(inflammatory NEAR/3 (myopath* or "muscle disease" or "muscle diseases")):ab,ti,kw	101
#55	inclusion-body:ab,ti,kw	115
#56	fibromyositis:ab,ti,kw	4
#57	inomyositis:ab,ti,kw	0
#58	#52 OR #53 OR #54 OR #55 OR #56 OR #57	658
#59	#51 or #58	658
#60	#48 and #59	44
#61	#60 with Cochrane Library publication date Between Jan 2017 and Dec 2019	19
Comments	0 results for Cochrane Systematic Reviews Database 19 Results for CENTRAL	

Date	11 Oct 2019
Database	Embase.com
Search strategy	
#1	(intravenous:ab,ti,kw OR subcutaneous:ab,ti,kw) AND (immunoglob*:ab,ti,kw OR antibod*:ab,ti,kw)
#2	ivig:ab,ti,kw OR scig:ab,ti,kw
#3	intraglobin*:ab,ti,kw
#4	#1 OR #2 OR #3
#5	'subcutaneous immunotherapy'/exp
#6	#4 OR #5



#7	'immunoglobulin'/exp	493274
#8	'intravenous drug administration'/exp	380151
#9	'subcutaneous drug administration'/exp	97813
#10	#8 OR #9	461361
#11	#7 AND #10	12129
#12	intravenous:ab,ti,kw	374631
#13	subcutaneous:ab,ti,kw	177576
#14	intradermal:ab,ti,kw	19039
#15	iv:ab,ti,kw	493466
#16	inject*:ab,ti,kw	953707
#17	perfus*:ab,ti,kw	277894
#18	#12 OR #13 OR #14 OR #15 OR #16 OR #17	2046489
#19	#7 AND #18	59081
#20	immunoglob*:ab,ti,kw	191972
#21	immune AND glob*:ab,ti,kw	33587
#22	ig:ab,ti,kw	48169
#23	#20 OR #21 OR #22	250678
#24	#18 AND #23	42553
#25	#10 AND #23	6091
#26	alphaglobin:ab,ti,kw,tn	12
#27	endobulin:ab,ti,kw,tn	293
#28	flebogamma:ab,ti,kw,tn	284
#29	gamimmune:ab,ti,tn	50
#30	gammagard:ab,ti,tn	765
#31	gammonativ:ab,ti,tn	64
#32	gamunex:ab,ti,tn	324
#33	globulin AND n:ab,ti,tn	6308
#34	iveegam:ab,ti,tn	115



#35	privigen:ab,ti,kw,tn	354
#36	sandoglobulin:ab,ti,kw,tn	1203
#37	venimmune:ab,ti,kw,tn	2
#38	venoglobulin:ab,ti,kw,tn	263
#39	venoglobulin:ab,ti,kw,tn	263
#40	hyqvia:ab,ti,kw,tn	55
#41	octagam:ab,ti,kw,tn	402
#42	hizentra:ab,ti,kw,tn	275
#43	'gamunex c':ab,ti,kw,tn	47
#44	gammaked:ab,ti,kw,tn	13
#45	#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44	9434
#46	#6 OR #11 OR #19 OR #24 OR #25 OR #45	111859
#47	'myositis':de	15517
#48	'polymyositis':de	8288
#49	#47 OR #48	22130
#50	myositis:ab,ti,kw,jt	14104
#51	polymyositis:ab,ti,kw,jt	8485
#52	(inflammatory NEAR/3 (myopath* OR 'muscle disease' OR 'muscle diseases')):ab,ti,kw	5258
#53	'inclusion body':ab,ti,kw	6139
#54	fibromyositis:ab,ti,kw	29
#55	inomyositis:ab,ti,kw	0
#56	#50 OR #51 OR #52 OR #53 OR #54 OR #55	25316
#57	#49 OR #56	33306
#58	#46 AND #57	1457
#59	random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti)	1712359
#60	#58 AND #59	154



#61	#60 AND [2017-2019]/py	25
#62	#61 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	12
#63	#62 NOT [medline]/lim	1
Comments	Line 63 exported for RCT	

Date	October 10, 2019	
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to October 10, 2019>	
Search strategy		
1	Myositis/	7973
2	polymyositis/	2438
3	1 or 2	10035
4	myositis.ab,ti,kf,jw.	9597
5	polymyositis.ab,ti,kf,jw.	5806
6	(inflammatory adj3 (myopath* or muscle disease?)).ab,ti,kf.	3173
7	inclusion-body.ab,ti,kf.	4245
8	fibromyositis.ab,ti,kf.	21
9	inomyositis.ab,ti,kf.	0
10	4 or 5 or 6 or 7 or 8 or 9	17654
11	3 or 10	20406
12	Immunoglobulins, intravenous/	12737
13	IVIG.ti,kf.	1201
14	scig.ti,kf.	57
15	intraglobin*.ti,kf.	3
16	(intravenous and antibod*).ti,kf.	828
17	(intravenous and immunoglob*).ti,kf.	5397
18	(subcutaneous and antibod*).ti,kf.	338



19	(subcutaneous and immunoglob*).ti,kf.	346
20	12 or 13 or 14 or 15 or 16 or 17 or 18 or 19	15228
21	exp Immunoglobulins/	866274
22	exp Administration, Intravenous/	140623
23	exp Injections, Subcutaneous/	39627
24	22 or 23	175943
25	21 and 24	11772
26	intravenous.ti,kf.	69501
27	subcutaneous.ti,kf.	26443
28	intradermal.ti,kf.	3968
29	iv.ti,kf.	54974
30	inject*.ti,kf.	112159
31	perfus*.ti,kf.	60276
32	26 or 27 or 28 or 29 or 30 or 31	314893
33	21 and 32	15569
34	immunoglob*.ti,kf.	49905
35	immune glob*.ti,kf.	1548
36	Ig.ti,kf.	3743
37	34 or 35 or 36	54736
38	32 and 37	6642
39	24 and 37	1204
40	alphaglobin.ti,kf.	1
41	endobulin.ti,kf.	2
42	flebogamma.ti,kf.	14
43	gamimmune.ti,kf.	0
44	gammagard.ti,kf.	12
45	gammonativ.ti,kf.	0
46	gamunex.ti,kf.	5



47	globulin n.ti,kf.	3
48	iveegam.ti,kf.	0
49	privigen.ti,kf.	17
50	sandoglobulin.ti,kf.	16
51	venimmune.ti,kf.	0
52	venoglobulin.ti,kf.	2
53	venoglobulin.ti,kf.	2
54	HyQvia.ti,kf.	1
55	Octagam.ti,kf.	11
56	Hizentra.ti,kf.	21
57	Gamunex-C.ti,kf.	1
58	Gammaked.ti,kf.	0
59	or/40-58	99
60	20 or 25 or 33 or 38 or 39 or 59	33352
61	11 and 60	356
62	randomized controlled trial.pt.	491309
63	controlled clinical trial.pt.	93313
64	randomized.ti,ab.	493155
65	placebo.ti,ab.	206933
66	clinical trials as topic/	188681
67	randomly.ti,ab.	320359
68	trial?.ti.	274722
69	62 or 63 or 64 or 65 or 66 or 67 or 68	1275165
70	exp animal/ not humans/	4627155
71	69 not 70	1173815
72	61 and 71	53
73	limit 72 to yr="2017-Current"	5
Comments	Line 73 exported for RCT	



1.3.3 *Fetomaternal thrombocytopenia (FMAIT)*

Date	12/07/2019 12:40:13
Database	Cochrane@Wiley.com
Search strategy	
#0	[mh ^"Immunoglobulins, intravenous"]
	777
#0	IVIG:ti,kw
	278
#0	scig:ti,kw
	10
#0	intraglobin*:ti,kw
	2
#0	(intravenous NEAR/5 antibod*):ti,kw
	205
#0	(intravenous NEAR/5 immunoglob*):ti,kw
	1481
#0	(subcutaneous NEAR/5 antibod*):ti,kw
	151
#0	(subcutaneous NEAR/5 immunoglob*):ti,kw
	113
#9	[mh ^"Immunoglobulins, intravenous"] or IVIG:ti,kw or scig:ti,kw or intraglobin*:ti,kw or (intravenous NEAR/5 antibod*):ti,kw or (intravenous NEAR/5 immunoglob*):ti,kw or (subcutaneous NEAR/5 antibod*):ti,kw or (subcutaneous NEAR/5 immunoglob*):ti,kw
	2378
#10	[mh "Immunoglobulins"]
	22382
#11	[mh "Administration, Intravenous"]
	17966
#12	[mh "Injections, Subcutaneous"]
	4257
#13	#11 OR #12
	21726
#14	#10 AND #13
	1482
#15	intravenous:ti,kw
	52959
#16	subcutaneous:ti,kw
	12723
#17	intradermal:ti,kw
	1681
#18	iv:ti,kw
	21303
#19	inject*:ti,kw
	46767
#20	perfus*:ti,kw
	5526
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20
	108072
#22	#10 AND #21
	4703



#23	immunoglob*:ti,kw	11375
#24	immune glob*:ti,kw	637
#25	Ig:ti,kw	2189
#26	#23 OR #24 OR #25	12766
#27	#21 AND #26	3099
#28	#13 AND #26	501
#29	alphaglobin:ti,kw	0
#30	endobulin:ti,kw	0
#31	flebogamma:ti,kw	4
#32	gamimmune:ti,kw	0
#33	gammagard:ti,kw	9
#34	gammonativ:ti,kw	0
#35	gamunex:ti,kw	7
#36	globulin n:ti,kw	20
#37	iveegam:ti,kw	0
#38	privigen:ti,kw	1
#39	sandoglobulin:ti,kw	6
#40	venimmune:ti,kw	0
#41	venoglobulin:ti,kw	4
#42	HyQvia:ti,kw	4
#43	Octagam:ti,kw	14
#44	Hizentra:ti,kw	5
#45	Gamunex-C:ti,kw	2
#46	Gammaked:ti,kw	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	71
#48	#9 OR #14 or #22 or #27 or #28 or #47	6751
#49	[mh "Thrombocytopenia, Neonatal Alloimmune"]	8



#50	thrombocytopenia NEAR/3 feto?maternal:ab,ti,kw	2
#51	(thrombocytopenia NEAR/3 alloimmune):ab,ti,kw	28
#52	#49 OR #50 OR #51	28
#53	#48 AND #52	15
Comments	1 results for Cochrane Systematic Reviews Database 13 Results for CENTRAL	

Date	9 Jul 2019	
Database	Embase.com	
Search strategy		
#1	intravenous:ti AND immunoglob*:ti	6516
#2	subcutaneous:ti AND immunoglob*:ti	638
#3	intravenous:ti AND antibod*:ti	841
#4	subcutaneous:ti AND antibod*:ti	337
#5	ivig:ti	1717
#6	scig:ti	107
#7	intraglobin*:ti	7
#8	'subcutaneous immunotherapy'/exp	1612
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	10673
#10	'immunoglobulin'/exp	484610
#11	'intravenous drug administration'/exp	378760
#12	'subcutaneous drug administration'/exp	97788
#13	#11 OR #12	459946
#14	#10 AND #13	12087
#15	intravenous:ti	82790



#16	subcutaneous:ti	31890
#17	intradermal:ti	4183
#18	iv:ti	60644
#19	inject*:ti	126525
#20	perfus*:ti	72430
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	366735
#22	#10 AND #21	11931
#23	immunoglob*:ti	53742
#24	immune AND (globu*:ti OR globi*:ti)	3118
#25	ig:ti	4125
#26	#23 OR #24 OR #25	60617
#27	#21 AND #26	8284
#28	#13 AND #26	3228
#29	alphaglobin:ti	2
#30	endobulin:ti	2
#31	flebogamma:ti	19
#32	gamimmune:ti	0
#33	gammagard:ti	19
#34	gammonativ:ti	1
#35	gumnex:ti	8
#36	'globulin n':ti	4
#37	iveegam:ti	0
#38	privigen:ti	39
#39	sandoglobulin:ti	15
#40	venimmune:ti	0
#41	venoglobulin:ti	4
#42	hyqvia:ti	17
#43	octagam:ti	28



#44	hizentra:ti	55
#45	'gamunex c':ti	2
#46	gammaked:ti	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	209
#48	#9 OR #14 OR #22 OR #27 OR #28 OR #47	24873
#49	#48 NOT [medline]/lim	7933
#50	'neonatal alloimmune thrombocytopenia':exp	873
#51	(alloimmune NEAR/3 thrombocytopenia):ab,ti,kw	1453
#52	(fetomaternal NEAR/3 thrombocytopenia):ab,ti,kw	88
#53	#50 OR #51 OR #52	1630
#54	#49 AND #53	24
#55	#54 AND ('meta-analysis':exp OR 'meta-analysis' OR 'systematic review':exp OR 'systematic review')	0
#56	#54 AND (random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti))	2
#57	#54 NOT ('conference abstract':it OR 'conference paper':it OR 'conference review':it)	9
Comments	Line 55 shows no SR Line 56 exported for RCT Line 57 exported for All studies (not used)	

Date	July 08, 2019
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to July 08, 2019>
Search strategy	
1	(thrombocytopenia adj3 alloimmune).ab,ti,kf,jw.
2	thrombocytopenia ad3 fetomaternal.ab,ti,kf,jw.
3	exp Thrombocytopenia, Neonatal Alloimmune/
4	1 or 2 or 3



5	Immunoglobulins, intravenous/	12573
6	IVIG.ti,kf.	1170
7	scig.ti,kf.	54
8	intraglobin*.ti,kf.	3
9	(intravenous and antibod*).ti,kf.	815
10	(intravenous and immunoglob*).ti,kf.	5336
11	(subcutaneous and antibod*).ti,kf.	333
12	(subcutaneous and immunoglob*).ti,kf.	332
13	5 or 6 or 7 or 8 or 9 or 10 or 11 or 12	15030
14	exp Immunoglobulins/	858972
15	exp Administration, Intravenous/	139781
16	exp Injections, Subcutaneous/	39392
17	15 or 16	174885
18	14 and 17	11638
19	intravenous.ti,kf.	68919
20	subcutaneous.ti,kf.	26098
21	intradermal.ti,kf.	3935
22	iv.ti,kf.	54554
23	inject*.ti,kf.	110845
24	perfus*.ti,kf.	59655
25	19 or 20 or 21 or 22 or 23 or 24	311689
26	14 and 25	15386
27	immunoglob*.ti,kf.	49479
28	immune glob*.ti,kf.	1538
29	Ig.ti,kf.	3715
30	27 or 28 or 29	54282
31	25 and 30	6563
32	17 and 30	1198



33	alphaglobin.ti,kf.	1
34	endobulin.ti,kf.	2
35	flebogamma.ti,kf.	13
36	gamimmune.ti,kf.	0
37	gammagard.ti,kf.	12
38	gammonativ.ti,kf.	0
39	gamunex.ti,kf.	5
40	globulin n.ti,kf.	3
41	iveegam.ti,kf.	0
42	privigen.ti,kf.	17
43	sandoglobulin.ti,kf.	16
44	venimmune.ti,kf.	0
45	venoglobulin.ti,kf.	2
46	venoglobulin.ti,kf.	2
47	HyQvia.ti,kf.	1
48	Octagam.ti,kf.	11
49	Hizentra.ti,kf.	19
50	Gamunex-C.ti,kf.	1
51	Gammaked.ti,kf.	0
52	or/33-51	96
53	13 or 18 or 26 or 31 or 32 or 52	32926
54	4 and 53	154
55	limit 54 to systematic reviews	4
56	randomized controlled trial.pt.	485029
57	controlled clinical trial.pt.	93147
58	randomized.ti,ab.	483633
59	placebo.ti,ab.	204512
60	clinical trials as topic/	187556



61	randomly.ti,ab.	315017
62	trial?.ti.	268870
63	56 or 57 or 58 or 59 or 60 or 61 or 62	1257121
64	exp animal/ not humans/	4596228
65	63 not 64	1157131
66	54 and 65	10
Comments	Line 55 exported for SR Line 66 exported for RCT	

1.3.4 Guillain-Barre

Date	25/03/2019 16:33:30	
Database	Cochrane@Wiley.com	
Search strategy		
#1	[mh ^"Immunoglobulins, intravenous"]	766
#2	IVIG:ti,kw	228
#3	scig:ti,kw	10
#4	intraglobin*:ti,kw	2
#5	(intravenous NEAR/5 antibod*):ti,kw	207
#6	(intravenous NEAR/5 immunoglob*):ti,kw	1331
#7	(subcutaneous NEAR/5 antibod*):ti,kw	153
#8	(subcutaneous NEAR/5 immunoglob*):ti,kw	101
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	1781
#10	[mh "Immunoglobulins"]	21834
#11	[mh "Administration, Intravenous"]	17766
#12	[mh "Injections, Subcutaneous"]	4209
#13	#11 OR #12	21482
#14	#10 AND #13	1453
#15	intravenous:ti,kw	48965



#16	subcutaneous:ti,kw	11559
#17	intradermal:ti,kw	1526
#18	iv:ti,kw	20229
#19	inject*:ti,kw	41687
#20	perfus*:ti,kw	4808
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	96631
#22	#10 AND #21	4605
#23	immunoglob*:ti,kw	10917
#24	immune glob*:ti,kw	569
#25	Ig:ti,kw	1965
#26	#23 OR #24 OR #25	12080
#27	#21 AND #26	2878
#28	#13 AND #26	498
#29	alphaglobin:ti,kw	0
#30	endobulin:ti,kw	0
#31	flebogamma:ti,kw	2
#32	gamimmune:ti,kw	0
#33	gammagard:ti,kw	9
#34	gammonativ:ti,kw	0
#35	gamunex:ti,kw	6
#36	globulin n:ti,kw	20
#37	iveegam:ti,kw	0
#38	privigen:ti,kw	1
#39	sandoglobulin:ti,kw	6
#40	venimmune:ti,kw	0
#41	venoglobulin:ti,kw	4
#42	HyQvia:ti,kw	3
#43	Octagam:ti,kw	9



#44	Hizentra:ti,kw	2
#45	Gamunex-C:ti,kw	1
#46	Gammaked:ti,kw	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	59
#48	#9 or #14 or #22 or #27 or #28 or #47	6044
#49	#48 with Cochrane Library publication date Between Jan 2008 and Jan 2019	4148
#50	[mh "Guillain-Barre Syndrome"]	52
#51	acute autoimmune neuropath*:ab,ti,kw	23
#52	(acute NEAR/3 infectious polyneuritis):ab,ti,kw	0
#53	acute inflammatory demyelinating polyneuropath*:ab,ti,kw	16
#54	acute inflammatory demyelinating polyradiculoneuropath*:ab,ti,kw	9
#55	acute inflammatory polyneuropath*:ab,ti,kw	24
#56	acute inflammatory polyradiculoneuropath*:ab,ti,kw	15
#57	landry-guillain-barre syndrome:ab,ti,kw	0
#58	"fisher syndrome":ab,ti,kw	3
#59	"miller fisher variant":ab,ti,kw	0
#60	miller-fisher syndrome:ab,ti,kw	3
#61	"ophthalmoplegia, ataxia and areflexia syndrome":ab,ti,kw	0
#62	acute febrile polyneuritis:ab,ti,kw	0
#63	acute postinfective polyradiculoneuropath*:ab,ti,kw	0
#64	infectious neuronitis:ab,ti,kw	0
#65	inflammatory acute polyradiculoneuropath*:ab,ti,kw	15
#66	Landry paralysis:ab,ti,kw	0
#67	Landry syndrome:ab,ti,kw	12
#68	guillain-barr*:ab,ti,kw	224
#69	guilllaine-barr*:ab,ti,kw	0
#70	guillian-barr*:ab,ti,kw	5



#71	guilian-barre:ab,ti,kw	0
#72	#51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #70 OR #71	280
#73	#50 OR #72	280
#74	#49 AND #73	40
Comments	7 results for Cochrane Systematic Reviews Database 33 Results for CENTRAL	

Date	21 Mar 2019	
Database	Embase.com	
Search strategy		
#1	(intravenous:ab,ti,kw OR subcutaneous:ab,ti,kw) AND (immunoglob*:ab,ti,kw OR antibod*:ab,ti,kw)	
#2	ivig:ab,ti,kw OR scig:ab,ti,kw	15456
#3	intraglobin*:ab,ti,kw	34
#4	#1 OR #2 OR #3	56350
#5	'subcutaneous immunotherapy'/exp	1561
#6	#4 OR #5	57737
#7	'immunoglobulin'/exp	476978
#8	'intravenous drug administration'/exp	377709
#9	'subcutaneous drug administration'/exp	97741
#10	#8 OR #9	458852
#11	#7 AND #10	12058
#12	intravenous:ab,ti,kw	362573
#13	subcutaneous:ab,ti,kw	170606
#14	intradermal:ab,ti,kw	18470
#15	iv:ab,ti,kw	473297



#16	inject*:ab,ti,kw	922451
#17	perfus*:ab,ti,kw	270086
#18	#12 OR #13 OR #14 OR #15 OR #16 OR #17	1975978
#19	#7 AND #18	56464
#20	immunoglob*:ab,ti,kw	186399
#21	immune AND glob*:ab,ti,kw	31566
#22	ig:ab,ti,kw	46805
#23	#20 OR #21 OR #22	242261
#24	#18 AND #23	40698
#25	#10 AND #23	6050
#26	alphaglobin:ab,ti,kw,tn	11
#27	endobulin:ab,ti,kw,tn	292
#28	flebogamma:ab,ti,kw,tn	277
#29	gamimmune:ab,ti,tn	50
#30	gammagard:ab,ti,tn	760
#31	gammonativ:ab,ti,tn	64
#32	gamunex:ab,ti,tn	318
#33	globulin AND n:ab,ti,tn	6058
#34	iveegam:ab,ti,tn	115
#35	privigen:ab,ti,kw,tn	343
#36	sandoglobulin:ab,ti,kw,tn	1202
#37	venimmune:ab,ti,kw,tn	2
#38	venoglobulin:ab,ti,kw,tn	263
#39	venoglobulin:ab,ti,kw,tn	263
#40	hyqvia:ab,ti,kw,tn	49
#41	octagam:ab,ti,kw,tn	392
#42	hizentra:ab,ti,kw,tn	253
#43	'gamunex c':ab,ti,kw,tn	45



#44	gammaked:ab,ti,kw,tn	13
#45	#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44	9130
#46	#6 OR #11 OR #19 OR #24 OR #25 OR #45	106990
#47	#46 NOT [medline]/lim	43232
#48	#47 AND [2008-2019]/py	38013
#49	#48 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	6323
#50	'guillain barre syndrome':de	13985
#51	'acute autoimmune neuropathy':ab,ti,kw	5
#52	'acute autoimmune neuropathies':ab,ti,kw	6
#53	'acute infectious polyneuritis':ab,ti,kw	13
#54	'acute inflammatory demyelinating polyneuropathy':ab,ti,kw	535
#55	'acute inflammatory demyelinating polyneuropathies':ab,ti,kw	6
#56	'acute inflammatory demyelinating polyradiculoneuropathy':ab,ti,kw	272
#57	'acute inflammatory demyelinating polyradiculoneuropathies':ab,ti,kw	3
#58	'acute inflammatory polyneuropathy':ab,ti,kw	60
#59	'acute inflammatory polyneuropathies':ab,ti,kw	4
#60	'acute inflammatory polyradiculoneuropathy':ab,ti,kw	49
#61	'acute inflammatory polyradiculoneuropathies':ab,ti,kw	4
#62	'landry-guillain-barre syndrome':ab,ti,kw	134
#63	'fisher syndrome':ab,ti,kw	1321
#64	'miller fisher variant':ab,ti,kw	61
#65	'miller-fisher syndrome':ab,ti,kw	1013
#66	'ophthalmoplegia, ataxia and areflexia syndrome':ab,ti,kw	1
#67	'acute febrile polyneuritis':ab,ti,kw	4
#68	'acute postinfective polyradiculoneuropathy':ab,ti,kw	0
#69	'acute postinfective polyradiculoneuropathies':ab,ti,kw	0
#70	'infectious neuronitis':ab,ti,kw	8



#71	'inflammatory acute polyradiculoneuropathy':ab,ti,kw	1
#72	'inflammatory acute polyradiculoneuropathies':ab,ti,kw	0
#73	'landry paralysis':ab,ti,kw	8
#74	'landry syndrome':ab,ti,kw	10
#75	'guillain* barre':ab,ti,kw	11974
#76	'guilain* barre':ab,ti,kw	15
#77	'guillian? barre':ab,ti,kw	1
#78	'guilian? barre':ab,ti,kw	0
#79	#51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78	12826
#80	#50 OR #79	17822
#81	#49 AND #80	269
#82	#81 AND ('meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review')	5
#83	#81 AND (random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti))	20
#84	#81 NOT (#82 OR #83)	248
Comments	Line 82 exported for SR Line 83 exported for RCT Line 84 exported for All studies except SR or RCT	

Date	March 19, 2019	
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to March 19, 2019>	
Search strategy		
1	Immunoglobulins, intravenous/	12364
2	IVIG.ti,kf.	1118
3	scig.ti,kf.	48
4	intraglobin*.ti,kf.	3



5	(intravenous and antibod*).ti,kf.	796
6	(intravenous and immunoglob*).ti,kf.	5207
7	(subcutaneous and antibod*).ti,kf.	330
8	(subcutaneous and immunoglob*).ti,kf.	309
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8	14721
10	exp Immunoglobulins/	850448
11	exp Administration, Intravenous/	138819
12	exp Injections, Subcutaneous/	39116
13	11 or 12	173669
14	10 and 13	11509
15	intravenous.ti,kf.	68039
16	subcutaneous.ti,kf.	25500
17	intradermal.ti,kf.	3873
18	iv.ti,kf.	53903
19	inject*.ti,kf.	108935
20	perfus*.ti,kf.	58848
21	15 or 16 or 17 or 18 or 19 or 20	306925
22	10 and 21	15184
23	immunoglob*.ti,kf.	48900
24	immune glob*.ti,kf.	1530
25	Ig.ti,kf.	3676
26	23 or 24 or 25	53663
27	21 and 26	6410
28	13 and 26	1187
29	alphaglobin.ti,kf.	1
30	endobulin.ti,kf.	2
31	flebogamma.ti,kf.	13
32	gamimmune.ti,kf.	0



33	gammagard.ti,kf.	12
34	gammonativ.ti,kf.	0
35	gamunex.ti,kf.	5
36	globulin n.ti,kf.	3
37	iveegam.ti,kf.	0
38	privigen.ti,kf.	17
39	sandoglobulin.ti,kf.	16
40	venimmune.ti,kf.	0
41	venoglobulin.ti,kf.	2
42	venoglobulin.ti,kf.	2
43	HyQvia.ti,kf.	1
44	Octagam.ti,kf.	10
45	Hizentra.ti,kf.	19
46	Gamunex-C.ti,kf.	1
47	Gammaked.ti,kf.	0
48	or/29-47	95
49	9 or 14 or 22 or 27 or 28 or 48	32413
50	limit 49 to yr="2008-current"	12898
51	exp Guillain-Barre Syndrome/	4685
52	acute autoimmune neuropath*.ab,ti,kf.	7
53	acute infectious polyneuritis.ab,ti,kf.	10
54	acute inflammatory demyelinating polyneuropath*.ab,ti,kf.	301
55	acute inflammatory demyelinating polyradiculoneuropath*.ab,ti,kf.	177
56	acute inflammatory polyneuropath*.ab,ti,kf.	48
57	acute inflammatory polyradiculoneuropath*.ab,ti,kf.	30
58	landry-guillain-barre syndrome.ab,ti,kf.	126
59	fisher syndrome.ab,ti,kf.	911
60	miller fisher variant.ab,ti,kf.	36



61	miller-fisher syndrome.ab,ti,kf.	696
62	"ophthalmoplegia, ataxia and areflexia syndrome".ab,ti,kf.	4
63	acute febrile polyneuritis.ab,ti,kf.	4
64	acute postinfective polyradiculoneuropath*.ab,ti,kf.	0
65	infectious neuronitis.ab,ti,kf.	9
66	inflammatory acute polyradiculoneuropath*.ab,ti,kf.	0
67	Landry paralysis.ab,ti,kf.	6
68	Landry syndrome.ab,ti,kf.	9
69	guillain?-barre.ab,ti,kf.	8763
70	52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69	9361
71	51 or 70	10055
72	50 and 71	447
73	limit 72 to systematic reviews	25
74	randomized controlled trial.pt.	478099
75	controlled clinical trial.pt.	92974
76	randomized.ti,ab.	472128
77	placebo.ti,ab.	201616
78	clinical trials as topic/	186320
79	randomly.ti,ab.	308370
80	trial?.ti.	261936
81	74 or 75 or 76 or 77 or 78 or 79 or 80	1235412
82	exp animal/ not humans/	4558766
83	81 not 82	1137167
84	72 and 83	46
85	72 not (73 or 84)	391
86	85 not 82	389
87	remove duplicates from 86	389



Comments Line 73 exported for SR
Line 84 exported for RCT
Line 87 exported for All studies except SR or RCT



1.3.5 *Idiopathic thrombocytopenic purpura*

Date	25/03/2019 17:27:05
Database	Cochrane@Wiley.com
Search strategy	
#1	[mh ^"Immunoglobulins, intravenous"]
#2	IVIG:ti,kw
#3	scig:ti,kw
#4	intraglobin*:ti,kw
#5	(intravenous NEAR/5 antibod*):ti,kw
#6	(intravenous NEAR/5 immunoglob*):ti,kw
#7	(subcutaneous NEAR/5 antibod*):ti,kw
#8	(subcutaneous NEAR/5 immunoglob*):ti,kw
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10	[mh "Immunoglobulins"]
#11	[mh "Administration, Intravenous"]
#12	[mh "Injections, Subcutaneous"]
#13	#11 OR #12
#14	#10 AND #13
#15	intravenous:ti,kw
#16	subcutaneous:ti,kw
#17	intradermal:ti,kw
#18	iv:ti,kw
#19	inject*:ti,kw
#20	perfus*:ti,kw
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20
#22	#10 AND #21
#23	immunoglob*:ti,kw



#24	immune glob*:ti,kw	569
#25	Ig:ti,kw	1965
#26	#23 OR #24 OR #25	12080
#27	#21 AND #26	2878
#28	#13 AND #26	498
#29	alphaglobin:ti,kw	0
#30	endobulin:ti,kw	0
#31	flebogamma:ti,kw	2
#32	gamimmune:ti,kw	0
#33	gammagard:ti,kw	9
#34	gammonativ:ti,kw	0
#35	gamunex:ti,kw	6
#36	globulin n:ti,kw	20
#37	iveegam:ti,kw	0
#38	privigen:ti,kw	1
#39	sandoglobulin:ti,kw	6
#40	venimmune:ti,kw	0
#41	venoglobulin:ti,kw	4
#42	HyQvia:ti,kw	3
#43	Octagam:ti,kw	9
#44	Hizentra:ti,kw	2
#45	Gamunex-C:ti,kw	1
#46	Gammaked:ti,kw	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	59
#48	#9 or #14 or #22 or #27 or #28 or #47	6044
#49	#48 with Cochrane Library publication date Between Jan 2008 and Jan 2019	4148
#50	[mh ^"Purpura, Thrombocytopenic, Idiopathic"]	227



#51	idiopathic thrombocytopenic purpura:ab,ti,kw	549		
#52	autoimmune thrombocytopenia:ab,ti,kw	110		
#53	autoimmune thrombocytopaenia:ab,ti,kw	0		
#54	idiopathic thrombocytopenia:ab,ti,kw NOT (idiopathic AND thrombocytopenia):ab,ti,kw	0		
#55	(idiopathic AND thrombocytopaenia):ab,ti,kw	2		
#56	(morbus NEAR/3 werlhof*):ab,ti,kw	0		
#57	(Werlhof* NEAR/3disease):ab,ti,kw	0		
#58	(immune* NEAR/3 thrombocytop?enia):ab,ti,kw	319		
#59	(immune* NEAR/3 thrombocytopenic NEAR/3 purpura):ab,ti,kw	115		
#60	#51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59	726		
#61	#50 OR #60	726		
#62	#49 AND #61	69		
Comments	Line #54 shows a typing mistake. A check done on 21st of October 2019 display 6 results for the line corrected but 0 when combined with line #48.			
1 results for Cochrane Systematic Reviews Database				
68 Results for CENTRAL				

Date	21 Mar 2019
Database	Embase.com
Search strategy	
#1	(intravenous:ab,ti,kw OR subcutaneous:ab,ti,kw) AND (immunoglob*:ab,ti,kw OR antibod*:ab,ti,kw)
#2	ivig:ab,ti,kw OR scig:ab,ti,kw
#3	intraglobin*:ab,ti,kw
#4	#1 OR #2 OR #3
#5	'subcutaneous immunotherapy'/exp
#6	#4 OR #5
#7	'immunoglobulin'/exp



#8	'intravenous drug administration'/exp	377709
#9	'subcutaneous drug administration'/exp	97741
#10	#8 OR #9	458852
#11	#7 AND #10	12058
#12	intravenous:ab,ti,kw	362573
#13	subcutaneous:ab,ti,kw	170606
#14	intradermal:ab,ti,kw	18470
#15	iv:ab,ti,kw	473297
#16	inject*:ab,ti,kw	922451
#17	perfus*:ab,ti,kw	270086
#18	#12 OR #13 OR #14 OR #15 OR #16 OR #17	1975978
#19	#7 AND #18	56464
#20	immunoglob*:ab,ti,kw	186399
#21	immune AND glob*:ab,ti,kw	31566
#22	ig:ab,ti,kw	46805
#23	#20 OR #21 OR #22	242261
#24	#18 AND #23	40698
#25	#10 AND #23	6050
#26	alphaglobin:ab,ti,kw,tn	11
#27	endobulin:ab,ti,kw,tn	292
#28	flebogamma:ab,ti,kw,tn	277
#29	gamimmune:ab,ti,tn	50
#30	gammagard:ab,ti,tn	760
#31	gammonativ:ab,ti,tn	64
#32	gamunex:ab,ti,tn	318
#33	globulin AND n:ab,ti,tn	6058
#34	iveegam:ab,ti,tn	115
#35	privigen:ab,ti,kw,tn	343



#36	sandoglobulin:ab,ti,kw,tn	1202
#37	venimmune:ab,ti,kw,tn	2
#38	venoglobulin:ab,ti,kw,tn	263
#39	venoglobulin:ab,ti,kw,tn	263
#40	hyqvia:ab,ti,kw,tn	49
#41	octagam:ab,ti,kw,tn	392
#42	hizentra:ab,ti,kw,tn	253
#43	'gamunex c':ab,ti,kw,tn	45
#44	gammaked:ab,ti,kw,tn	13
#45	#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44	9130
#46	#6 OR #11 OR #19 OR #24 OR #25 OR #45	106990
#47	#46 NOT [medline]/lim	43232
#48	#47 AND [2008-2019]/py	38013
#49	#48 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	6323
#50	'idiopathic thrombocytopenic purpura'/exp	14611
#51	'idiopathic thrombocytopenic purpura':ab,ti,kw	5570
#52	'autoimmune thrombocytopenia':ab,ti,kw	1000
#53	'autoimmune thrombocytopenia':ab,ti,kw	14
#54	'idiopathic thrombocytopenia':ab,ti,kw	666
#55	'idiopathic thrombocytopenia':ab,ti,kw	10
#56	(werlhof* NEAR/3 disease):ab,ti,kw	273
#57	(werlhof* NEAR/3 morbus):ab,ti,kw	7
#58	(immune* NEAR/3 thrombocytopenia):ab,ti,kw	6008
#59	(immune* NEAR/3 thrombocytopenia):ab,ti,kw	68
#60	(immune* NEAR/3 'thrombocytopenic purpura'):ab,ti,kw	2990
#61	#51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60	15227



#62	#50 OR #61	19778
#63	#49 AND #62	203
#64	#63 AND ('meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review')	5
#65	#63 AND (random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti))	25
#66	#63 NOT (#64 OR #65)	176
Comments	Line 64 exported for SR Line 65 exported for RCT Line 66 exported for All studies except SR or RCT	

Date	March 19, 2019	
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to March 19, 2019>	
Search strategy		
1	Immunoglobulins, intravenous/	12364
2	IVIG.ti,kf.	1118
3	scig.ti,kf.	48
4	intraglobin*.ti,kf.	3
5	(intravenous and antibod*).ti,kf.	796
6	(intravenous and immunoglob*).ti,kf.	5207
7	(subcutaneous and antibod*).ti,kf.	330
8	(subcutaneous and immunoglob*).ti,kf.	309
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8	14721
10	exp Immunoglobulins/	850448
11	exp Administration, Intravenous/	138819
12	exp Injections, Subcutaneous/	39116
13	11 or 12	173669
14	10 and 13	11509



15	intravenous.ti,kf.	68039
16	subcutaneous.ti,kf.	25500
17	intradermal.ti,kf.	3873
18	iv.ti,kf.	53903
19	inject*.ti,kf.	108935
20	perfus*.ti,kf.	58848
21	15 or 16 or 17 or 18 or 19 or 20	306925
22	10 and 21	15184
23	immunoglob*.ti,kf.	48900
24	immune glob*.ti,kf.	1530
25	Ig.ti,kf.	3676
26	23 or 24 or 25	53663
27	21 and 26	6410
28	13 and 26	1187
29	alphaglobin.ti,kf.	1
30	endobulin.ti,kf.	2
31	flebogamma.ti,kf.	13
32	gamimmune.ti,kf.	0
33	gammagard.ti,kf.	12
34	gammonativ.ti,kf.	0
35	gamunex.ti,kf.	5
36	globulin n.ti,kf.	3
37	iveegam.ti,kf.	0
38	privigen.ti,kf.	17
39	sandoglobulin.ti,kf.	16
40	venimmune.ti,kf.	0
41	venoglobulin.ti,kf.	2
42	venoglobulin.ti,kf.	2



43	HyQvia.ti,kf.	1
44	Octagam.ti,kf.	10
45	Hizentra.ti,kf.	19
46	Gamunex-C.ti,kf.	1
47	Gammaked.ti,kf.	0
48	or/29-47	95
49	9 or 14 or 22 or 27 or 28 or 48	32413
50	limit 49 to yr="2008-current"	12898
51	Purpura, Thrombocytopenic, Idiopathic/	5939
52	idiopathic thrombocytopenic purpura.ab,ti,kf.	4348
53	autoimmune thrombocytop?enia.ab,ti,kf.	705
54	idiopathic thrombocytop?enia.ab,ti,kf.	442
55	morbus werlhof.ab,ti,kf.	2
56	Werlhof disease.ab,ti,kf.	16
57	Werlhof's disease.ab,ti,kf.	226
58	Werlhofs disease.ab,ti,kf.	226
59	immune* thrombocytop?enia.ab,ti,kf.	3069
60	immune* thrombocytopenic purpura.ab,ti,kf.	1960
61	52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60	10059
62	51 or 61	11298
63	50 and 62	439
64	limit 63 to systematic reviews	21
65	randomized controlled trial.pt.	478099
66	controlled clinical trial.pt.	92974
67	randomized.ti,ab.	472128
68	placebo.ti,ab.	201616
69	clinical trials as topic/	186320
70	randomly.ti,ab.	308370



71	trial?.ti.	261936
72	65 or 66 or 67 or 68 or 69 or 70 or 71	1235412
73	exp animal/ not humans/	4558766
74	72 not 73	1137167
75	63 and 74	38
76	63 not (64 or 75 or 73)	369
Comments	Line 64 exported for SR Line 75 exported for RCT Line 76 exported for All studies except SR or RCT	

1.3.6 Kawasaki disease

Date	06/06/2019 17:38:44	
Database	Cochrane@Wiley.com	
Search strategy		
#1	[mh ^"Immunoglobulins, intravenous"]	774
#2	IVIG:ti,kw	277
#3	scig:ti,kw	10
#4	intraglobin*:ti,kw	2
#5	(intravenous NEAR/5 antibod*):ti,kw	205
#6	(intravenous NEAR/5 immunoglob*):ti,kw	1477
#7	(subcutaneous NEAR/5 antibod*):ti,kw	151
#8	(subcutaneous NEAR/5 immunoglob*):ti,kw	113
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	1966
#10	[mh "Immunoglobulins"]	22270
#11	[mh "Administration, Intravenous"]	17927
#12	[mh "Injections, Subcutaneous"]	4249
#13	#11 OR #12	21680
#14	#10 AND #13	1477



#15	intravenous:ti,kw	52740
#16	subcutaneous:ti,kw	12668
#17	intradermal:ti,kw	1676
#18	iv:ti,kw	21245
#19	inject*:ti,kw	46398
#20	perfus*:ti,kw	5460
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	107359
#22	#10 AND #21	4682
#23	immunoglob*:ti,kw	11349
#24	immune glob*:ti,kw	632
#25	Ig:ti,kw	2183
#26	#23 OR #24 OR #25	12731
#27	#21 AND #26	3090
#28	#13 AND #26	501
#29	alphaglobin:ti,kw	0
#30	endobulin:ti,kw	0
#31	flebogamma:ti,kw	4
#32	gamimmune:ti,kw	0
#33	gammagard:ti,kw	9
#34	gammonativ:ti,kw	0
#35	gamunex:ti,kw	7
#36	globulin n:ti,kw	20
#37	iveegam:ti,kw	0
#38	privigen:ti,kw	1
#39	sandoglobulin:ti,kw	6
#40	venimmune:ti,kw	0
#41	venoglobulin:ti,kw	4
#42	HyQvia:ti,kw	4



#43	Octagam:ti,kw	14
#44	Hizentra:ti,kw	5
#45	Gamunex-C:ti,kw	2
#46	Gammaked:ti,kw	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	71
#48	#9 or #14 or #22 or #27 or #28 or #47	6353
#49	[mh ^"Mucocutaneous Lymph Node Syndrome"]	94
#50	(kawasaki NEAR/3 disease):ab,ti,kw	253
#51	(kawasaki NEAR/3 syndrome*):ab,ti,kw	20
#52	mucocutaneous NEAR/3 "lymph node" NEAR/3 syndrome*:ab,ti,kw	181
#53	acute inflammatory demyelinating polyradiculoneuropath*:ab,ti,kw	13
#54	mucocutaneous lymphnode syndrome*:ab,ti,kw	1
#55	viral NEAR/3 mucocutaneous lymphadenopath*:ab,ti,kw	0
#56	"kawasaki's disease":ab,ti,kw	252
#57	#50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56	295
#58	#49 OR #57	295
#59	#48 AND #58	123
#60	#59 with Cochrane Library publication date Between Jan 2003 and Dec 2019	101
Comments	5 results for Cochrane Systematic Reviews Database 96 Results for CENTRAL	

Date	4 Jun 2019
Database	Embase.com
Search strategy	
#1	(intravenous:ab,ti,kw OR subcutaneous:ab,ti,kw) AND (immunoglob*:ab,ti,kw OR antibody*:ab,ti,kw)
#2	ivig:ab,ti,kw OR scig:ab,ti,kw



#3	intraglobin*:ab,ti,kw	34
#4	#1 OR #2 OR #3	57198
#5	'subcutaneous immunotherapy'/exp	1589
#6	#4 OR #5	58611
#7	'immunoglobulin'/exp	481978
#8	'intravenous drug administration'/exp	378380
#9	'subcutaneous drug administration'/exp	97772
#10	#8 OR #9	459551
#11	#7 AND #10	12073
#12	intravenous:ab,ti,kw	366357
#13	subcutaneous:ab,ti,kw	172857
#14	intradermal:ab,ti,kw	18679
#15	iv:ab,ti,kw	479944
#16	inject*:ab,ti,kw	932450
#17	perfus*:ab,ti,kw	272844
#18	#12 OR #13 OR #14 OR #15 OR #16 OR #17	1999076
#19	#7 AND #18	57193
#20	immunoglob*:ab,ti,kw	188171
#21	immune AND glob*:ab,ti,kw	32245
#22	ig:ab,ti,kw	47228
#23	#20 OR #21 OR #22	244959
#24	#18 AND #23	41243
#25	#10 AND #23	6058
#26	alphaglobin:ab,ti,kw,tn	12
#27	endobulin:ab,ti,kw,tn	293
#28	flebogamma:ab,ti,kw,tn	278
#29	gamimmune:ab,ti,tn	50
#30	gammagard:ab,ti,tn	762



#31	gammonativ:ab,ti,tn	64
#32	gamunex:ab,ti,tn	319
#33	globulin AND n:ab,ti,tn	6142
#34	iveegam:ab,ti,tn	115
#35	privigen:ab,ti,kw,tn	344
#36	sandoglobulin:ab,ti,kw,tn	1203
#37	venimmune:ab,ti,kw,tn	2
#38	venoglobulin:ab,ti,kw,tn	263
#39	venoglobulin:ab,ti,kw,tn	263
#40	hyqvia:ab,ti,kw,tn	51
#41	octagam:ab,ti,kw,tn	395
#42	hizentra:ab,ti,kw,tn	259
#43	'gamunex c':ab,ti,kw,tn	46
#44	gammaked:ab,ti,kw,tn	13
#45	#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44	9231
#46	#6 OR #11 OR #19 OR #24 OR #25 OR #45	108324
#47	#46 NOT [medline]/lim	43664
#48	'mucocutaneous lymph node syndrome':exp	10673
#49	'kawasaki disease':ab,ti,kw	8006
#50	'kawasaki* disease':ab,ti,kw	8009
#51	'kawasaki syndrome*':ab,ti,kw	656
#52	'mucocutaneous lymph node syndrome*':ab,ti,kw	696
#53	'mucocutaneous lymphnode syndrome*':ab,ti,kw	22
#54	'viral mucocutaneous lymphadenopath*':ab,ti,kw	0
#55	#49 OR #50 OR #51 OR #52 OR #53 OR #54	8829
#56	#48 OR #55	11144
#57	#47 AND #56	1269



#58	#57 AND [2003-2019]/py	1117
#59	#58 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	374
#60	#59 AND ('meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review')	13
#61	#59 AND (random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti))	22
#62	#59 NOT (#60 OR #61)	343
Comments	Line 60 exported for SR Line 61 exported for RCT Line 62 exported for All studies except SR or RCT	

Date	June 04, 2019	
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to June 04, 2019>	
Search strategy		
1	Immunoglobulins, intravenous/	12520
2	IVIG.ti,kf.	1160
3	scig.ti,kf.	54
4	intraglobin*.ti,kf.	3
5	(intravenous and antibod*).ti,kf.	810
6	(intravenous and immunoglob*).ti,kf.	5313
7	(subcutaneous and antibod*).ti,kf.	332
8	(subcutaneous and immunoglob*).ti,kf.	327
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8	14970



10	exp Immunoglobulins/	856497
11	exp Administration, Intravenous/	139488
12	exp Injections, Subcutaneous/	39311
13	11 or 12	174519
14	10 and 13	11602
15	intravenous.ti,kf.	68752
16	subcutaneous.ti,kf.	25984
17	intradermal.ti,kf.	3922
18	iv.ti,kf.	54371
19	inject*.ti,kf.	110423
20	perfus*.ti,kf.	59463
21	15 or 16 or 17 or 18 or 19 or 20	310629
22	10 and 21	15316
23	immunoglob*.ti,kf.	49346
24	immune glob*.ti,kf.	1533
25	Ig.ti,kf.	3702
26	23 or 24 or 25	54136
27	21 and 26	6532
28	13 and 26	1196
29	alphaglobin.ti,kf.	1
30	endobulin.ti,kf.	2
31	flebogamma.ti,kf.	13
32	gamimmune.ti,kf.	0
33	gammagard.ti,kf.	12
34	gammonativ.ti,kf.	0
35	gamunex.ti,kf.	5
36	globulin n.ti,kf.	3
37	iveegam.ti,kf.	0



38	privigen.ti,kf.	17
39	sandoglobulin.ti,kf.	16
40	venimmune.ti,kf.	0
41	venoglobulin.ti,kf.	2
42	venoglobulin.ti,kf.	2
43	HyQvia.ti,kf.	1
44	Octagam.ti,kf.	11
45	Hizentra.ti,kf.	19
46	Gamunex-C.ti,kf.	1
47	Gammaked.ti,kf.	0
48	or/29-47	96
49	9 or 14 or 22 or 27 or 28 or 48	32801
50	Mucocutaneous Lymph Node Syndrome/	5709
51	kawasaki disease.ab,ti,kf.	5708
52	kawasaki syndrome?.ab,ti,kf.	523
53	mucocutaneous lymph node syndrome?.ab,ti,kf.	496
54	mucocutaneous lymphnode syndrome?.ab,ti,kf.	12
55	viral mucocutaneous lymphadenopath*.ab,ti,kf.	0
56	kawasaki's disease.ab,ti,kf.	266
57	51 or 52 or 53 or 54 or 55 or 56	6591
58	50 or 57	7079
59	49 and 58	1295
60	limit 59 to yr="2003-Current"	974
61	limit 60 to systematic reviews	34
62	randomized controlled trial.pt.	483223
63	controlled clinical trial.pt.	93097
64	randomized.ti,ab.	480314
65	placebo.ti,ab.	203697



66	clinical trials as topic/	187199
67	randomly.ti,ab.	312995
68	trial?.ti.	266881
69	62 or 63 or 64 or 65 or 66 or 67 or 68	1250811
70	exp animal/ not humans/	4586077
71	69 not 70	1151222
72	60 and 71	81
73	60 not (61 or 72)	867
Comments	Line 61 exported for SR Line 72 exported for RCT Line 73 exported for All studies except SR or RCT	



1.3.7 Multifocal Motor Neuropathy

Date	06/06/2019 18:08:48	
Database	Cochrane@Wiley.com	
Search strategy		
#1	[mh ^"Immunoglobulins, intravenous"]	774
#2	IVIG:ti,kw	277
#3	scig:ti,kw	10
#4	intraglobin*:ti,kw	2
#5	(intravenous NEAR/5 antibod*):ti,kw	205
#6	(intravenous NEAR/5 immunoglob*):ti,kw	1477
#7	(subcutaneous NEAR/5 antibod*):ti,kw	151
#8	(subcutaneous NEAR/5 immunoglob*):ti,kw	113
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	1966
#10	[mh "Immunoglobulins"]	22270
#11	[mh "Administration, Intravenous"]	17927
#12	[mh "Injections, Subcutaneous"]	4249
#13	#11 OR #12	21680
#14	#10 AND #13	1477
#15	intravenous:ti,kw	52740
#16	subcutaneous:ti,kw	12668
#17	intradermal:ti,kw	1676
#18	iv:ti,kw	21245
#19	inject*:ti,kw	46398
#20	perfus*:ti,kw	5460
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	107359
#22	#10 AND #21	4682
#23	immunoglob*:ti,kw	11349



#24	immune glob*:ti,kw	632
#25	Ig:ti,kw	2183
#26	#23 OR #24 OR #25	12731
#27	#21 AND #26	3090
#28	#13 AND #26	501
#29	alphaglobin:ti,kw	0
#30	endobulin:ti,kw	0
#31	flebogamma:ti,kw	4
#32	gamimmune:ti,kw	0
#33	gammagard:ti,kw	9
#34	gammonativ:ti,kw	0
#35	gamunex:ti,kw	7
#36	globulin n:ti,kw	20
#37	iveegam:ti,kw	0
#38	privigen:ti,kw	1
#39	sandoglobulin:ti,kw	6
#40	venimmune:ti,kw	0
#41	venoglobulin:ti,kw	4
#42	HyQvia:ti,kw	4
#43	Octagam:ti,kw	14
#44	Hizentra:ti,kw	5
#45	Gamunex-C:ti,kw	2
#46	Gammaked:ti,kw	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	71
#48	#9 or #14 or #22 or #27 or #28 or #47	6353
#49	multifocal motor neuropath*:ab,ti,kw	74
#50	conduction block*:ab,ti,kw	1196



#51	motor neuropath*:ab,ti,kw	1241
#52	#50 OR #51	2403
#53	multifocal:ab,ti,kw	1411
#54	#52 AND #53	67
#55	#49 OR #54	76
#56	#48 AND #55	44
#57	#56	44
#58	#49 OR #57	74
#59	#48 AND #58	44
#60	#59 with Cochrane Library publication date Between Jan 2007 and Dec 2019	38
Comments	4 results for Cochrane Systematic Reviews Database 34 Results for CENTRAL	

Date	18 Jun 2019	
Database	Embase.com	
Search strategy		
#1	(intravenous:ab,ti,kw OR subcutaneous:ab,ti,kw) AND (immunoglob*:ab,ti,kw OR 50953 antibod*:ab,ti,kw)	
#2	ivig:ab,ti,kw OR scig:ab,ti,kw	15813
#3	intraglobin*:ab,ti,kw	34
#4	#1 OR #2 OR #3	57334
#5	'subcutaneous immunotherapy'/exp	1593
#6	#4 OR #5	58750
#7	'immunoglobulin'/exp	482898
#8	'intravenous drug administration'/exp	378534
#9	'subcutaneous drug administration'/exp	97775
#10	#8 OR #9	459708
#11	#7 AND #10	12080



#12	intravenous:ab,ti,kw	367100
#13	subcutaneous:ab,ti,kw	173284
#14	intradermal:ab,ti,kw	18703
#15	iv:ab,ti,kw	481049
#16	inject*:ab,ti,kw	934282
#17	perfus*:ab,ti,kw	273201
#18	#12 OR #13 OR #14 OR #15 OR #16 OR #17	2003091
#19	#7 AND #18	57332
#20	immunoglob*:ab,ti,kw	188513
#21	immune AND glob*:ab,ti,kw	32370
#22	ig:ab,ti,kw	47305
#23	#20 OR #21 OR #22	245467
#24	#18 AND #23	41339
#25	#10 AND #23	6063
#26	alphaglobin:ab,ti,kw,tn	12
#27	endobulin:ab,ti,kw,tn	293
#28	flebogamma:ab,ti,kw,tn	278
#29	gamimmune:ab,ti,tn	50
#30	gammagard:ab,ti,tn	762
#31	gammonativ:ab,ti,tn	64
#32	gamunex:ab,ti,tn	319
#33	globulin AND n:ab,ti,tn	6152
#34	iveegam:ab,ti,tn	115
#35	privigen:ab,ti,kw,tn	344
#36	sandoglobulin:ab,ti,kw,tn	1203
#37	venimmune:ab,ti,kw,tn	2
#38	venoglobulin:ab,ti,kw,tn	263
#39	venoglobulin:ab,ti,kw,tn	263



#40	hyqvia:ab,ti,kw,tn	51
#41	octagam:ab,ti,kw,tn	397
#42	hizentra:ab,ti,kw,tn	259
#43	'gamunex c':ab,ti,kw,tn	46
#44	gammaked:ab,ti,kw,tn	13
#45	#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44	9243
#46	#6 OR #11 OR #19 OR #24 OR #25 OR #45	108560
#47	#46 NOT [medline]/lim	43765
#48	#47 AND [2007-2019]/py	38793
#49	#48 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	6348
#50	(conduction NEAR/2 block*):ab,ti,kw	6992
#51	(motor NEAR/2 neuropath*):ab,ti,kw	5372
#52	#50 OR #51	11610
#53	multifocal:ab,ti,kw	41691
#54	#52 AND #53	1560
#55	#49 AND #54	42
#56	#55 AND ('meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review')	1
#57	#55 AND (random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti))	8
#58	#55 NOT (#56 OR #57)	33
Comments	Line 56 exported for SR Line 57 exported for RCT Line 58 exported for All studies except SR or RCT	

Date	June 04, 2019
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to June 04, 2019>

**Search strategy**

1	Immunoglobulins, intravenous/	12520
2	IVIG.ti,kf.	1160
3	scig.ti,kf.	54
4	intraglobin*.ti,kf.	3
5	(intravenous and antibod*).ti,kf.	810
6	(intravenous and immunoglob*).ti,kf.	5313
7	(subcutaneous and antibod*).ti,kf.	332
8	(subcutaneous and immunoglob*).ti,kf.	327
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8	14970
10	exp Immunoglobulins/	856497
11	exp Administration, Intravenous/	139488
12	exp Injections, Subcutaneous/	39311
13	11 or 12	174519
14	10 and 13	11602
15	intravenous.ti,kf.	68752
16	subcutaneous.ti,kf.	25984
17	intradermal.ti,kf.	3922
18	iv.ti,kf.	54371
19	inject*.ti,kf.	110423
20	perfus*.ti,kf.	59463
21	15 or 16 or 17 or 18 or 19 or 20	310629
22	10 and 21	15316
23	immunoglob*.ti,kf.	49346
24	immune glob*.ti,kf.	1533
25	Ig.ti,kf.	3702
26	23 or 24 or 25	54136
27	21 and 26	6532



28	13 and 26	1196
29	alphaglobin.ti,kf.	1
30	endobulin.ti,kf.	2
31	flebogamma.ti,kf.	13
32	gamimmune.ti,kf.	0
33	gammagard.ti,kf.	12
34	gammonativ.ti,kf.	0
35	gamunex.ti,kf.	5
36	globulin n.ti,kf.	3
37	iveegam.ti,kf.	0
38	privigen.ti,kf.	17
39	sandoglobulin.ti,kf.	16
40	venimmune.ti,kf.	0
41	venoglobulin.ti,kf.	2
42	venoglobulin.ti,kf.	2
43	HyQvia.ti,kf.	1
44	Octagam.ti,kf.	11
45	Hizentra.ti,kf.	19
46	Gamunex-C.ti,kf.	1
47	Gammaked.ti,kf.	0
48	or/29-47	96
49	9 or 14 or 22 or 27 or 28 or 48	32801
50	randomized controlled trial.pt.	483223
51	controlled clinical trial.pt.	93097
52	randomized.ti,ab.	480314
53	placebo.ti,ab.	203697
54	clinical trials as topic/	187199
55	randomly.ti,ab.	312995



56	trial?.ti.	266881
57	50 or 51 or 52 or 53 or 54 or 55 or 56	1250811
58	exp animal/ not humans/	4586077
59	57 not 58	1151222
60	multipolar motor neuropath*.ab,ti,kf.	749
61	conduction block*.ab,ti,kf.	3928
62	motor neuropath*.ab,ti,kf.	2133
63	61 or 62	5687
64	multipolar.ab,ti,kf.	28241
65	63 and 64	923
66	60 or 65	923
67	49 and 66	295
68	limit 67 to yr="2007-2019"	160
69	limit 68 to systematic reviews	11
70	59 and 68	37
71	68 not (69 or 70)	117
Comments	Line 69 exported for SR Line 70 exported for RCT Line 71 exported for All studies except SR or RCT	



1.3.8 Myasthenia Gravis

Date	06/06/2019 17:31:50	
Database	Cochrane@Wiley.com	
Search strategy		
#1	[mh ^"Immunoglobulins, intravenous"]	774
#2	IVIG:ti,kw	277
#3	scig:ti,kw	10
#4	intraglobin*:ti,kw	2
#5	(intravenous NEAR/5 antibod*):ti,kw	205
#6	(intravenous NEAR/5 immunoglob*):ti,kw	1477
#7	(subcutaneous NEAR/5 antibod*):ti,kw	151
#8	(subcutaneous NEAR/5 immunoglob*):ti,kw	113
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	1966
#10	[mh "Immunoglobulins"]	22270
#11	[mh "Administration, Intravenous"]	17927
#12	[mh "Injections, Subcutaneous"]	4249
#13	#11 OR #12	21680
#14	#10 AND #13	1477
#15	intravenous:ti,kw	52740
#16	subcutaneous:ti,kw	12668
#17	intradermal:ti,kw	1676
#18	iv:ti,kw	21245
#19	inject*:ti,kw	46398
#20	perfus*:ti,kw	5460
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	107359
#22	#10 AND #21	4682
#23	immunoglob*:ti,kw	11349



#24	immune glob*:ti,kw	632
#25	Ig:ti,kw	2183
#26	#23 OR #24 OR #25	12731
#27	#21 AND #26	3090
#28	#13 AND #26	501
#29	alphaglobin:ti,kw	0
#30	endobulin:ti,kw	0
#31	flebogamma:ti,kw	4
#32	gamimmune:ti,kw	0
#33	gammagard:ti,kw	9
#34	gammonativ:ti,kw	0
#35	gamunex:ti,kw	7
#36	globulin n:ti,kw	20
#37	iveegam:ti,kw	0
#38	privigen:ti,kw	1
#39	sandoglobulin:ti,kw	6
#40	venimmune:ti,kw	0
#41	venoglobulin:ti,kw	4
#42	HyQvia:ti,kw	4
#43	Octagam:ti,kw	14
#44	Hizentra:ti,kw	5
#45	Gamunex-C:ti,kw	2
#46	Gammaked:ti,kw	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	71
#48	#9 or #14 or #22 or #27 or #28 or #47	6353
#49	[mh "myasthenia gravis"]	168
#50	"myasthenia gravis":ab,ti,kw	548



#51	#49 OR #50	548
#52	#48 AND #51	58
#53	#52 with Cochrane Library publication date Between Jan 2011 and Dec 2019	41
Comments	2 results for Cochrane Systematic Reviews Database 39 Results for CENTRAL	

Date	27 May 2019	
Database	Embase.com	
Search strategy		
#1	(intravenous:ab,ti,kw OR subcutaneous:ab,ti,kw) AND (immunoglob*:ab,ti,kw OR antibody*:ab,ti,kw)	
#2	ivig:ab,ti,kw OR scig:ab,ti,kw	15715
#3	intraglobin*:ab,ti,kw	34
#4	#1 OR #2 OR #3	57107
#5	'subcutaneous immunotherapy'/exp	1588
#6	#4 OR #5	58520
#7	'immunoglobulin'/exp	481491
#8	'intravenous drug administration'/exp	378344
#9	'subcutaneous drug administration'/exp	97772
#10	#8 OR #9	459515
#11	#7 AND #10	12072
#12	intravenous:ab,ti,kw	365974
#13	subcutaneous:ab,ti,kw	172691
#14	intradermal:ab,ti,kw	18663
#15	iv:ab,ti,kw	479374
#16	inject*:ab,ti,kw	931641
#17	perfus*:ab,ti,kw	272604
#18	#12 OR #13 OR #14 OR #15 OR #16 OR #17	1997130



#19	#7 AND #18	57125
#20	immunoglob*:ab,ti,kw	188036
#21	immune AND glob*:ab,ti,kw	32190
#22	ig:ab,ti,kw	47197
#23	#20 OR #21 OR #22	244745
#24	#18 AND #23	41192
#25	#10 AND #23	6057
#26	alphaglobin:ab,ti,kw,tn	12
#27	endobulin:ab,ti,kw,tn	293
#28	flebogamma:ab,ti,kw,tn	278
#29	gamimmune:ab,ti,tn	50
#30	gammagard:ab,ti,tn	762
#31	gammonativ:ab,ti,tn	64
#32	gamunex:ab,ti,tn	319
#33	'globulin n':ab,ti,tn	121
#34	iveegam:ab,ti,tn	115
#35	privigen:ab,ti,kw,tn	344
#36	sandoglobulin:ab,ti,kw,tn	1203
#37	venimmune:ab,ti,kw,tn	2
#38	venoglobulin:ab,ti,kw,tn	263
#39	venoglobulin:ab,ti,kw,tn	263
#40	hyqvia:ab,ti,kw,tn	49
#41	octagam:ab,ti,kw,tn	395
#42	hizentra:ab,ti,kw,tn	259
#43	'gamunex c':ab,ti,kw,tn	46
#44	gammaked:ab,ti,kw,tn	13
#45	#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44	3284



#46	#6 OR #11 OR #19 OR #24 OR #25 OR #45	102695
#47	#46 NOT [medline]/lim	41602
#48	#47 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	10528
#49	'myasthenia gravis'/exp	23129
#50	'myasthenia gravis':ab,ti,kw	17967
#51	#49 OR #50	24658
#52	#48 AND #51	219
#53	#52 AND [2011-2019]/py	110
#54	#53 AND ('meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review')	2
#55	#53 AND (random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti))	13
#56	#53 NOT (#54 OR #55)	96
Comments	Line 54 exported for SR Line 55 exported for RCT Line 56 exported for All studies except SR or RCT	

Date	May 24, 2019	
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to May 24, 2019>	
Search strategy		
1	Immunoglobulins, intravenous/	12500
2	IVIG.ti,kf.	1155
3	scig.ti,kf.	51
4	intraglobin*.ti,kf.	3
5	(intravenous and antibod*).ti,kf.	807
6	(intravenous and immunoglob*).ti,kf.	5307
7	(subcutaneous and antibod*).ti,kf.	331
8	(subcutaneous and immunoglob*).ti,kf.	326



9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8	14943
10	exp Immunoglobulins/	855782
11	exp Administration, Intravenous/	139407
12	exp Injections, Subcutaneous/	39291
13	11 or 12	174418
14	10 and 13	11592
15	intravenous.ti,kf.	68662
16	subcutaneous.ti,kf.	25920
17	intradermal.ti,kf.	3917
18	iv.ti,kf.	54309
19	inject*.ti,kf.	110232
20	perfus*.ti,kf.	59356
21	15 or 16 or 17 or 18 or 19 or 20	310127
22	10 and 21	15299
23	immunoglob*.ti,kf.	49284
24	immune glob*.ti,kf.	1534
25	Ig.ti,kf.	3698
26	23 or 24 or 25	54072
27	21 and 26	6525
28	13 and 26	1196
29	alphaglobin.ti,kf.	1
30	endobulin.ti,kf.	2
31	flebogamma.ti,kf.	13
32	gamimmune.ti,kf.	0
33	gammagard.ti,kf.	12
34	gammonativ.ti,kf.	0
35	gamunex.ti,kf.	5
36	globulin n.ti,kf.	3



37	iveegam.ti,kf.	0
38	privigen.ti,kf.	17
39	sandoglobulin.ti,kf.	16
40	venimmune.ti,kf.	0
41	venoglobulin.ti,kf.	2
42	venoglobulin.ti,kf.	2
43	HyQvia.ti,kf.	1
44	Octagam.ti,kf.	11
45	Hizentra.ti,kf.	19
46	Gamunex-C.ti,kf.	1
47	Gammaked.ti,kf.	0
48	or/29-47	96
49	9 or 14 or 22 or 27 or 28 or 48	32756
50	exp Myasthenia Gravis/	14440
51	myasthenia gravis.ab,ti,kf,jw.	13971
52	50 or 51	17308
53	49 and 52	395
54	limit 53 to yr="2011-Current"	139
55	limit 54 to systematic reviews	10
56	randomized controlled trial.pt.	482595
57	controlled clinical trial.pt.	93085
58	randomized.ti,ab.	478822
59	placebo.ti,ab.	203304
60	clinical trials as topic/	187099
61	randomly.ti,ab.	312175
62	trial?.ti.	265962
63	56 or 57 or 58 or 59 or 60 or 61 or 62	1248147
64	exp animal/ not humans/	4583131



65	63 not 64	1148693
66	54 and 65	25
67	54 not (66 or 55)	110
Comments	Line 55 exported for SR Line 66 exported for RCT Line 67 exported for All studies except SR or RCT	

1.3.9 *Pemphigus (Immunobullous disease)*

Date	11/10/2019 18:03:02
Database	Cochrane@Wiley.com
Search strategy	
#1	[mh ^"Immunoglobulins, intravenous"]
#2	IVIG:ti,kw
#3	scig:ti,kw
#4	intraglobin*:ti,kw
#5	(intravenous NEAR/5 antibod*):ti,kw
#6	(intravenous NEAR/5 immunoglob*):ti,kw
#7	(subcutaneous NEAR/5 antibod*):ti,kw
#8	(subcutaneous NEAR/5 immunoglob*):ti,kw
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10	[mh "Immunoglobulins"]
#11	[mh "Administration, Intravenous"]
#12	[mh "Injections, Subcutaneous"]
#13	#11 OR #12
#14	#10 AND #13
#15	intravenous:ti,kw
#16	subcutaneous:ti,kw
#17	intradermal:ti,kw



#18	iv:ti,kw	21452
#19	inject*:ti,kw	47819
#20	perfus*:ti,kw	5670
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	109915
#22	#10 AND #21	4808
#23	immunoglob*:ti,kw	11441
#24	immune glob*:ti,kw	649
#25	Ig:ti,kw	2220
#26	#23 OR #24 OR #25	12858
#27	#21 AND #26	3112
#28	#13 AND #26	501
#29	alphaglobin:ti,kw	0
#30	endobulin:ti,kw	0
#31	flebogamma:ti,kw	4
#32	gamimmune:ti,kw	0
#33	gammagard:ti,kw	9
#34	gammonativ:ti,kw	0
#35	gamunex:ti,kw	7
#36	globulin n:ti,kw	20
#37	iveegam:ti,kw	0
#38	privigen:ti,kw	1
#39	sandoglobulin:ti,kw	6
#40	venimmune:ti,kw	0
#41	venoglobulin:ti,kw	4
#42	HyQvia:ti,kw	4
#43	Octagam:ti,kw	14
#44	Hizentra:ti,kw	5
#45	Gamunex-C:ti,kw	2



#46	Gammaked:ti,kw	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	71
#48	#9 or #14 or #22 or #27 or #28 or #47	6484
#49	[mh ^"pemphigus"]	63
#50	[mh ^"Skin Diseases, Vesiculobullous"]	15
#51	#49 OR #50	76
#52	pemphig*:ab,ti,kw	314
#53	(bullous NEAR/5 (pemphi* or disease? or disorder? or dermatos* or impetigo)):ab,ti,kw	182
#54	(vesiculobullous NEAR/5 (disease? or disorder? or dermatos* or impetigo)):ab,ti,kw	18
#55	acantholysis:ab,ti,kw,so	11
#56	Hailey-Hailey:ab,ti,kw	4
#57	((autoimmune or hereditary) NEAR/5 ("bullous disease" OR "bullous diseases")):ab,ti,kw	9
#58	senear-usher syndrome:ab,ti,kw	0
#59	((autoimmune or hereditary) NEAR/5 ("skin disease" OR "skin diseases")):ab,ti,kw	20
#60	vesiculopustular eruption?:ab,ti,kw	0
#61	((autoimmune or hereditary or chronic) NEAR/5 ("blistering disease" OR "blistering diseases")):ab,ti,kw	20
#62	immunobullous:ab,ti,kw	7
#63	#52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62	403
#64	#51 or #63	403
#65	#48 AND #64	22
#66	#65 with Cochrane Library publication date Between Jan 2017 and Dec 2019	14
Comments	0 results for Cochrane Systematic Reviews Database 14 Results for CENTRAL	



Database	Embase.com	
Search strategy		
#1	(intravenous:ab,ti,kw OR subcutaneous:ab,ti,kw) AND (immunoglob*:ab,ti,kw OR 52731 antibod*:ab,ti,kw)	
#2	ivig:ab,ti,kw OR scig:ab,ti,kw	16504
#3	intraglobin*:ab,ti,kw	34
#4	#1 OR #2 OR #3	59436
#5	'subcutaneous immunotherapy'/exp	1679
#6	#4 OR #5	60918
#7	'immunoglobulin'/exp	493274
#8	'intravenous drug administration'/exp	380151
#9	'subcutaneous drug administration'/exp	97813
#10	#8 OR #9	461361
#11	#7 AND #10	12129
#12	intravenous:ab,ti,kw	374631
#13	subcutaneous:ab,ti,kw	177576
#14	intradermal:ab,ti,kw	19039
#15	iv:ab,ti,kw	493466
#16	inject*:ab,ti,kw	953707
#17	perfus*:ab,ti,kw	277894
#18	#12 OR #13 OR #14 OR #15 OR #16 OR #17	2046489
#19	#7 AND #18	59081
#20	immunoglob*:ab,ti,kw	191972
#21	immune AND glob*:ab,ti,kw	33587
#22	ig:ab,ti,kw	48169
#23	#20 OR #21 OR #22	250678
#24	#18 AND #23	42553
#25	#10 AND #23	6091



#26	alphaglobin:ab,ti,kw,tn	12
#27	endobulin:ab,ti,kw,tn	293
#28	flebogamma:ab,ti,kw,tn	284
#29	gamimmune:ab,ti,tn	50
#30	gammagard:ab,ti,tn	765
#31	gammonativ:ab,ti,tn	64
#32	gamunex:ab,ti,tn	324
#33	globulin AND n:ab,ti,tn	6308
#34	iveegam:ab,ti,tn	115
#35	privigen:ab,ti,kw,tn	354
#36	sandoglobulin:ab,ti,kw,tn	1203
#37	venimmune:ab,ti,kw,tn	2
#38	venoglobulin:ab,ti,kw,tn	263
#39	venoglobulin:ab,ti,kw,tn	263
#40	hyqvia:ab,ti,kw,tn	55
#41	octagam:ab,ti,kw,tn	402
#42	hizentra:ab,ti,kw,tn	275
#43	'gamunex c':ab,ti,kw,tn	47
#44	gammaked:ab,ti,kw,tn	13
#45	#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44	9434
#46	#6 OR #11 OR #19 OR #24 OR #25 OR #45	111859
#47	'pemphigus'/exp	14301
#48	'bullous skin disease'/de	4812
#49	#47 OR #48	18365
#50	pemphig*:ab,ti,kw	17633
#51	(bullous NEAR/5 (pemphi* OR disease\$ OR disorder\$ OR dermatos* OR impetigo)):ab,ti,kw	9587



#52	(vesiculobullous NEAR/5 (disease\$ OR disorder\$ OR dermatos*) OR 370 impetigo)):ab,ti,kw	
#53	acantholysis:ab,ti,kw,jt	1475
#54	'hailey hailey':ab,ti,kw	791
#55	((autoimmune OR hereditary) NEAR/5 ('bullos disease' OR 'bullos diseases')):ab,ti,kw	949
#56	'senear usher' AND syndrome:ab,ti,kw	79
#57	((autoimmune OR hereditary) NEAR/5 ('skin disease' OR 'skin diseases')):ab,ti,kw	1194
#58	'vesiculopustular eruption\$':ab,ti,kw	70
#59	((autoimmune OR hereditary OR chronic) NEAR/5 ('blistering disease' OR 'blistering diseases')):ab,ti,kw	1444
#60	immunobullous:ab,ti,kw	350
#61	#50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60	22668
#62	#49 OR #61	28429
#63	#46 AND #62	1069
#64	random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti)	1712359
#65	#63 AND #64	82
#66	#65 AND [2017-2019]/py	15
#67	#66 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	8
#68	#67 NOT [medline]/lim	1
Comments	Line 68 exported for RCT	

Date	October 10, 2019
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to October 10, 2019>
Search strategy	
1	pemphigus/
2	Skin Diseases, Vesiculobullous/



3	1 or 2	13055
4	pemphig*.ab,ti,kf.	14100
5	(bullous adj5 (pemphi* or disease? or disorder? or dermatos* or impetigo)).ab,ti,kf.	7075
6	(vesiculobullous adj5 (disease? or disorder? or dermatos* or impetigo)).ab,ti,kf.	248
7	acantholysis.ab,ti,kf,jw.	969
8	Hailey-Hailey.ab,ti,kf.	591
9	((autoimmune or hereditary) adj5 bullous disease).ab,ti,kf.	335
10	senear-usher syndrome.ab,ti,kf.	69
11	((autoimmune or hereditary) adj5 skin disease).ab,ti,kf.	484
12	vesiculopustular eruption.ab,ti,kf.	41
13	((autoimmune or hereditary or chronic) adj5 blistering disease).ab,ti,kf.	688
14	immunobullous.ab,ti,kf.	228
15	4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14	17476
16	3 or 15	21476
17	Immunoglobulins, intravenous/	12737
18	IVIG.ti,kf.	1201
19	scig.ti,kf.	57
20	intraglobin*.ti,kf.	3
21	(intravenous and antibod*).ti,kf.	828
22	(intravenous and immunoglob*).ti,kf.	5397
23	(subcutaneous and antibod*).ti,kf.	338
24	(subcutaneous and immunoglob*).ti,kf.	346
25	17 or 18 or 19 or 20 or 21 or 22 or 23 or 24	15228
26	exp Immunoglobulins/	866274
27	exp Administration, Intravenous/	140623
28	exp Injections, Subcutaneous/	39627
29	27 or 28	175943
30	26 and 29	11772



31	intravenous.ti,kf.	69501
32	subcutaneous.ti,kf.	26443
33	intradermal.ti,kf.	3968
34	iv.ti,kf.	54974
35	inject*.ti,kf.	112159
36	perfus*.ti,kf.	60276
37	31 or 32 or 33 or 34 or 35 or 36	314893
38	26 and 37	15569
39	immunoglob*.ti,kf.	49905
40	immune glob*.ti,kf.	1548
41	Ig.ti,kf.	3743
42	39 or 40 or 41	54736
43	37 and 42	6642
44	29 and 42	1204
45	alphaglobin.ti,kf.	1
46	endobulin.ti,kf.	2
47	flebogamma.ti,kf.	14
48	gamimmune.ti,kf.	0
49	gammagard.ti,kf.	12
50	gammonativ.ti,kf.	0
51	gamunex.ti,kf.	5
52	globulin n.ti,kf.	3
53	iveegam.ti,kf.	0
54	privigen.ti,kf.	17
55	sandoglobulin.ti,kf.	16
56	venimmune.ti,kf.	0
57	venoglobulin.ti,kf.	2
58	venoglobulin.ti,kf.	2



59	HyQvia.ti,kf.	1
60	Octagam.ti,kf.	11
61	Hizentra.ti,kf.	21
62	Gamunex-C.ti,kf.	1
63	Gammaked.ti,kf.	0
64	or/45-63	99
65	25 or 30 or 38 or 43 or 44 or 64	33352
66	16 and 65	418
67	randomized controlled trial.pt.	491309
68	controlled clinical trial.pt.	93313
69	randomized.ti,ab.	493155
70	placebo.ti,ab.	206933
71	clinical trials as topic/	188681
72	randomly.ti,ab.	320359
73	trial?.ti.	274722
74	67 or 68 or 69 or 70 or 71 or 72 or 73	1275165
75	exp animal/ not humans/	4627155
76	74 not 75	1173815
77	66 and 76	33
78	limit 77 to yr="2017-Current"	7
Comments	Line 78 exported for RCT	

1.3.10 Post transfusion purpura

Date	15/10/2019 23:23:42
Database	Cochrane@Wiley.com
Search strategy	
#1	[mh ^"Transfusion reaction"]
#2	[mh ^"Transfusion Medicine"]



#3	[mh "Blood transfusion"]	3438
#4	#1 or #2 or #3	3583
#5	transfusion*:ab,ti,kw	15629
#6	transfused:ab,ti,kw	2104
#7	(blood NEXT receiv*):ab,ti,kw	14
#8	(plasma NEXT exchang*):ab,ti,kw	770
#9	#5 or #6 or #7 or #8	16719
#10	#4 or #9	16719
#11	[mh "Purpura"]	391
#12	purpura:ab,ti,kw,so	1455
#13	petechi*:ab,ti,kw	279
#14	"idiopathic thrombocytopenic purpura":ab,ti,kw	497
#15	(autoimmune NEAR/3 thrombocytop?enia):ab,ti,kw	39
#16	(idiopathic NEAR/3 thrombocytop?enia):ab,ti,kw	26
#17	morbus werlhof:ab,ti,kw	0
#18	Werlhof disease:ab,ti,kw	2
#19	Werlhof's disease:ab,ti,kw	2
#20	Werlhofs disease:ab,ti,kw	0
#21	(immune* NEAR/3 thrombocytop?enia):ab,ti,kw	404
#22	#12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21	1807
#23	#11 or #22	1807
#24	#10 and #23	224
#25	[mh ^"Immunoglobulins, intravenous"]	786
#26	IVIG:ti,kw	285
#27	scig:ti,kw	10
#28	intraglobin*:ti,kw	2
#29	(intravenous and antibod*):ti,kw	2039
#30	(intravenous and immunoglob*):ti,kw	1976



#31	(subcutaneous and antibod*):ti,kw	1315
#32	(subcutaneous and immunoglob*):ti,kw	518
#33	#25 or #26 or #27 or #28 or #29 or #30 or #31 or #32	4846
#34	[mh "Immunoglobulins"]	22872
#35	[mh "Administration, Intravenous"]	18094
#36	[mh "Injections, Subcutaneous"]	4303
#37	#35 or #36	21896
#38	#34 and #37	1515
#39	intravenous:ti,kw	53460
#40	subcutaneous:ti,kw	12875
#41	intradermal:ti,kw	1694
#42	iv:ti,kw	21452
#43	inject*:ti,kw	47819
#44	perfus*:ti,kw	5670
#45	#39 or #40 or #41 or #42 or #43 or #44	109915
#46	#34 and #45	4808
#47	immunoglob*:ti,kw	11442
#48	immune NEXT glob*:ti,kw	427
#49	Ig:ti,kw	2220
#50	#47 or #48 or #49	12677
#51	#45 and #50	3088
#52	#37 and #50	498
#53	alphaglobin:ti,kw	0
#54	endobulin:ti,kw	0
#55	flebogamma:ti,kw	4
#56	gamimmune:ti,kw	0
#57	gammagard:ti,kw	9
#58	gammonativ:ti,kw	0



#59	gamunex:ti,kw	7
#60	globulin n:ti,kw	20
#61	iveegam:ti,kw	0
#62	privigen:ti,kw	1
#63	sandoglobulin:ti,kw	6
#64	venimmune:ti,kw	0
#65	venoglobulin:ti,kw	4
#66	venoglobulin:ti,kw	4
#67	HyQvia:ti,kw	4
#68	Octagam:ti,kw	14
#69	Hizentra:ti,kw	5
#70	Gamunex-C:ti,kw	2
#71	Gammaked:ti,kw	0
#72	#53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71	71
#73	#33 or #38 or #46 or #51 or #52 or #72	7250
#74	#24 and #73	14
Comments	1 result for Cochrane Systematic Reviews Database 13 Results for CENTRAL	

Date	15 Oct 2019
Database	Embase.com
Search strategy	
#1	'blood transfusion reaction'/exp
#2	'transfusion medicine'/de
#3	'transfusion'/exp
#4	#1 OR #2 OR #3
#5	transfusion*:ab,ti,kw



#6	transfused:ab,ti,kw	23330
#7	(blood NEAR/4 receiv*):ab,ti,kw	17164
#8	(plasma NEAR/4 exchang*):ab,ti,kw	15611
#9	#5 OR #6 OR #7 OR #8	201725
#10	#4 OR #9	381767
#11	'purpura'/exp	66686
#12	purpura:ab,ti,kw,jt	30811
#13	petechi*:ab,ti,kw	5606
#14	'idiopathic thrombocytopenic purpura':ab,ti,kw	5642
#15	autoimmune AND thrombocytop\$enia:ab,ti,kw	6562
#16	idiopathic AND thrombocytop\$enia:ab,ti,kw	8703
#17	'morbus werlhof':ab,ti,kw	6
#18	'werlhof disease':ab,ti,kw	8
#19	(werlhof* NEAR/4 disease):ab,ti,kw	274
#20	'werlhofs disease':ab,ti,kw	0
#21	immune* AND thrombocytop\$enia:ab,ti,kw	12649
#22	#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21	49489
#23	#11 OR #22	81538
#24	#10 AND #23	13813
#25	(intravenous:ab,ti,kw OR subcutaneous:ab,ti,kw) AND (immunoglob*:ab,ti,kw OR antibod*:ab,ti,kw)	52755
#26	ivig:ab,ti,kw OR scig:ab,ti,kw	16510
#27	intraglobin*:ab,ti,kw	34
#28	#25 OR #26 OR #27	59460
#29	'subcutaneous immunotherapy'/exp	1682
#30	#28 OR #29	60945
#31	'immunoglobulin'/exp	493398
#32	'intravenous drug administration'/exp	380175



#33	'subcutaneous drug administration'/exp	97815
#34	#32 OR #33	461387
#35	#31 AND #34	12130
#36	intravenous:ab,ti,kw	374747
#37	subcutaneous:ab,ti,kw	177632
#38	intradermal:ab,ti,kw	19044
#39	iv:ab,ti,kw	493626
#40	inject*:ab,ti,kw	954083
#41	perfus*:ab,ti,kw	278003
#42	#36 OR #37 OR #38 OR #39 OR #40 OR #41	2047235
#43	#31 AND #42	59105
#44	immunoglob*:ab,ti,kw	192049
#45	immune AND glob*:ab,ti,kw	33618
#46	ig:ab,ti,kw	48180
#47	#44 OR #45 OR #46	250791
#48	#42 AND #47	42574
#49	#34 AND #47	6092
#50	alphaglobin:ab,ti,kw,tn	12
#51	endobulin:ab,ti,kw,tn	293
#52	flebogamma:ab,ti,kw,tn	284
#53	gamimmune:ab,ti,tn	50
#54	gammagard:ab,ti,tn	765
#55	gammonativ:ab,ti,tn	64
#56	gamunex:ab,ti,tn	324
#57	globulin AND n:ab,ti,tn	6310
#58	iveegam:ab,ti,tn	115
#59	privigen:ab,ti,kw,tn	354
#60	sandoglobulin:ab,ti,kw,tn	1203



#61	venimmune:ab,ti,kw,tn	2
#62	venoglobulin:ab,ti,kw,tn	263
#63	venoglobulin:ab,ti,kw,tn	263
#64	hyqvia:ab,ti,kw,tn	55
#65	octagam:ab,ti,kw,tn	402
#66	hizentra:ab,ti,kw,tn	275
#67	'gamunex c':ab,ti,kw,tn	47
#68	gammaked:ab,ti,kw,tn	13
#69	#50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68	9436
#70	#30 OR #35 OR #43 OR #48 OR #49 OR #69	111901
#71	#24 AND #70	1679
#72	#71 AND [2008-2019]/py	1107
#73	#72 NOT [medline]/lim	764
#74	#73 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	106
Comments	Line 74 exported for All studies but conference proceedings	

Date	October 14, 2019	
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to October 14, 2019>	
Search strategy		
1	Transfusion reaction/	15803
2	Transfusion Medicine/	210
3	exp Blood transfusion/	83628
4	1 or 2 or 3	94596
5	transfusion*.ab,ti,kf.	110074
6	transfused.ab,ti,kf.	12933
7	(blood adj4 receiv*).ab,ti,kf.	10501



8	plasma exchang*.ab,ti,kf.	8075
9	5 or 6 or 7 or 8	126654
10	4 or 9	162314
11	exp Purpura/	26254
12	purpura.ab,ti,kf,jw.	23629
13	petechi*.ab,ti,kf.	3507
14	idiopathic thrombocytopenic purpura.ab,ti,kf.	4402
15	autoimmune thrombocytop?enia.ab,ti,kf.	715
16	idiopathic thrombocytop?enia.ab,ti,kf.	450
17	morbus werlhof.ab,ti,kf.	2
18	Werlhof disease.ab,ti,kf.	17
19	Werlhof's disease.ab,ti,kf.	226
20	Werlhofs disease.ab,ti,kf.	226
21	immune* thrombocytop?enia.ab,ti,kf.	3292
22	12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21	30251
23	11 or 22	36961
24	10 and 23	3738
25	Immunoglobulins, intravenous/	12737
26	IVIG.ti,kf.	1204
27	scig.ti,kf.	57
28	intraglobin*.ti,kf.	3
29	(intravenous and antibod*).ti,kf.	828
30	(intravenous and immunoglob*).ti,kf.	5403
31	(subcutaneous and antibod*).ti,kf.	338
32	(subcutaneous and immunoglob*).ti,kf.	347
33	25 or 26 or 27 or 28 or 29 or 30 or 31 or 32	15236
34	exp Immunoglobulins/	866395
35	exp Administration, Intravenous/	140642



36	exp Injections, Subcutaneous/	39632
37	35 or 36	175967
38	34 and 37	11776
39	intravenous.ti,kf.	69534
40	subcutaneous.ti,kf.	26464
41	intradermal.ti,kf.	3969
42	iv.ti,kf.	54997
43	inject*.ti,kf.	112249
44	perfus*.ti,kf.	60302
45	39 or 40 or 41 or 42 or 43 or 44	315080
46	34 and 45	15570
47	immunoglob*.ti,kf.	49929
48	immune glob*.ti,kf.	1550
49	Ig.ti,kf.	3743
50	47 or 48 or 49	54762
51	45 and 50	6650
52	37 and 50	1204
53	alphaglobin.ti,kf.	1
54	endobulin.ti,kf.	2
55	flebogamma.ti,kf.	14
56	gamimmune.ti,kf.	0
57	gammagard.ti,kf.	12
58	gammonativ.ti,kf.	0
59	gamunex.ti,kf.	5
60	globulin n.ti,kf.	3
61	iveegam.ti,kf.	0
62	privigen.ti,kf.	17
63	sandoglobulin.ti,kf.	16



64	venimmune.ti,kf.	0
65	venoglobulin.ti,kf.	2
66	venoglobulin.ti,kf.	2
67	HyQvia.ti,kf.	1
68	Octagam.ti,kf.	11
69	Hizentra.ti,kf.	21
70	Gamunex-C.ti,kf.	1
71	Gammaked.ti,kf.	0
72	or/53-71	99
73	33 or 38 or 46 or 51 or 52 or 72	33366
74	24 and 73	233
75	limit 74 to yr="2008-Current"	81
Comments	Line 75 exported for All studies	



1.3.11 Primary Immunodeficiency

Date	17/06/2019 02:50:05
Database	Cochrane@Wiley.com
Search strategy	
#1	[mh ^"Immunoglobulins, intravenous"]
#2	IVIG:ti,kw
#3	scig:ti,kw
#4	intraglobin*:ti,kw
#5	(intravenous NEAR/5 antibod*):ti,kw
#6	(intravenous NEAR/5 immunoglob*):ti,kw
#7	(subcutaneous NEAR/5 antibod*):ti,kw
#8	(subcutaneous NEAR/5 immunoglob*):ti,kw
#9	#2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10	[mh "Immunoglobulins"]
#11	[mh "Administration, Intravenous"]
#12	[mh "Injections, Subcutaneous"]
#13	#11 OR #12
#14	#10 AND #13
#15	intravenous:ti,kw
#16	subcutaneous:ti,kw
#17	intradermal:ti,kw
#18	iv:ti,kw
#19	inject*:ti,kw
#20	perfus*:ti,kw
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20
#22	#10 AND #21
#23	immunoglob*:ti,kw



#24	immune glob*:ti,kw	632
#25	Ig:ti,kw	2183
#26	#23 OR #24 OR #25	12731
#27	#21 AND #26	3090
#28	#13 AND #26	501
#29	alphaglobin:ti,kw	0
#30	endobulin:ti,kw	0
#31	flebogamma:ti,kw	4
#32	gamimmune:ti,kw	0
#33	gammagard:ti,kw	9
#34	gammonativ:ti,kw	0
#35	gamunex:ti,kw	7
#36	globulin n:ti,kw	20
#37	iveegam:ti,kw	0
#38	privigen:ti,kw	1
#39	sandoglobulin:ti,kw	6
#40	venimmune:ti,kw	0
#41	venoglobulin:ti,kw	4
#42	HyQvia:ti,kw	4
#43	Octagam:ti,kw	14
#44	Hizentra:ti,kw	5
#45	Gamunex-C:ti,kw	2
#46	Gammaked:ti,kw	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	71
#48	#1 OR #9 or #14 or #22 or #27 or #28 or #47	6353
#49	#48 with Cochrane Library publication date Between Jan 2006 and Dec 2019	4879
#50	[mh "Immunologic Deficiency Syndromes"]	11384



#51	[mh "HIV Infections"]	11135
#52	#48 NOT #49	1474
#53	(primary NEAR/3 immunodeficienc*):ab,ti,kw	198
#54	(antibod* NEAR/3 deficiency syndrome*):ab,ti,kw	11
#55	(immuno* NEAR/3 deficiency syndrome*):ab,ti,kw	540
#56	agammaglobulinemia*:ab,ti,kw	69
#57	hypogammaglobulinemia*:ab,ti,kw	84
#58	ataxia telangiectasia:ab,ti,kw	55
#59	louis bar syndrome:ab,ti,kw	1
#60	Common Variable Immunodeficiency:ab,ti,kw	118
#61	acquired hypogammaglobulinemia:ab,ti,kw	2
#62	common variable hypogammaglobulinemia:ab,ti,kw	4
#63	common variable immune deficiency:ab,ti,kw	62
#64	late-onset immunoglobulin deficienc*:ab,ti,kw	7
#65	dysgammaglobulinemia*:ab,ti,kw	4
#66	higm2 syndrome:ab,ti,kw	0
#67	higm3 syndrome:ab,ti,kw	0
#68	higm5 syndrome:ab,ti,kw	0
#69	hyper igm immunodeficienc*:ab,ti,kw	8
#70	hyper igm syndrome?:ab,ti,kw	11
#71	higm1:ab,ti,kw	0
#72	iga deficienc*:ab,ti,kw	123
#73	igg deficienc*:ab,ti,kw	220
#74	blv infection*:ab,ti,kw	2
#75	deltaretrovirus infection*:ab,ti,kw	7
#76	htlv infection*:ab,ti,kw	54
#77	htlv-blv infection*:ab,ti,kw	0
#78	human t lymphotropic virus 1 infection*:ab,ti,kw	30



#79	htlv-i infection*:ab,ti,kw	21
#80	htlv-ii infection*:ab,ti,kw	0
#81	human t lymphotropic virus 2 infection*:ab,ti,kw	25
#82	leukocyte-adhesion deficiency syndrome?:ab,ti,kw	1
#83	lymphopenia*:ab,ti,kw	610
#84	lymphocytopenia*:ab,ti,kw	979
#85	t-lymphocytopenia*:ab,ti,kw	2
#86	aldrich syndrome:ab,ti,kw	30
#87	thrombocytopenia immunodeficiency syndrome*:ab,ti,kw	61
#88	imd2:ab,ti,kw	0
#89	(immunodeficiency NEAR/2 2):ab,ti,kw	41
#90	wiskott syndrome:ab,ti,kw	28
#91	chronic granulomatous disease*:ab,ti,kw	150
#92	autosomal dominant hies:ab,ti,kw	2
#93	autosomal recessive hies:ab,ti,kw	0
#94	buckley syndrome:ab,ti,kw	80
#95	"hie syndrome":ab,ti,kw OR "hies syndrome":ab,ti,kw	0
#96	hyper ige syndrome*:ab,ti,kw	9
#97	hyper immunoglobulin e syndrome*:ab,ti,kw	25
#98	hyper-ige syndrome*:ab,ti,kw	1
#99	job syndrome:ab,ti,kw	138
#100	job's syndrome:ab,ti,kw	137
#101	job-buckley syndrome:ab,ti,kw	0
#102	bare lymphocyte syndrome:ab,ti,kw	3
#103	familial reticuloendothelios*:ab,ti,kw	0
#104	omenn syndrome:ab,ti,kw	2
#105	omenn's syndrome:ab,ti,kw	2
#106	omenns syndrome:ab,ti,kw	0



#107	severe combined immune deficienc*:ab,ti,kw	107
#108	severe combined immunodeficienc*:ab,ti,kw	138
#109	severe combined immunologic deficienc*:ab,ti,kw	12
#110	(immunodeficiency NEAR/2 4):ab,ti,kw	8
#111	(immunodeficiency NEAR/2 6):ab,ti,kw	8
#112	("x linked" NEAR/2 immunodeficiency):ab,ti,kw	4
#113	("x linked" NEAR/2 scid):ab,ti,kw	2
#114	scidx:ab,ti,kw	0
#115	scidx1:ab,ti,kw	4
#116	("x linked" NEAR/2 scids):ab,ti,kw	0
#117	x-scid:ab,ti,kw	1
#118	xscid:ab,ti,kw	1
#119	#52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82 OR #83 OR #84 OR #85 OR #86 OR #87 OR #88 OR #89 OR #90 OR #91 OR #92 OR #93 OR #94 OR #95 OR #96 OR #97 OR #98 OR #99 OR #100 OR #101 OR #102 OR #103 OR #104 OR #105 OR #106 OR #107 OR #108 OR #109 OR #110 OR #111 OR #112 OR #113 OR #114 OR #115 OR #116 OR #117 OR #118	4498
#120	#49 AND 119	115
Comments	22 results for Cochrane Systematic Reviews Database 92 Results for CENTRAL	

Date 5 Jun 2019

Database Embase.com

Search strategy



#1	(intravenous:ab,ti,kw OR subcutaneous:ab,ti,kw) AND (immunoglob*:ab,ti,kw OR antibod*:ab,ti,kw)	50849
#2	ivig:ab,ti,kw OR scig:ab,ti,kw	15768
#3	intraglobin*:ab,ti,kw	34
#4	#1 OR #2 OR #3	57209
#5	'subcutaneous immunotherapy'/exp	1589
#6	#4 OR #5	58622
#7	'immunoglobulin'/exp	482056
#8	'intravenous drug administration'/exp	378385
#9	'subcutaneous drug administration'/exp	97772
#10	#8 OR #9	459556
#11	#7 AND #10	12073
#12	intravenous:ab,ti,kw	366396
#13	subcutaneous:ab,ti,kw	172881
#14	intradermal:ab,ti,kw	18680
#15	iv:ab,ti,kw	480008
#16	inject*:ab,ti,kw	932566
#17	perfus*:ab,ti,kw	272877
#18	#12 OR #13 OR #14 OR #15 OR #16 OR #17	1999330
#19	#7 AND #18	57205
#20	immunoglob*:ab,ti,kw	188196
#21	immune AND glob*:ab,ti,kw	32257
#22	ig:ab,ti,kw	47231
#23	#20 OR #21 OR #22	244996
#24	#18 AND #23	41250
#25	#10 AND #23	6058
#26	alphaglobin:ab,ti,kw,tn	12
#27	endobulin:ab,ti,kw,tn	293



#28	flebogamma:ab,ti,kw,tn	278
#29	gammimmune:ab,ti,tn	50
#30	gammagard:ab,ti,tn	762
#31	gammonativ:ab,ti,tn	64
#32	gamunex:ab,ti,tn	319
#33	globulin AND n:ab,ti,tn	6142
#34	iveegam:ab,ti,tn	115
#35	privigen:ab,ti,kw,tn	344
#36	sandoglobulin:ab,ti,kw,tn	1203
#37	venimmune:ab,ti,kw,tn	2
#38	venoglobulin:ab,ti,kw,tn	263
#39	venoglobulin:ab,ti,kw,tn	263
#40	hyqvia:ab,ti,kw,tn	51
#41	octagam:ab,ti,kw,tn	395
#42	hizentra:ab,ti,kw,tn	259
#43	'gamunex c':ab,ti,kw,tn	46
#44	gammaked:ab,ti,kw,tn	13
#45	#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44	9231
#46	#6 OR #11 OR #19 OR #24 OR #25 OR #45	108343
#47	#46 NOT [medline]/lim	43675
#48	#47 AND [2006-2019]/py	38951
#49	#48 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	6112
#50	'immune deficiency'/exp	286368
#51	'human immunodeficiency virus infection'/exp	366573
#52	#50 NOT #51	142007
#53	(primary NEAR/3 immunodeficienc*):ab,ti,kw	8897
#54	(antibod* NEAR/3 'deficiency syndrome'):ab,ti,kw	247



#55	(antibod* NEAR/3 'deficiency syndromes'):ab,ti,kw	142
#56	(immuno* NEAR/3 'deficiency syndrome'):ab,ti,kw	386
#57	agammaglobulinemia*:ab,ti,kw	2276
#58	'ataxia telangiectasia':ab,ti,kw	7269
#59	'louis bar syndrome':ab,ti,kw	123
#60	'common variable immunodeficiency':ab,ti,kw	3700
#61	'acquired hypogammaglobulinemia':ab,ti,kw	116
#62	'common variable hypogammaglobulinemia':ab,ti,kw	126
#63	'common variable immune deficiency':ab,ti,kw	411
#64	'common variable immune deficiencies':ab,ti,kw	5
#65	'late-onset immunoglobulin deficiency':ab,ti,kw	16
#66	'late-onset immunoglobulin deficiencies':ab,ti,kw	0
#67	dysgammaglobulinemia*:ab,ti,kw	299
#68	higm?:ab,ti,kw AND near2:ab,ti,kw AND syndrome:ab,ti,kw	0
#69	(higm? NEAR/2 syndrome):ab,ti,kw	38
#70	('hyper igm' NEAR/2 immunodeficienc*):ab,ti,kw	135
#71	('hyper igm' NEAR/2 syndrome*):ab,ti,kw	725
#72	higm1:ab,ti,kw	46
#73	(ig? NEAR/2 deficienc*):ab,ti,kw	4475
#74	(blv NEAR/2 infection*):ab,ti,kw	416
#75	(deltaretrovirus NEAR/2 infection*):ab,ti,kw	2
#76	(htlv NEAR/2 infection*):ab,ti,kw	3934
#77	('htlv blv' NEAR/2 infection*):ab,ti,kw	0
#78	('human t lymphotropic virus 1' NEAR/2 infection*):ab,ti,kw	26
#79	('htlv-i' NEAR/2 infection*):ab,ti,kw	1489
#80	('htlv-ii' NEAR/2 infection*):ab,ti,kw	265
#81	('human t lymphotropic virus 2' NEAR/2 infection*):ab,ti,kw	0
#82	'leukocyte-adhesion deficiency syndrome':ab,ti,kw	46



#83	lymphopenia*:ab,ti,kw	10358
#84	lymphocytopenia*:ab,ti,kw	2281
#85	't lymphocytopenia*:ab,ti,kw	333
#86	'aldrich syndrome':ab,ti,kw	2995
#87	'thrombocytopenia immunodeficiency syndrome':ab,ti,kw	0
#88	'imd2':ab,ti,kw	23
#89	'immunodeficiency 2':ab,ti,kw	54
#90	'immunodeficiencies 2':ab,ti,kw	8
#91	'wiskott syndrome':ab,ti,kw	1
#92	'wiskott-aldrich syndrome':ab,ti,kw	2877
#93	'chronic granulomatous disease':ab,ti,kw	4726
#94	'chronic granulomatous diseases':ab,ti,kw	75
#95	'autosomal dominant hies':ab,ti,kw	42
#96	'autosomal recessive hies':ab,ti,kw	23
#97	'buckley syndrome':ab,ti,kw	19
#98	'hie syndrome':ab,ti,kw	20
#99	'hies syndrome':ab,ti,kw	5
#100	'hyper ige syndrome':ab,ti,kw	1028
#101	'hyper immunoglobulin e syndrome':ab,ti,kw	81
#102	'hyper-ige syndrome':ab,ti,kw	1028
#103	'job syndrome':ab,ti,kw	99
#104	'jobs syndrome':ab,ti,kw	9
#105	'job s syndrome':ab,ti,kw	225
#106	'job-buckley syndrome':ab,ti,kw	5
#107	'bare lymphocyte syndrome':ab,ti,kw	191
#108	'familial reticuloendothelios*':ab,ti,kw	11
#109	'omenn syndrome':ab,ti,kw	341
#110	'omenns syndrome':ab,ti,kw	1



#111	'omenn s syndrome':ab,ti,kw	87
#112	'severe combined immune deficiency':ab,ti,kw	754
#113	'severe combined immune deficiencies':ab,ti,kw	19
#114	'severe combined immunodeficiency':ab,ti,kw	6204
#115	'severe combined immunodeficiencies':ab,ti,kw	175
#116	'severe combined immunologic deficiency':ab,ti,kw	4
#117	'severe combined immunologic deficiencies':ab,ti,kw	0
#118	'immunodeficiency 4':ab,ti,kw	35
#119	'immunodeficiency 6':ab,ti,kw	12
#120	('x linked' NEAR/2 immunodeficiency):ab,ti,kw	644
#121	('x linked' NEAR/2 scid):ab,ti,kw	162
#122	scidx:ab,ti,kw	2
#123	scidx1:ab,ti,kw	26
#124	('x linked' NEAR/2 scids):ab,ti,kw	1
#125	'x scid':ab,ti,kw	195
#126	xscid:ab,ti,kw	125
#127	#53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82 OR #83 OR #84 OR #85 OR #86 OR #87 OR #88 OR #89 OR #90 OR #91 OR #92 OR #93 OR #94 OR #95 OR #96 OR #97 OR #98 OR #99 OR #100 OR #101 OR #102 OR #103 OR #104 OR #105 OR #106 OR #107 OR #108 OR #109 OR #110 OR #111 OR #112 OR #113 OR #114 OR #115 OR #116 OR #117 OR #118 OR #119 OR #120 OR #121 OR #122 OR #123 OR #124 OR #125 OR #126	55634
#128	#127 OR #52	168511
#129	#49 AND #128	496
#130	#129 AND ('meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review')	16
#131	#129 AND (random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti))	48
#132	#129 NOT (#130 OR #131)	435



Comments Line 130 exported for SR
Line 131 exported for RCT
Line 132 exported for All studies except SR or RCT

Date	June 04, 2019
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to June 04, 2019>
Search strategy	
1	Immunoglobulins, intravenous/ 12520
2	IVIG.ti,kf. 1160
3	scig.ti,kf. 54
4	intraglobin*.ti,kf. 3
5	(intravenous and antibod*).ti,kf. 810
6	(intravenous and immunoglob*).ti,kf. 5313
7	(subcutaneous and antibod*).ti,kf. 332
8	(subcutaneous and immunoglob*).ti,kf. 327
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 14970
10	exp Immunoglobulins/ 856497
11	exp Administration, Intravenous/ 139488
12	exp Injections, Subcutaneous/ 39311
13	11 or 12 174519
14	10 and 13 11602
15	intravenous.ti,kf. 68752
16	subcutaneous.ti,kf. 25984
17	intradermal.ti,kf. 3922
18	iv.ti,kf. 54371
19	inject*.ti,kf. 110423
20	perfus*.ti,kf. 59463



21	15 or 16 or 17 or 18 or 19 or 20	310629
22	10 and 21	15316
23	immunoglob*.ti,kf.	49346
24	immune glob*.ti,kf.	1533
25	Ig.ti,kf.	3702
26	23 or 24 or 25	54136
27	21 and 26	6532
28	13 and 26	1196
29	alphaglobin.ti,kf.	1
30	endobulin.ti,kf.	2
31	flebogamma.ti,kf.	13
32	gamimmune.ti,kf.	0
33	gammagard.ti,kf.	12
34	gammonativ.ti,kf.	0
35	gamunex.ti,kf.	5
36	globulin n.ti,kf.	3
37	iveegam.ti,kf.	0
38	privigen.ti,kf.	17
39	sandoglobulin.ti,kf.	16
40	venimmune.ti,kf.	0
41	venoglobulin.ti,kf.	2
42	venoglobulin.ti,kf.	2
43	HyQvia.ti,kf.	1
44	Octagam.ti,kf.	11
45	Hizentra.ti,kf.	19
46	Gamunex-C.ti,kf.	1
47	Gammaked.ti,kf.	0
48	or/29-47	96



49	9 or 14 or 22 or 27 or 28 or 48	32801
50	exp Immunologic Deficiency Syndromes/	314360
51	exp HIV Infections/	270497
52	50 not 51	43863
53	(primary adj3 immunodeficienc*).ab,ti,kf.	5290
54	(antibod* adj3 deficiency syndrome?).ab,ti,kf.	291
55	(immuno* adj3 deficiency syndrome?).ab,ti,kf.	356
56	agammaglobulinemia?.ab,ti,kf.	2073
57	hypogammaglobulinemia?.ab,ti,kf.	2761
58	ataxia telangiectasia.ab,ti,kf.	6166
59	louis bar syndrome.ab,ti,kf.	96
60	Common Variable Immunodeficiency.ab,ti,kf.	2385
61	acquired hypogammaglobulinemia.ab,ti,kf.	95
62	common variable hypogammaglobulinemia.ab,ti,kf.	108
63	common variable immune deficiency.ab,ti,kf.	208
64	late-onset immunoglobulin deficienc*.ab,ti,kf.	13
65	dysgammaglobulinemia?.ab,ti,kf.	230
66	higm2 syndrome.ab,ti,kf.	2
67	higm3 syndrome.ab,ti,kf.	0
68	higm5 syndrome.ab,ti,kf.	0
69	hyper igm immunodeficienc*.ab,ti,kf.	29
70	hyper igm syndrome?.ab,ti,kf.	482
71	higm1.ab,ti,kf.	41
72	iga deficienc*.ab,ti,kf.	1802
73	igg deficienc*.ab,ti,kf.	93
74	blv infection?.ab,ti,kf.	356
75	deltaretrovirus infection?.ab,ti,kf.	1
76	htlv infection?.ab,ti,kf.	295



77	htlv-blv infection?.ab,ti,kf.	0
78	human t lymphotropic virus 1 infection?.ab,ti,kf.	11
79	htlv-i infection?.ab,ti,kf.	1102
80	htlv-ii infection?.ab,ti,kf.	238
81	human t lymphotropic virus 2 infection?.ab,ti,kf.	0
82	leukocyte-adhesion deficiency syndrome?.ab,ti,kf.	35
83	lymphopenia?.ab,ti,kf.	5873
84	lymphocytopenia?.ab,ti,kf.	1620
85	t-lymphocytopenia?.ab,ti,kf.	282
86	aldrich syndrome.ab,ti,kf.	2190
87	thrombocytopenia immunodeficiency syndrome?.ab,ti,kf.	0
88	imd2.ab,ti,kf.	29
89	immunodeficienc* 2.ab,ti,kf.	18
90	wiskott syndrome.ab,ti,kf.	1
91	wiskott-aldrich syndrome.ab,ti,kf.	2108
92	chronic granulomatous disease?.ab,ti,kf.	3528
93	autosomal dominant hies.ab,ti,kf.	23
94	autosomal recessive hies.ab,ti,kf.	13
95	buckley syndrome.ab,ti,kf.	13
96	hie? syndrome.ab,ti,kf.	17
97	hyper ige syndrome?.ab,ti,kf.	595
98	hyper immunoglobulin e syndrome?.ab,ti,kf.	55
99	hyper-ige syndrome?.ab,ti,kf.	595
100	job syndrome.ab,ti,kf.	51
101	job's syndrome.ab,ti,kf.	151
102	job-buckley syndrome.ab,ti,kf.	3
103	bare lymphocyte syndrome.ab,ti,kf.	145
104	familial reticuloendothelios*.ab,ti,kf.	10



105	omenn syndrome.ab,ti,kf.	198
106	omenn's syndrome.ab,ti,kf.	66
107	omenns syndrome.ab,ti,kf.	66
108	severe combined immune deficienc*.ab,ti,kf.	589
109	severe combined immunodeficienc*.ab,ti,kf.	4995
110	severe combined immunologic deficienc*.ab,ti,kf.	9
111	immunodeficiency 4.ab,ti,kf.	14
112	immunodeficiency 6.ab,ti,kf.	3
113	("x linked" adj2 immunodeficiency).ab,ti,kf.	448
114	("x linked" adj2 scid).ab,ti,kf.	111
115	scidx.ab,ti,kf.	1
116	scidx1.ab,ti,kf.	20
117	("x linked" adj2 scids).ab,ti,kf.	1
118	x-scid.ab,ti,kf.	124
119	xscid.ab,ti,kf.	97
120	53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119	39322
121	49 and 120	1275
122	limit 121 to yr="2006-Current"	736
123	limit 122 to systematic reviews	25
124	randomized controlled trial.pt.	483223
125	controlled clinical trial.pt.	93097
126	randomized.ti,ab.	480314
127	placebo.ti,ab.	203697
128	clinical trials as topic/	187199
129	randomly.ti,ab.	312995



130	trial?.ti.	266881
131	124 or 125 or 126 or 127 or 128 or 129 or 130	1250811
132	exp animal/ not humans/	4586077
133	131 not 132	1151222
134	122 and 133	60
135	122 not (123 or 134)	661
Comments	Line 123 exported for SR Line 134 exported for RCT Line 135 exported for All studies except SR or RCT	



1.3.12 Pure red cell aplasia (*Erythroblastopenia*)

Date	12/07/2019 14:04:07
Database	Cochrane@Wiley.com
Search strategy	
#0	[mh ^"Immunoglobulins, intravenous"]
	777
#0	IVIG:ti,kw
	278
#0	scig:ti,kw
	10
#0	intraglobin*:ti,kw
	2
#0	(intravenous NEAR/5 antibod*):ti,kw
	205
#0	(intravenous NEAR/5 immunoglob*):ti,kw
	1481
#0	(subcutaneous NEAR/5 antibod*):ti,kw
	151
#0	(subcutaneous NEAR/5 immunoglob*):ti,kw
	113
#9	[mh ^"Immunoglobulins, intravenous"] or IVIG:ti,kw or scig:ti,kw or intraglobin*:ti,kw or (intravenous NEAR/5 antibod*):ti,kw or (intravenous NEAR/5 immunoglob*):ti,kw or (subcutaneous NEAR/5 antibod*):ti,kw or (subcutaneous NEAR/5 immunoglob*):ti,kw
	2378
#10	[mh "Immunoglobulins"]
	22382
#11	[mh "Administration, Intravenous"]
	17966
#12	[mh "Injections, Subcutaneous"]
	4257
#13	#11 OR #12
	21726
#14	#10 AND #13
	1482
#15	intravenous:ti,kw
	52959
#16	subcutaneous:ti,kw
	12723
#17	intradermal:ti,kw
	1681
#18	iv:ti,kw
	21303
#19	inject*:ti,kw
	46767
#20	perfus*:ti,kw
	5526
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20
	108072
#22	#10 AND #21
	4703



#23	immunoglob*:ti,kw	11375
#24	immune glob*:ti,kw	637
#25	lg:ti,kw	2189
#26	#23 OR #24 OR #25	12766
#27	#21 AND #26	3099
#28	#13 AND #26	501
#29	alphaglobin:ti,kw	0
#30	endobulin:ti,kw	0
#31	flebogamma:ti,kw	4
#32	gamimmune:ti,kw	0
#33	gammagard:ti,kw	9
#34	gammonativ:ti,kw	0
#35	gamunex:ti,kw	7
#36	globulin n:ti,kw	20
#37	iveegam:ti,kw	0
#38	privigen:ti,kw	1
#39	sandoglobulin:ti,kw	6
#40	venimmune:ti,kw	0
#41	venoglobulin:ti,kw	4
#42	HyQvia:ti,kw	4
#43	Octagam:ti,kw	14
#44	Hizentra:ti,kw	5
#45	Gamunex-C:ti,kw	2
#46	Gammaked:ti,kw	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	71
#48	#9 OR #14 or #22 or #27 or #28 or #47	6751
#49	[mh ^"Anemia, Aplastic"]	184



#50	[mh "Erythroblasts"]	5
#51	#49 AND #50	0
#52	[mh "Red-Cell Aplasia, Pure"]	4
#53	[mh "Erythroblasts"/PA]	3
#54	#51 or #52 or #53	7
#55	erythroblastopenia:ab,ti,kw	2
#56	"pure red cell anemia":ab,ti,kw	28
#57	(erythroblast* NEAR/3 (anemia OR aplasia OR hypoplasia)):ab,ti,kw	0
#58	(erythroid* NEAR/3 (anemia OR aplasia OR hypoplasia)):ab,ti,kw	8
#59	b19:ab,ti,kw AND (anemia:ab,ti,kw OR erythroblast:ab,ti,kw)	6
#60	#55 OR #56 OR #57 OR #58 OR #59	44
#61	#54 OR #60	51
#62	#48 AND #61	4
Comments	0 results for Cochrane Systematic Reviews Database 4 Results for CENTRAL	

Date	12 Jul 2019	
Database	Embase.com	
Search strategy		
#1	intravenous:ti AND immunoglob*:ti	6521
#2	subcutaneous:ti AND immunoglob*:ti	638
#3	intravenous:ti AND antibod*:ti	841
#4	subcutaneous:ti AND antibod*:ti	337
#5	ivig:ti	1719
#6	scig:ti	107
#7	intraglobin*:ti	7
#8	'subcutaneous immunotherapy'/exp	1613



#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	10681
#10	'immunoglobulin'/exp	484894
#11	'intravenous drug administration'/exp	378834
#12	'subcutaneous drug administration'/exp	97788
#13	#11 OR #12	460020
#14	#10 AND #13	12091
#15	intravenous:ti	82817
#16	subcutaneous:ti	31915
#17	intradermal:ti	4186
#18	iv:ti	60672
#19	inject*:ti	126602
#20	perfus*:ti	72464
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	366923
#22	#10 AND #21	11939
#23	immunoglob*:ti	53759
#24	immune AND (globu*:ti OR globi*:ti)	3119
#25	ig:ti	4126
#26	#23 OR #24 OR #25	60636
#27	#21 AND #26	8289
#28	#13 AND #26	3228
#29	alphaglobin:ti	2
#30	endobulin:ti	2
#31	flebogamma:ti	19
#32	gamimmune:ti	0
#33	gammagard:ti	19
#34	gammonativ:ti	1
#35	gamunex:ti	8
#36	'globulin n':ti	4



#37	iveegam:ti	0
#38	privigen:ti	39
#39	sandoglobulin:ti	15
#40	venimmune:ti	0
#41	venoglobulin:ti	4
#42	hyqvia:ti	17
#43	octagam:ti	28
#44	hizentra:ti	55
#45	'gamunex c':ti	2
#46	gammaked:ti	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	209
#48	#9 OR #14 OR #22 OR #27 OR #28 OR #47	24887
#49	'aplastic anemia'/exp AND 'erythroblast'/exp OR 'pure red cell anemia'/exp	3575
#50	(erythroblast* NEAR/3 (anemia OR aplasia OR hypoplasia)):ab,ti,kw	378
#51	(erythroid* NEAR/3 (anemia OR aplasia OR hypoplasia)):ab,ti,kw	617
#52	b19:ab,ti,kw AND (anemia:ab,ti,kw OR erythroblast:ab,ti,kw)	867
#53	#50 OR #51 OR #52	1789
#54	#49 OR #53	5025
#55	#48 AND #54	119
#56	#55 NOT [medline]/lim	19
#57	#56 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	10
#58	#57 AND [2000-2019]/py	4
#59	#58 AND ('meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review')	0
#60	#58 AND (random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti))	0
#61	#58 NOT #60	4
Comments	Line 59 shows 0 exported SR	



Line 60 shows 0 exported RCT

Line 61 exported for All studies

Date	October 18, 2019
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to October 18, 2019>
Search strategy	
1	Immunoglobulins, intravenous/ 12756
2	IVIG.ti,kf. 1209
3	scig.ti,kf. 58
4	intraglobin*.ti,kf. 3
5	(intravenous and antibod*).ti,kf. 830
6	(intravenous and immunoglob*).ti,kf. 5409
7	(subcutaneous and antibod*).ti,kf. 340
8	(subcutaneous and immunoglob*).ti,kf. 349
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 15264
10	exp Immunoglobulins/ 867444
11	exp Administration, Intravenous/ 140900
12	exp Injections, Subcutaneous/ 39686
13	11 or 12 176275
14	10 and 13 11802
15	intravenous.ti,kf. 69616
16	subcutaneous.ti,kf. 26484
17	intradermal.ti,kf. 3971
18	iv.ti,kf. 55055
19	inject*.ti,kf. 112347
20	perfus*.ti,kf. 60484
21	15 or 16 or 17 or 18 or 19 or 20 315513



22	10 and 21	15598
23	immunoglob*.ti,kf.	49979
24	immune glob*.ti,kf.	1552
25	Ig.ti,kf.	3747
26	23 or 24 or 25	54815
27	21 and 26	6657
28	13 and 26	1206
29	alphaglobin.ti,kf.	1
30	endobulin.ti,kf.	2
31	flebogamma.ti,kf.	14
32	gamimmune.ti,kf.	0
33	gammagard.ti,kf.	12
34	gammonativ.ti,kf.	0
35	gamunex.ti,kf.	5
36	globulin n.ti,kf.	3
37	iveegam.ti,kf.	0
38	privigen.ti,kf.	17
39	sandoglobulin.ti,kf.	16
40	venimmune.ti,kf.	0
41	venoglobulin.ti,kf.	2
42	venoglobulin.ti,kf.	2
43	HyQvia.ti,kf.	1
44	Octagam.ti,kf.	11
45	Hizentra.ti,kf.	21
46	Gamunex-C.ti,kf.	1
47	Gammaked.ti,kf.	0
48	or/29-47	99
49	9 or 14 or 22 or 27 or 28 or 48	33430



50	Anemia, Aplastic/	13471
51	exp Erythroblasts/	3946
52	50 and 51	123
53	exp Red-Cell Aplasia, Pure/	1998
54	exp erythroblasts/pa	555
55	52 or 53 or 54	2635
56	erythroblastopenia.ab,ti,kf,jw.	411
57	pure red cell anemia.ab,ti,kf,jw.	35
58	(erythroblast* adj3 anemia).ab,ti,kf,jw.	1048
59	(erythroblast* adj3 aplasia).ab,ti,kf,jw.	22
60	(erythroblast* adj3 hypoplasia).ab,ti,kf,jw.	17
61	(erythroid? adj3 aplasia).ab,ti,kf,jw.	124
62	(erythroid? adj3 anemia).ab,ti,kf,jw.	114
63	(erythroid? adj3 hypoplasia).ab,ti,kf,jw.	255
64	(anemia and B19).ab,ti,kf,jw.	635
65	(erythroblast* and b19).ab,ti,kf,jw.	100
66	56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65	2534
67	55 or 66	4750
68	49 and 67	124
69	limit 68 to yr="2000-2019"	84
Comments	Line 69 exported for All studies	

1.3.13 Secondary Immunodeficiency

Date	November 01, 2019
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to November 01, 2019>
Search strategy	



1	(secondary adj3 immun# deficienc*).ab,ti,kf.	155
2	(acquired adj3 immun# deficienc*).ab,ti,kf.	6239
3	(induce* adj3 immun# deficienc*).ab,ti,kf.	135
4	(immun# deficienc* adj3 after).ab,ti,kf.	60
5	(immun# deficienc* adj3 following).ab,ti,kf.	42
6	(immun# deficienc* adj3 develop*).ab,ti,kf.	206
7	(immun# deficienc* adj3 cause*).ab,ti,kf.	266
8	(immun# deficienc* adj3 associate*).ab,ti,kf.	469
9	(immun# deficienc* adj3 resulted).ab,ti,kf.	5
10	(immun# deficienc* adj3 related).ab,ti,kf.	347
11	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10	7175
12	(secondary adj3 immun#deficienc*).ab,ti,kf.	803
13	(acquired adj3 immun#deficienc*).ab,ti,kf.	21030
14	(induce* adj3 immun#deficienc*).ab,ti,kf.	1047
15	(immun#deficienc* adj3 after).ab,ti,kf.	559
16	(immun#deficienc* adj3 following).ab,ti,kf.	223
17	(immun#deficienc* adj3 develop*).ab,ti,kf.	1152
18	(immun#deficienc* adj3 cause*).ab,ti,kf.	1685
19	(immun#deficienc* adj3 associate*).ab,ti,kf.	4143
20	(immun#deficienc* adj3 resulted).ab,ti,kf.	57
21	(immun#deficienc* adj3 related).ab,ti,kf.	2100
22	12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21	29563
23	(secondary adj3 (immuno suppress* or immuno depress* or immune suppress* or immune depress*)).ab,ti,kf.	40
24	(acquired adj3 (immuno suppress* or immuno depress* or immune suppress* or immune depress*)).ab,ti,kf.	21
25	(induce* adj3 (immuno suppress* or immuno depress* or immune suppress* or immune depress*)).ab,ti,kf.	997



26	((immuno suppress* or immuno depress* or immune suppress* or immune depress*) adj3 after).ab,ti,kf.	209
27	((immuno suppress* or immuno depress* or immune suppress* or immune depress*) adj3 following).ab,ti,kf.	95
28	((immuno suppress* or immuno depress* or immune suppress* or immune depress*) adj3 develop*).ab,ti,kf.	131
29	((immuno suppress* or immuno depress* or immune suppress* or immune depress*) adj3 cause*).ab,ti,kf.	283
30	((immuno suppress* or immuno depress* or immune suppress* or immune depress*) adj3 associate*).ab,ti,kf.	461
31	((immuno suppress* or immuno depress* or immune suppress* or immune depress*) adj3 resulted).ab,ti,kf.	24
32	((immuno suppress* or immuno depress* or immune suppress* or immune depress*) adj3 related).ab,ti,kf.	130
33	23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32	2224
34	(secondary adj3 immun###?press*).ab,ti,kf.	405
35	(acquired adj3 immun###?press*).ab,ti,kf.	202
36	(induce* adj3 immun###?press*).ab,ti,kf.	5465
37	(immun###?press* adj3 after).ab,ti,kf.	4806
38	(immun###?press* adj3 following).ab,ti,kf.	1393
39	(immun###?press* adj3 develop*).ab,ti,kf.	1826
40	(immun###?press* adj3 cause*).ab,ti,kf.	1939
41	(immun###?press* adj3 associate*).ab,ti,kf.	3338
42	(immun###?press* adj3 resulted).ab,ti,kf.	437
43	(immun###?press* adj3 related).ab,ti,kf.	1563
44	34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43	19845
45	(secondary adj3 immunologic?? def#c*).ab,ti,kf.	35
46	(acquired adj3 immunologic?? def#c*).ab,ti,kf.	60
47	(induce* adj3 immunologic?? def#c*).ab,ti,kf.	21
48	(immunologic?? def#c* adj3 after).ab,ti,kf.	9



49	(immunologic?? def#c* adj3 following).ab,ti,kf.	4
50	(immunologic?? def#c* adj3 develop*).ab,ti,kf.	24
51	(immunologic?? def#c* adj3 cause*).ab,ti,kf.	37
52	(immunologic?? def#c* adj3 associate*).ab,ti,kf.	64
53	(immunologic?? def#c* adj3 resulted).ab,ti,kf.	1
54	(immunologic?? def#c* adj3 related).ab,ti,kf.	22
55	45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54	260
56	11 or 22 or 33 or 44 or 55	57269
57	Protein-Losing Enteropathies/	2171
58	exudative enteropath*.ab,ti,kf.	163
59	idiopathic hypercatabolic hypoproteinemia?.ab,ti,kf.	2
60	protein losing enteropath*.ab,ti,kf.	1632
61	58 or 59 or 60	1770
62	57 or 61	2839
63	(secondary or acquired or induce* or after or following or develop* or cause* or resulted or related).ab,ti,kf.	12774215
64	agammaglobulinemia/	6283
65	63 and 64	2182
66	((secondary or acquired or induce* or after or following or develop* or cause* or resulted or related) adj3 agammaglobulin*).ab,ti,kf.	214
67	((secondary or acquired or induce* or after or following or develop* or cause* or resulted or related) adj3 hypogammaglobulin*).ab,ti,kf.	530
68	66 or 67	736
69	65 or 68	2423
70	56 or 62 or 69	62179
71	Immunoglobulins, intravenous/	12788
72	IVIG.ti,kf.	1213
73	scig.ti,kf.	59
74	intraglobin*.ti,kf.	3



75	(intravenous and antibod*).ti,kf.	833
76	(intravenous and immunoglob*).ti,kf.	5419
77	(subcutaneous and antibod*).ti,kf.	342
78	(subcutaneous and immunoglob*).ti,kf.	350
79	71 or 72 or 73 or 74 or 75 or 76 or 77 or 78	15294
80	exp Immunoglobulins/	868570
81	exp Administration, Intravenous/	141034
82	exp Injections, Subcutaneous/	39733
83	81 or 82	176454
84	80 and 83	11821
85	intravenous.ti,kf.	69696
86	subcutaneous.ti,kf.	26533
87	intradermal.ti,kf.	3975
88	iv.ti,kf.	55103
89	inject*.ti,kf.	112500
90	perfus*.ti,kf.	60558
91	85 or 86 or 87 or 88 or 89 or 90	315912
92	80 and 91	15627
93	immunoglob*.ti,kf.	50032
94	immune glob*.ti,kf.	1554
95	Ig.ti,kf.	3752
96	93 or 94 or 95	54872
97	91 and 96	6667
98	83 and 96	1208
99	alphaglobin.ti,kf.	1
100	endobulin.ti,kf.	2
101	flebogamma.ti,kf.	14
102	gamimmune.ti,kf.	0



103	gammagard.ti,kf.	12
104	gammonativ.ti,kf.	0
105	gamunex.ti,kf.	5
106	globulin n.ti,kf.	3
107	iveegam.ti,kf.	0
108	privigen.ti,kf.	17
109	sandoglobulin.ti,kf.	16
110	venimmune.ti,kf.	0
111	venoglobulin.ti,kf.	2
112	venoglobulin.ti,kf.	2
113	HyQvia.ti,kf.	1
114	Octagam.ti,kf.	11
115	Hizentra.ti,kf.	21
116	Gamunex-C.ti,kf.	1
117	Gammaked.ti,kf.	0
118	or/99-117	99
119	79 or 84 or 92 or 97 or 98 or 118	33485
120	70 and 119	759
121	limit 120 to yr="2008-2019"	321
122	('systematic review'.ti. or 'meta-analysis'.pt. or 'meta-analysis'.ti. or 'systematic literature review'.ti. or 'this systematic review'.tw. or 'pooling project'.tw. or ('systematic review'.ab,ti. and review.pt.) or 'meta synthesis'.ti. or 'meta synthesis'.ti. or 'integrative review'.tw. or 'integrative research review'.tw. or 'rapid review'.tw. or 'consensus development conference'.pt. or 'practice guideline'.pt. or 'drug class reviews'.ti. or 'cochrane database syst rev'.ja. or 'acp journal club'.ja. or 'health technol assess'.ja. or 'evid rep technol assess summ'.ja. or 'jbi database system rev implement rep'.ja. or ('clinical guideline' and management).tw. or (('evidence based'.ti. or evidence-based medicine/ or 'best practice'.ti. or 'best practices'.ti. or 'evidence synthesis'.ab,ti.) and (((review.pt. or diseases category/ or behavior.mp.) and behavior mechanisms/) or therapeutics/ or 'evaluation studies'.pt. or 'validation studies'.pt. or guideline.pt. or pmcbook.mp.)) or ((systematic or systematically or critical or 'study selection' or ((predetermined or	372366



inclusion) and criteri*) or 'exclusion criteri*' or 'main outcome measures' or 'standard of care' or 'standards of care').tw. and ((survey or surveys or overview* or review or reviews or search* or handsearch).tw. or analysis.ti. or critique.ab,ti. or appraisal.tw. or (reduction.tw. and (risk/ or risk.tw.) and (death or recurrence).mp.)) and ((literature or articles or publications or publication or bibliography or bibliographies or published or pooled data or unpublished or citation or citations or database or internet or textbooks or references or scales or papers or datasets or trials or meta-analy* or (clinical and studies)).tw. or treatment outcome/ or 'treatment outcome'.tw. or pmcbook.mp.))) not (letter or 'newspaper article').pt. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

123	121 and 122	11
124	randomized controlled trial.pt.	493679
125	controlled clinical trial.pt.	93406
126	randomized.ti,ab.	495896
127	placebo.ti,ab.	208027
128	clinical trials as topic/	189033
129	randomly.ti,ab.	321724
130	trial?.ti.	276471
131	124 or 125 or 126 or 127 or 128 or 129 or 130	1280666
132	exp animal/ not humans/	4639799
133	131 not 132	1179017
134	121 and 133	32
Comments	Line 122: NLM systematic review filter translated for Ovid Line 124-133 Cochrane RCT filter maximizing both sensitivity and specificity	

Date	6 Nov 2019
Database	Embase.com

**Search strategy**

#1	(secondary NEAR/3 'immun? deficienc*'):ab,ti,kw	226
#2	(acquired NEAR/3 'immun? deficienc*'):ab,ti,kw	7103
#3	(induce* NEAR/3 'immun? deficienc*'):ab,ti,kw	165
#4	('immun? deficienc*' NEXT/3 after):ab,ti,kw	81
#5	('immun? deficienc*' NEXT/3 following):ab,ti,kw	38
#6	('immun? deficienc*' NEAR/3 develop*):ab,ti,kw	247
#7	('immun? deficienc*' NEAR/3 cause*):ab,ti,kw	346
#8	('immun? deficienc*' NEAR/3 associate*):ab,ti,kw	599
#9	('immun? deficienc*' NEAR/3 resulted):ab,ti,kw	5
#10	('immun? deficienc*' NEAR/3 related):ab,ti,kw	406
#11	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10	8393
#12	(secondary NEAR/3 immun?deficienc*):ab,ti,kw	1228
#13	(acquired NEAR/3 immun?deficienc*):ab,ti,kw	20121
#14	(induce* NEAR/3 immun?deficienc*):ab,ti,kw	1200
#15	(immun?deficienc* NEAR/3 after):ab,ti,kw	689
#16	(immun?deficienc* NEAR/3 following):ab,ti,kw	263
#17	(immun?deficienc* NEAR/3 develop*):ab,ti,kw	1407
#18	(immun?deficienc* NEAR/3 cause*):ab,ti,kw	2247
#19	(immun?deficienc* NEAR/3 associate*):ab,ti,kw	5071
#20	(immun?deficienc* NEAR/3 resulted):ab,ti,kw	66
#21	(immun?deficienc* NEAR/3 related):ab,ti,kw	2382
#22	#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21	31014
#23	(secondary NEAR/3 ('immun\$ suppress*' OR 'immun\$ depress*')):ab,ti,kw	61
#24	(acquired NEAR/3 ('immun\$ suppress*' OR 'immun\$ depress*')):ab,ti,kw	39
#25	(induce* NEAR/3 ('immun\$ suppress*' OR 'immun\$ depress*')):ab,ti,kw	1431
#26	('immun\$ suppress*' OR 'immun\$ depress*') NEAR/3 after):ab,ti,kw	361
#27	('immun\$ suppress*' OR 'immun\$ depress*') NEAR/3 following):ab,ti,kw	143



#28	(('immun\$ suppress*' OR 'immun\$ depress*') NEAR/3 develop*):ab,ti,kw	202
#29	(('immun\$ suppress*' OR 'immun\$ depress*') NEAR/3 cause*):ab,ti,kw	377
#30	(('immun\$ suppress*' OR 'immun\$ depress*') NEAR/3 associate*):ab,ti,kw	701
#31	(('immun\$ suppress*' OR 'immun\$ depress*') NEAR/3 resulted):ab,ti,kw	32
#32	(('immun\$ suppress*' OR 'immun\$ depress*') NEAR/3 related):ab,ti,kw	180
#33	#23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32	3279
#34	(secondary NEAR/3 immun???\$press*):ab,ti,kw	664
#35	(acquired NEAR/3 immun???\$press*):ab,ti,kw	306
#36	(induce* NEAR/3 immun???\$press*):ab,ti,kw	7059
#37	(immun???\$press* NEAR/3 after):ab,ti,kw	7499
#38	(immun???\$press* NEAR/3 following):ab,ti,kw	2090
#39	(immun???\$press* NEAR/3 develop*):ab,ti,kw	2593
#40	(immun???\$press* NEAR/3 cause*):ab,ti,kw	2664
#41	(immun???\$press* NEAR/3 associate*):ab,ti,kw	5079
#42	(immun???\$press* NEAR/3 resulted):ab,ti,kw	578
#43	(immun???\$press* NEAR/3 related):ab,ti,kw	2345
#44	#34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43	28662
#45	(secondary NEAR/3 'immunologic\$\$ def?c*'):ab,ti,kw	34
#46	(acquired NEAR/3 'immunologic\$\$ def?c*'):ab,ti,kw	53
#47	(induce* NEAR/3 'immunologic\$\$ def?c*'):ab,ti,kw	30
#48	('immunologic\$\$ def?c*' NEAR/3 after):ab,ti,kw	14
#49	('immunologic\$\$ def?c*' NEAR/3 following):ab,ti,kw	7
#50	('immunologic\$\$ def?c*' NEAR/3 develop*):ab,ti,kw	43
#51	('immunologic\$\$ def?c*' NEAR/3 cause*):ab,ti,kw	51
#52	('immunologic\$\$ def?c*' NEAR/3 associate*):ab,ti,kw	93
#53	('immunologic\$\$ def?c*' NEAR/3 resulted):ab,ti,kw	1
#54	('immunologic\$\$ def?c*' NEAR/3 related):ab,ti,kw	38
#55	#45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54	346



#56	#11 OR #22 OR #33 OR #44 OR #55	69622
#57	'protein losing gastroenteropathy'/de	3432
#58	'exudative enteropath*':ab,ti,kw	188
#59	'idiopathic hypercatabolic hypoproteinemia\$':ab,ti,kw	3
#60	'protein losing enteropath*':ab,ti,kw	2288
#61	#58 OR #59 OR #60	2467
#62	#57 OR #61	3978
#63	secondary:ab,ti,kw OR acquired:ab,ti,kw OR induce*:ab,ti,kw OR after:ab,ti,kw OR following:ab,ti,kw OR develop*:ab,ti,kw OR cause*:ab,ti,kw OR resulted:ab,ti,kw OR related:ab,ti,kw	16257270
#64	'agammaglobulinemia'/exp	9425
#65	#63 AND #64	4460
#66	((secondary OR acquired OR induce* OR after OR following OR develop* OR cause* OR resulted OR related) NEAR/3 agammaglobulin*):ab,ti,kw	274
#67	((secondary OR acquired OR induce* OR after OR following OR develop* OR cause* OR resulted OR related) NEAR/3 hypogammaglobulin*):ab,ti,kw	902
#68	#66 OR #67	1166
#69	#65 OR #68	5186
#70	#56 OR #62 OR #69	77912
#71	(intravenous:ab,ti,kw OR subcutaneous:ab,ti,kw) AND (immunoglob*:ab,ti,kw OR antibod*:ab,ti,kw)	53013
#72	ivig:ab,ti,kw OR scig:ab,ti,kw	16634
#73	intraglobin*:ab,ti,kw	34
#74	#71 OR #72 OR #73	59782
#75	'subcutaneous immunotherapy'/exp	1695
#76	#74 OR #75	61278
#77	'immunoglobulin'/exp	494932
#78	'intravenous drug administration'/exp	380445
#79	'subcutaneous drug administration'/exp	97824



#80	#78 OR #79	461665
#81	#77 AND #80	12148
#82	intravenous:ab,ti,kw	375947
#83	subcutaneous:ab,ti,kw	178296
#84	intradermal:ab,ti,kw	19095
#85	iv:ab,ti,kw	495779
#86	inject*:ab,ti,kw	957070
#87	perfus*:ab,ti,kw	278722
#88	#82 OR #83 OR #84 OR #85 OR #86 OR #87	2054203
#89	#77 AND #88	59354
#90	immunoglob*:ab,ti,kw	192619
#91	immune AND glob*:ab,ti,kw	33825
#92	ig:ab,ti,kw	48313
#93	#90 OR #91 OR #92	251640
#94	#88 AND #93	42767
#95	#80 AND #93	6102
#96	alphaglobin:ab,ti,kw,tn	12
#97	endobulin:ab,ti,kw,tn	293
#98	flebogamma:ab,ti,kw,tn	286
#99	gamimmune:ab,ti,tn	50
#100	gammagard:ab,ti,tn	768
#101	gammonativ:ab,ti,tn	64
#102	gamunex:ab,ti,tn	327
#103	globulin AND n:ab,ti,tn	6329
#104	iveegam:ab,ti,tn	115
#105	privigen:ab,ti,kw,tn	356
#106	sandoglobulin:ab,ti,kw,tn	1203
#107	venimmune:ab,ti,kw,tn	2



#108	venoglobulin:ab,ti,kw,tn	263
#109	venoglobulin:ab,ti,kw,tn	263
#110	hyqvia:ab,ti,kw,tn	55
#111	octagam:ab,ti,kw,tn	404
#112	hizentra:ab,ti,kw,tn	276
#113	'gamunex c':ab,ti,kw,tn	48
#114	gammaked:ab,ti,kw,tn	13
#115	#96 OR #97 OR #98 OR #99 OR #100 OR #101 OR #102 OR #103 OR #104 OR #105 OR #106 OR #107 OR #108 OR #109 OR #110 OR #111 OR #112 OR #113 OR #114	9460
#116	#76 OR #81 OR #89 OR #94 OR #95 OR #115	112386
#117	#116 AND #70	3340
#118	#117 AND [2008-2019]/py	2142
#119	#118 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	816
#120	#119 NOT [medline]/lim	169
#121	#120 AND ('meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review')	9
#122	#120 AND (random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti))	13
#123	#120 NOT (#121 OR #122)	149

Comments

Date	13/11/2019 21:51:23
Database	Cochrane@Wiley.com
Search strategy	
#1	(secondary NEAR/3 (immun? NEXT deficienc*)):ab,ti,kw
#2	(acquired NEAR/3 (immun? NEXT deficienc*)):ab,ti,kw
#3	(induce* NEAR/3 (immun? NEXT deficienc*)):ab,ti,kw
#4	((immun? NEXT deficienc*) NEXT/3 after):ab,ti,kw



#5	((immun? NEXT deficienc*) NEXT/3 following):ab,ti,kw	0
#6	((immun? NEXT deficienc*) NEAR/3 develop*):ab,ti,kw	7
#7	((immun? NEXT deficienc*) NEAR/3 cause*):ab,ti,kw	3
#8	((immun? NEXT deficienc*) NEAR/3 associate*):ab,ti,kw	12
#9	((immun? NEXT deficienc*) NEAR/3 resulted):ab,ti,kw	0
#10	((immun? NEXT deficienc*) NEAR/3 related):ab,ti,kw	26
#11	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10	1119
#12	(secondary NEAR/3 immun?deficienc*):ab,ti,kw	38
#13	(acquired NEAR/3 immun?deficienc*):ab,ti,kw	2115
#14	(induce* NEAR/3 immun?deficienc*):ab,ti,kw	13
#15	(immun?deficienc* NEXT/3 after):ab,ti,kw	12
#16	(immun?deficienc* NEXT/3 following):ab,ti,kw	2
#17	(immun?deficienc* NEAR/3 develop*):ab,ti,kw	33
#18	(immun?deficienc* NEAR/3 cause*):ab,ti,kw	24
#19	(immun?deficienc* NEAR/3 associate*):ab,ti,kw	159
#20	(immun?deficienc* NEAR/3 resulted):ab,ti,kw	0
#21	(immun?deficienc* NEAR/3 related):ab,ti,kw	68
#22	#12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21	2373
#23	(secondary NEAR/3 (immun? NEXT (suppress* OR depress*)))):ab,ti,kw	4
#24	(acquired NEAR/3 (immun? NEXT (suppress* OR depress*)))):ab,ti,kw	0
#25	(induce* NEAR/3 (immun? NEXT (suppress* OR depress*)))):ab,ti,kw	47
#26	((immun? NEXT (suppress* OR depress*)) NEXT/3 after):ab,ti,kw	20
#27	((immun? NEXT (suppress* OR depress*)) NEAR/3 following):ab,ti,kw	4
#28	((immun? NEXT (suppress* OR depress*)) NEAR/3 develop*):ab,ti,kw	2
#29	((immun? NEXT (suppress* OR depress*)) NEAR/3 cause*):ab,ti,kw	9
#30	((immun? NEXT (suppress* OR depress*)) NEAR/3 associate*):ab,ti,kw	22
#31	((immun? NEXT (suppress* OR depress*)) NEAR/3 resulted):ab,ti,kw	0
#32	((immun? NEXT (suppress* OR depress*)) NEAR/3 related):ab,ti,kw	7



#33	#23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32	109
#34	(secondary NEAR/3 (immun?suppress* or immun?depress*)):ab,ti,kw	39
#35	(acquired NEAR/3 (immun?suppress* or immun?depress*)):ab,ti,kw	7
#36	(induce* NEAR/3 (immun?suppress* or immun?depress*)):ab,ti,kw	211
#37	((immun?suppress* or immun?depress*) NEAR/3 after):ab,ti,kw	471
#38	((immun?suppress* or immun?depress*) NEAR/3 following):ab,ti,kw	136
#39	((immun?suppress* or immun?depress*) NEAR/3 develop*):ab,ti,kw	48
#40	((immun?suppress* or immun?depress*) NEAR/3 cause*):ab,ti,kw	69
#41	((immun?suppress* or immun?depress*) NEAR/3 associate*):ab,ti,kw	246
#42	((immun?suppress* or immun?depress*) NEAR/3 resulted):ab,ti,kw	27
#43	((immun?suppress* or immun?depress*) NEAR/3 related):ab,ti,kw	87
#44	#34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43	1233
#45	(secondary NEAR/3 (immunologic?? NEXT def?c*)):ab,ti,kw	0
#46	(acquired NEAR/3 (immunologic?? NEXT def?c*)):ab,ti,kw	1
#47	(induce* NEAR/3 (immunologic?? NEXT def?c*)):ab,ti,kw	4
#48	((immunologic?? NEXT def?c*) NEAR/3 after):ab,ti,kw	0
#49	((immunologic?? NEXT def?c*) NEAR/3 following):ab,ti,kw	0
#50	((immunologic?? NEXT def?c*) NEAR/3 develop*):ab,ti,kw	1
#51	((immunologic?? NEXT def?c*) NEAR/3 cause*):ab,ti,kw	0
#52	((immunologic?? NEXT def?c*) NEAR/3 associate*):ab,ti,kw	1
#53	((immunologic?? NEXT def?c*) NEAR/3 resulted):ab,ti,kw	0
#54	((immunologic?? NEXT def?c*) NEAR/3 related):ab,ti,kw	0
#55	#45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54	7
#56	#11 or #22 or #33 or #44 or #55	4575
#57	[mh ^"Protein-Losing Enteropathies"]	5
#58	exudative enteropath*:ab,ti,kw	0
#59	idiopathic hypercatabolic hypoproteinemia?:ab,ti,kw	0
#60	protein losing enteropath*:ab,ti,kw	17



#61	#58 or #59 or #60	17
#62	#57 or #61	17
#63	(secondary or acquired or induce* or after or following or develop* or cause* or resulted or related):ab,ti,kw	994076
#64	[mh ^"agammaglobulinemia"]	43
#65	#63 and #64	27
#66	((secondary or acquired or induce* or after or following or develop* or cause* or resulted or related) NEAR/3 agammaglobulin*):ab,ti,kw	3
#67	((secondary or acquired or induce* or after or following or develop* or cause* or resulted or related) NEAR/3 hypogammaglobulin*):ab,ti,kw	23
#68	#66 or #67	25
#69	#65 or #68	43
#70	#56 or #62 or #69	4635
#71	[mh ^"Immunoglobulins, intravenous"]	786
#72	IVIG:ti,kw	285
#73	scig:ti,kw	10
#74	intraglobin*:ti,kw	2
#75	(intravenous NEAR/5 antibod*):ti,kw	205
#76	(intravenous NEAR/5 immunoglob*):ti,kw	1474
#77	(subcutaneous NEAR/5 antibod*):ti,kw	151
#78	(subcutaneous NEAR/5 immunoglob*):ti,kw	119
#79	#71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78	1974
#80	[mh "Immunoglobulins"]	22998
#81	[mh "Administration, Intravenous"]	18130
#82	[mh "Injections, Subcutaneous"]	4319
#83	#81 OR #82	21945
#84	#80 AND #83	1528
#85	intravenous:ti,kw	53614
#86	subcutaneous:ti,kw	12924



#87	intradermal:ti,kw	1701
#88	iv:ti,kw	21499
#89	inject*:ti,kw	48069
#90	perfus*:ti,kw	5709
#91	#85 OR #86 OR #87 OR #88 OR #89 OR #90	110411
#92	#80 AND #91	4834
#93	immunoglob*:ti,kw	11462
#94	immune glob*:ti,kw	654
#95	Ig:ti,kw	2227
#96	#93 OR #94 OR #95	12886
#97	#91 AND #96	3116
#98	#83 AND #96	501
#99	alphaglobin:ti,kw	0
#100	endobulin:ti,kw	0
#101	flebogamma:ti,kw	4
#102	gamimmune:ti,kw	0
#103	gammagard:ti,kw	9
#104	gammonativ:ti,kw	0
#105	gamunex:ti,kw	7
#106	globulin n:ti,kw	20
#107	iveegam:ti,kw	0
#108	privigen:ti,kw	1
#109	sandoglobulin:ti,kw	6
#110	venimmune:ti,kw	0
#111	venoglobulin:ti,kw	4
#112	HyQvia:ti,kw	4
#113	Octagam:ti,kw	14
#114	Hizentra:ti,kw	5



#115	Gamunex-C:ti,kw	2
#116	Gammaked:ti,kw	0
#117	#99 OR #100 OR #101 OR #102 OR #103 OR #104 OR #105 OR #106 OR #107 OR #108 OR #109 OR #110 OR #41 OR #112 OR #113 OR #114 OR #115 OR #116	313
#118	#79 or #84 or #92 or #97 or #98 or #117	6747
#119	#70 AND #118	331
#120	#119 with Cochrane Library publication date Between Jan 2008 and Dec 2019	234
Comments		

1.3.14 Solid Organ Transplantation

Date	12/07/2019 14:11:59	
Database	Cochrane@Wiley.com	
Search strategy		
#0	[mh ^"Immunoglobulins, intravenous"]	777
#0	IVIG:ti,kw	278
#0	scig:ti,kw	10
#0	intraglobin*:ti,kw	2
#0	(intravenous NEAR/5 antibod*):ti,kw	205
#0	(intravenous NEAR/5 immunoglob*):ti,kw	1481
#0	(subcutaneous NEAR/5 antibod*):ti,kw	151
#0	(subcutaneous NEAR/5 immunoglob*):ti,kw	113
#9	[mh ^"Immunoglobulins, intravenous"] or IVIG:ti,kw or scig:ti,kw or intraglobin*:ti,kw or (intravenous NEAR/5 antibod*):ti,kw or (intravenous NEAR/5 immunoglob*):ti,kw or (subcutaneous NEAR/5 antibod*):ti,kw or (subcutaneous NEAR/5 immunoglob*):ti,kw	2378
#10	[mh "Immunoglobulins"]	22382
#11	[mh "Administration, Intravenous"]	17966
#12	[mh "Injections, Subcutaneous"]	4257
#13	#11 OR #12	21726



#14	#10 AND #13	1482
#15	intravenous:ti,kw	52959
#16	subcutaneous:ti,kw	12723
#17	intradermal:ti,kw	1681
#18	iv:ti,kw	21303
#19	inject*:ti,kw	46767
#20	perfus*:ti,kw	5526
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	108072
#22	#10 AND #21	4703
#23	immunoglob*:ti,kw	11375
#24	immune glob*:ti,kw	637
#25	Ig:ti,kw	2189
#26	#23 OR #24 OR #25	12766
#27	#21 AND #26	3099
#28	#13 AND #26	501
#29	alphaglobulin:ti,kw	0
#30	endobulin:ti,kw	0
#31	flebogamma:ti,kw	4
#32	gamimmune:ti,kw	0
#33	gammagard:ti,kw	9
#34	gammonativ:ti,kw	0
#35	gamunex:ti,kw	7
#36	globulin n:ti,kw	20
#37	iveegam:ti,kw	0
#38	privigen:ti,kw	1
#39	sandoglobulin:ti,kw	6
#40	venimmune:ti,kw	0
#41	venoglobulin:ti,kw	4



#42	HyQvia:ti,kw	4
#43	Octagam:ti,kw	14
#44	Hizentra:ti,kw	5
#45	Gamunex-C:ti,kw	2
#46	Gammaked:ti,kw	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	71
#48	#9 OR #14 or #22 or #27 or #28 or #47	6751
#49	[mh "Graft Rejection"]	2192
#50	(graft* NEAR/5 reject*):ab,ti,kw	4667
#51	(transplant* NEAR/5 reject*):ab,ti,kw	1765
#52	((graft* or allograft* or organ* or transplant*) and reject*):ti,kw	4553
#53	#50 OR #51 OR #52	5412
#54	#49 OR #53	5412
#55	#48 AND #54	203
#56	"pure red cell anemia":ab,ti,kw	28
#57	(erythroblast* NEAR/3 (anemia OR aplasia OR hypoplasia)):ab,ti,kw	0
#58	(erythroid* NEAR/3 (anemia OR aplasia OR hypoplasia)):ab,ti,kw	8
#59	b19:ab,ti,kw AND (anemia:ab,ti,kw OR erythroblast:ab,ti,kw)	6
#60	#55 OR #56 OR #57 OR #58 OR #59	245
#61	#54 OR #60	5454
#62	#48 AND #61	207
#63	#62 with Publication Year from 2004 to 2019, in Trials	168
Comments	Line #62 is a mix of search for transplant reject and pure red cell anemia. The publication year filter should have been set on line #55. No results missed, just a little more noise. The same search run on 21st of October 2019 shows less results on line 9 (1973), and no more SR. 3 results for Cochrane Systematic Reviews Database 168 Results for CENTRAL	



Date	12 Jul 2019
Database	Embase.com
Search strategy	
#1	intravenous:ti AND immunoglob*:ti
#2	subcutaneous:ti AND immunoglob*:ti
#3	intravenous:ti AND antibod*:ti
#4	subcutaneous:ti AND antibod*:ti
#5	ivig:ti
#6	scig:ti
#7	intraglobin*:ti
#8	'subcutaneous immunotherapy'/exp
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10	'immunoglobulin'/exp
#11	'intravenous drug administration'/exp
#12	'subcutaneous drug administration'/exp
#13	#11 OR #12
#14	#10 AND #13
#15	intravenous:ti
#16	subcutaneous:ti
#17	intradermal:ti
#18	iv:ti
#19	inject*:ti
#20	perfus*:ti
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20
#22	#10 AND #21
#23	immunoglob*:ti
#24	immune AND (globu*:ti OR globi*:ti)
#25	ig:ti



#26	#23 OR #24 OR #25	60636
#27	#21 AND #26	8289
#28	#13 AND #26	3228
#29	alphaglobin:ti	2
#30	endobulin:ti	2
#31	flebogamma:ti	19
#32	gamimmune:ti	0
#33	gammagard:ti	19
#34	gammonativ:ti	1
#35	gamunex:ti	8
#36	'globulin n':ti	4
#37	iveegam:ti	0
#38	privigen:ti	39
#39	sandoglobulin:ti	15
#40	venimmune:ti	0
#41	venoglobulin:ti	4
#42	hyqvia:ti	17
#43	octagam:ti	28
#44	hizentra:ti	55
#45	'gamunex c':ti	2
#46	gammaked:ti	0
#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	209
#48	#9 OR #14 OR #22 OR #27 OR #28 OR #47	24887
#49	'graft rejection':exp	110014
#50	(graft* NEAR/5 reject*):ab,ti,kw	27629
#51	(transplant* NEAR/5 reject*):ab,ti,kw	28786



#52	(graft*:ti,kw OR allograft*:ti,kw OR organ*:ti,kw OR transplant*:ti,kw) AND reject*:ti,kw	25601
#53	#50 OR #51 OR #52	57347
#54	#49 OR #53	126107
#55	#48 AND #54	673
#56	#55 NOT [medline]/lim	194
#57	#56 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	43
#58	#57 AND [2004-2019]/py	19
#59	#58 AND ('meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review')	0
#60	#58 AND (random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti))	3
#61	#58 NOT #60	16
Comments	Line 59 shows no SR exported Line 60 exported for RCT Line 61 exported for All studies except SR or RCT	

Date	July 10, 2019	
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to July 10, 2019>	
Search strategy		
1	Graft Rejection/	58155
2	(graft* adj5 reject*).ab,ti,kf,jw.	17761
3	(transplant* adj5 reject*).ab,ti,kf,jw.	16634
4	((graft* or allograft* or organ* or transplant*) and reject*).ti,kf.	15981
5	2 or 3 or 4	37037
6	1 or 5	72644
7	Immunoglobulins, intravenous/	12586
8	IVIG.ti,kf.	1169



9	scig.ti,kf.	54
10	intraglobin*.ti,kf.	3
11	(intravenous and antibod*).ti,kf.	815
12	(intravenous and immunoglob*).ti,kf.	5335
13	(subcutaneous and antibod*).ti,kf.	333
14	(subcutaneous and immunoglob*).ti,kf.	331
15	7 or 8 or 9 or 10 or 11 or 12 or 13 or 14	15039
16	exp Immunoglobulins/	859270
17	exp Administration, Intravenous/	139807
18	exp Injections, Subcutaneous/	39396
19	17 or 18	174914
20	16 and 19	11645
21	intravenous.ti,kf.	68924
22	subcutaneous.ti,kf.	26091
23	intradermal.ti,kf.	3934
24	iv.ti,kf.	54554
25	inject*.ti,kf.	110823
26	perfus*.ti,kf.	59663
27	21 or 22 or 23 or 24 or 25 or 26	311674
28	16 and 27	15391
29	immunoglob*.ti,kf.	49486
30	immune glob*.ti,kf.	1538
31	Ig.ti,kf.	3712
32	29 or 30 or 31	54286
33	27 and 32	6561
34	19 and 32	1199
35	alphaglobin.ti,kf.	1
36	endobulin.ti,kf.	2



37	flebogamma.ti,kf.	13
38	gamimmune.ti,kf.	0
39	gammagard.ti,kf.	12
40	gammonativ.ti,kf.	0
41	gamunex.ti,kf.	5
42	globulin n.ti,kf.	3
43	iveegam.ti,kf.	0
44	privigen.ti,kf.	17
45	sandoglobulin.ti,kf.	16
46	venimmune.ti,kf.	0
47	venoglobulin.ti,kf.	2
48	venoglobulin.ti,kf.	2
49	HyQvia.ti,kf.	1
50	Octagam.ti,kf.	11
51	Hizentra.ti,kf.	19
52	Gamunex-C.ti,kf.	1
53	Gammaked.ti,kf.	0
54	or/35-53	96
55	15 or 20 or 28 or 33 or 34 or 54	32943
56	6 and 55	817
57	randomized controlled trial.pt.	485251
58	controlled clinical trial.pt.	93153
59	randomized.ti,ab.	483716
60	placebo.ti,ab.	204507
61	clinical trials as topic/	187601
62	randomly.ti,ab.	315035
63	trial?.ti.	268918
64	57 or 58 or 59 or 60 or 61 or 62 or 63	1257282



65	exp animal/ not humans/	4597467
66	64 not 65	1157230
67	56 and 66	78
68	limit 67 to yr="2004-Current"	49
Comments	Line 68 exported for RCT	

1.3.15 Streptococcal toxic shock syndrome

Date	25/03/2019 13:00:44
Database	Cochrane@Wiley.com
Search strategy	
#1	[mh ^"Immunoglobulins, intravenous"]
#2	IVIG:ti,kw
#3	scig:ti,kw
#4	intraglobin*:ti,kw
#5	(intravenous NEAR/5 antibod*):ti,kw
#6	(intravenous NEAR/5 immunoglob*):ti,kw
#7	(subcutaneous NEAR/5 antibod*):ti,kw
#8	(subcutaneous NEAR/5 immunoglob*):ti,kw
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10	[mh "Immunoglobulins"]
#11	[mh "Administration, Intravenous"]
#12	[mh "Injections, Subcutaneous"]
#13	#11 OR #12
#14	#10 AND #13
#15	intravenous:ti,kw
#16	subcutaneous:ti,kw
#17	intradermal:ti,kw
#18	iv:ti,kw



#19	inject*:ti,kw	41687
#20	perfus*:ti,kw	4808
#21	#15 OR #16 OR #17 OR #18 OR #19 OR #20	96631
#22	#10 AND #21	4605
#23	immunoglob*:ti,kw	10917
#24	immune glob*:ti,kw	569
#25	Ig:ti,kw	1965
#26	#23 OR #24 OR #25	12080
#27	#21 AND #26	2878
#28	#13 AND #26	498
#29	alphaglobin:ti,kw	0
#30	endobulin:ti,kw	0
#31	flebogamma:ti,kw	2
#32	gamimmune:ti,kw	0
#33	gammagard:ti,kw	9
#34	gammonativ:ti,kw	0
#35	gamunex:ti,kw	6
#36	globulin n:ti,kw	20
#37	iveegam:ti,kw	0
#38	privigen:ti,kw	1
#39	sandoglobulin:ti,kw	6
#40	venimmune:ti,kw	0
#41	venoglobulin:ti,kw	4
#42	HyQvia:ti,kw	3
#43	Octagam:ti,kw	9
#44	Hizentra:ti,kw	2
#45	Gamunex-C:ti,kw	1
#46	Gammaked:ti,kw	0



#47	#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46	59
#48	#9 or #14 or #22 or #27 or #28 or #47	6044
#49	#48 with Cochrane Library publication date Between Jan 2008 and Jan 2019	4148
#50	[mh "Streptococcal Infections"]	1503
#51	[mh ^"Streptococcus pyogenes"]	266
#52	strep*:ab,ti,kw	6808
#53	flesh-eating:ab,ti,kw	0
#54	pyogenes:ab,ti,kw	446
#55	pyogen*:ab,ti,kw	562
#56	ecthyma*:ab,ti,kw	7
#57	(endocarditis NEAR/3 bact*):ab,ti,kw	224
#58	(endocarditis NEAR/3 lenta):ab,ti,kw	2
#59	erysipela*:ab,ti,kw	137
#60	impetigo:ab,ti,kw	218
#61	pneumococ*:ab,ti,kw	1910
#62	(rheumat* NEAR/3 fever):ab,ti,kw	170
#63	(acute NEAR/3 rheumat* NEAR/3 (arthrit* or articular)):ab,ti,kw	23
#64	inflammatory rheumatism*:ab,ti,kw	143
#65	(polyarthrit* NEAR/3 rheumat*):ab,ti,kw	25
#66	(bouillaud?? NEAR/3 disease):ab,ti,kw	0
#67	(rheumatic NEAR/3 heart):ab,ti,kw	255
#68	(scarlet NEAR/3 fever):ab,ti,kw	53
#69	(acute NEAR/3 inflammatory NEAR/3 arthritis):ab,ti,kw	5
#70	(bacterial NEAR/3 meningitis):ab,ti,kw	307
#71	(rheumatic NEAR/3 (mitral or valve)):ab,ti,kw	80
#72	#50 OR #51	1544



#73	#52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71	9273
#74	#72 OR #73	9273
#75	[mh "shock"]	1931
#76	shock:ab,ti,kw	7511
#77	(circulatory NEAR/3 (failure or collapse)):ab,ti,kw	104
#78	forward failure:ab,ti,kw	465
#79	sepsis:ab,ti,kw	8084
#80	enterotoxin*:ab,ti,kw	125
#81	exotoxin:ab,ti,kw	35
#82	superantigen:ab,ti,kw	20
#83	#76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82	14989
#84	#75 OR #83	15455
#85	#74 AND #84	408
#86	#49 AND #85	8
Comments	0 results for Cochrane Systematic Reviews Database 8 Results for CENTRAL	

Date	21 Mar 2019
Database	Embase.com
Search strategy	
#1	(intravenous:ab,ti,kw OR subcutaneous:ab,ti,kw) AND (immunoglob*:ab,ti,kw OR antibod*:ab,ti,kw)
#2	ivig:ab,ti,kw OR scig:ab,ti,kw
#3	intraglobin*:ab,ti,kw
#4	#1 OR #2 OR #3



#5	'subcutaneous immunotherapy'/exp	1561
#6	#4 OR #5	57737
#7	'immunoglobulin'/exp	476978
#8	'intravenous drug administration'/exp	377709
#9	'subcutaneous drug administration'/exp	97741
#10	#8 OR #9	458852
#11	#7 AND #10	12058
#12	intravenous:ab,ti,kw	362573
#13	subcutaneous:ab,ti,kw	170606
#14	intradermal:ab,ti,kw	18470
#15	iv:ab,ti,kw	473297
#16	inject*:ab,ti,kw	922451
#17	perfus*:ab,ti,kw	270086
#18	#12 OR #13 OR #14 OR #15 OR #16 OR #17	1975978
#19	#7 AND #18	56464
#20	immunoglob*:ab,ti,kw	186399
#21	immune AND glob*:ab,ti,kw	31566
#22	ig:ab,ti,kw	46805
#23	#20 OR #21 OR #22	242261
#24	#18 AND #23	40698
#25	#10 AND #23	6050
#26	alphaglobin:ab,ti,kw,tn	11
#27	endobulin:ab,ti,kw,tn	292
#28	flebogamma:ab,ti,kw,tn	277
#29	gamimmune:ab,ti,tn	50
#30	gammagard:ab,ti,tn	760
#31	gammonativ:ab,ti,tn	64
#32	gamunex:ab,ti,tn	318



#33	globulin AND n:ab,ti,tn	6058
#34	iveegam:ab,ti,tn	115
#35	privigen:ab,ti,kw,tn	343
#36	sandoglobulin:ab,ti,kw,tn	1202
#37	venimmune:ab,ti,kw,tn	2
#38	venoglobulin:ab,ti,kw,tn	263
#39	venoglobulin:ab,ti,kw,tn	263
#40	hyqvia:ab,ti,kw,tn	49
#41	octagam:ab,ti,kw,tn	392
#42	hizentra:ab,ti,kw,tn	253
#43	'gamunex c':ab,ti,kw,tn	45
#44	gammaked:ab,ti,kw,tn	13
#45	#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44	9130
#46	#6 OR #11 OR #19 OR #24 OR #25 OR #45	106990
#47	#46 NOT [medline]/lim	43232
#48	#47 AND [2008-2019]/py	38013
#49	#48 NOT ('conference abstract'/it OR 'conference paper'/it OR 'conference review'/it)	6323
#50	'streptococcus infection'/exp	59040
#51	'streptococcus pyogenes'/exp	15244
#52	#50 OR #51	70753
#53	strep*:ab,ti,kw	228802
#54	'flesh eating':ab,ti,kw	124
#55	pyogen???:ab,ti,kw	21112
#56	ecthyma*:ab,ti,kw	937
#57	(endocarditis NEAR/3 bact*):ab,ti,kw	7549
#58	(endocarditis NEAR/3 lenta):ab,ti,kw	194



#59	erysipela*:ab,ti,kw	2663
#60	impetigo:ab,ti,kw	2044
#61	pneumococ*:ab,ti,kw	31074
#62	(rheumat* NEAR/3 fever):ab,ti,kw	9359
#63	(acute NEAR/3 rheumat* NEAR/3 (arthrit* OR articular)):ab,ti,kw	777
#64	(inflammatory NEAR/2 rheumatism*):ab,ti,kw	789
#65	(polyarthrit* NEAR/3 rheumat*):ab,ti,kw	1658
#66	(bouillaud* NEAR/3 disease):ab,ti,kw	202
#67	(rheumatic NEAR/3 heart):ab,ti,kw	7370
#68	(scarlet NEAR/3 fever):ab,ti,kw	1878
#69	(acute NEAR/3 inflammatory NEAR/3 arthritis):ab,ti,kw	218
#70	(bacterial NEAR/3 meningitis):ab,ti,kw	9348
#71	(rheumatic NEAR/3 (mitral OR valve)):ab,ti,kw	3757
#72	#53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71	294944
#73	#72 OR #52	317238
#74	'shock'/exp	131829
#75	shock:ab,ti,kw,jt	228441
#76	(circulatory NEAR/3 (failure OR collapse)):ab,ti,kw	5040
#77	'forward failure':ab,ti,kw	35
#78	sepsis:ab,ti,kw	138848
#79	enterotoxin*:ab,ti,kw	13367
#80	exotoxin*:ab,ti,kw	5470
#81	superantigen*:ab,ti,kw	5791
#82	'crush syndrome':ab,ti,kw	968
#83	'capillary leak syndrome':ab,ti,kw	927
#84	'cardiopulmonary collapse':ab,ti,kw	189
#85	'cardiovascular collapse':ab,ti,kw	2275



#86	'cardiorespiratory collapse':ab,ti,kw	108
#87	'cardiorespiratory decompensation':ab,ti,kw	37
#88	'cardiopulmonary decompensation':ab,ti,kw	74
#89	'cardiovascular decompensation':ab,ti,kw	152
#90	'electrical storm':ab,ti,kw	925
#91	#75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82 OR #83 OR #84 OR #85 OR #86 OR #87 OR #88 OR #89 OR #90	370841
#92	#91 OR #74	412063
#93	#73 AND #92	14081
#94	#49 AND #93	29
#95	#94 AND ('meta-analysis'/exp OR 'meta-analysis' OR 'systematic review'/exp OR 'systematic review')	1
#96	#94 AND (random*:ab,ti OR placebo*:de,ab,ti OR ((double NEXT/1 blind*):ab,ti))	1
#97	#94 NOT (#95 OR #96)	28
Comments	Line 95 exported for SR Line 96 exported for RCT Line 97 exported for All studies except SR or RCT	

Date	March 19, 2019	
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to March 19, 2019>	
Search strategy		
1	Immunoglobulins, intravenous/	12364
2	IVIG.ti,kf.	1118
3	scig.ti,kf.	48
4	intraglobin*.ti,kf.	3
5	(intravenous and antibod*).ti,kf.	796
6	(intravenous and immunoglob*).ti,kf.	5207



7	(subcutaneous and antibod*).ti,kf.	330
8	(subcutaneous and immunoglob*).ti,kf.	309
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8	14721
10	exp Immunoglobulins/	850448
11	exp Administration, Intravenous/	138819
12	exp Injections, Subcutaneous/	39116
13	11 or 12	173669
14	10 and 13	11509
15	intravenous.ti,kf.	68039
16	subcutaneous.ti,kf.	25500
17	intradermal.ti,kf.	3873
18	iv.ti,kf.	53903
19	inject*.ti,kf.	108935
20	perfus*.ti,kf.	58848
21	15 or 16 or 17 or 18 or 19 or 20	306925
22	10 and 21	15184
23	immunoglob*.ti,kf.	48900
24	immune glob*.ti,kf.	1530
25	Ig.ti,kf.	3676
26	23 or 24 or 25	53663
27	21 and 26	6410
28	13 and 26	1187
29	alphaglobin.ti,kf.	1
30	endobulin.ti,kf.	2
31	flebogamma.ti,kf.	13
32	gamimmune.ti,kf.	0
33	gammagard.ti,kf.	12
34	gammonativ.ti,kf.	0



35	gamunex.ti,kf.	5
36	globulin n.ti,kf.	3
37	iveegam.ti,kf.	0
38	privigen.ti,kf.	17
39	sandoglobulin.ti,kf.	16
40	venimmune.ti,kf.	0
41	venoglobulin.ti,kf.	2
42	venoglobulin.ti,kf.	2
43	HyQvia.ti,kf.	1
44	Octagam.ti,kf.	10
45	Hizentra.ti,kf.	19
46	Gamunex-C.ti,kf.	1
47	Gammaked.ti,kf.	0
48	or/29-47	95
49	9 or 14 or 22 or 27 or 28 or 48	32413
50	limit 49 to yr="2008-current"	12898
51	exp Streptococcal Infections/	76516
52	Streptococcus pyogenes/	13015
53	strep*.ab,ti,kf.	196079
54	flesh-eating.ab,ti,kf.	98
55	pyogenes.ab,ti,kf.	10709
56	pyogen##.ab,ti,kf.	17832
57	ecthyma?.ab,ti,kf.	735
58	(endocarditis adj3 bact*).ab,ti,kf.	6830
59	(endocarditis adj3 lenta).ab,ti,kf.	217
60	erysipela?.ab,ti,kf.	2164
61	impetigo.ab,ti,kf.	1562
62	pneumococ*.ab,ti,kf.	25662



63	(rheumat* adj3 fever).ab,ti,kf.	9295
64	(acute adj3 rheumat* adj3 (arthritis* or articular)).ab,ti,kf.	655
65	inflammatory rheumatism?.ab,ti,kf.	485
66	(polyarthrit* adj3 rheumat*).ab,ti,kf.	1315
67	(bouillaud?? adj3 disease).ab,ti,kf.	215
68	(rheumatic adj3 heart).ab,ti,kf.	6753
69	(scarlet adj3 fever).ab,ti,kf.	2398
70	(acute adj3 inflammatory adj3 arthritis).ab,ti,kf.	153
71	(bacterial adj3 meningitis).ab,ti,kf.	7374
72	(rheumatic adj3 (mitral or valve)).ab,ti,kf.	2457
73	51 or 52	82200
74	or/53-72	253335
75	73 or 74	273863
76	exp shock/	71203
77	shock.ab,ti,kf,jw.	175632
78	(circulatory adj3 (failure or collapse)).ab,ti,kf.	3428
79	forward failure.ab,ti,kf.	25
80	sepsis.ab,ti,kf.	89098
81	enterotoxin?.ab,ti,kf.	11784
82	exotoxin.ab,ti,kf.	3651
83	superantigen.ab,ti,kf.	3414
84	77 or 78 or 79 or 80 or 81 or 82	267365
85	76 or 84	291002
86	75 and 85	9789
87	50 and 86	46
88	limit 87 to systematic reviews	4
89	randomized controlled trial.pt.	478099
90	controlled clinical trial.pt.	92974



91	randomized.ti,ab.	472128
92	placebo.ti,ab.	201616
93	clinical trials as topic/	186320
94	randomly.ti,ab.	308370
95	trial?.ti.	261936
96	89 or 90 or 91 or 92 or 93 or 94 or 95	1235412
97	exp animal/ not humans/	4558766
98	96 not 97	1137167
99	87 and 98	4
100	87 not (88 or 99 or 97)	36

Comments
Line 88 exported for SR
Line 99 exported for RCT
Line 100 exported for All studies except SR or RCT

1.4 Ongoing studies

Following search strategy was used on 1 of October 2019:

Clinical trials.gov	
Immune Globulins, Immunoglobulins Intravenous FILTERED on Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation	146 studies
Studies Interventional Studies	
Immune Globulins Immunoglobulins, subcutaneous FILTERED on Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation	238 Studies
Studies Interventional Studies	
Netherlands Trial Registry (NTR)	
Search term: immunoglobulin	52 studies
EU Clinical Trials Register	
Search term: immunoglobulin AND intravenous FILTERED on ongoing with a date limit from 01 January 2015 till 1 October 2019	108 studies
Search term: immunoglobulin AND subcutaneous FILTERED on ongoing with a date limit from 01 January 2015 till 1 October 2019	46 studies



1.5 Economic searches

1.5.1 MEDLINE

Date	May 10, 2019
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to May 10, 2019>
Search strategy	
1	Immunoglobulins, intravenous/ 12455
2	IVIG.ti,kf. 1138
3	scig.ti,kf. 49
4	intraglobin*.ti,kf. 3
5	(intravenous and antibod*).ti,kf. 803
6	(intravenous and immunoglob*).ti,kf. 5254
7	(subcutaneous and antibod*).ti,kf. 330
8	(subcutaneous and immunoglob*).ti,kf. 317
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 14842
10	exp Immunoglobulins/ 854599
11	exp Administration, Intravenous/ 139302
12	exp Injections, Subcutaneous/ 39265
13	11 or 12 174290
14	10 and 13 11575
15	intravenous.ti,kf. 68381
16	subcutaneous.ti,kf. 25691
17	intradermal.ti,kf. 3901
18	iv.ti,kf. 54173
19	inject*.ti,kf. 109711
20	perfus*.ti,kf. 59212
21	15 or 16 or 17 or 18 or 19 or 20 308842



22	10 and 21	15269
23	immunoglob*.ti,kf.	49118
24	immune glob*.ti,kf.	1532
25	Ig.ti,kf.	3691
26	23 or 24 or 25	53897
27	21 and 26	6464
28	13 and 26	1194
29	alphaglobin.ti,kf.	1
30	endobulin.ti,kf.	2
31	flebogamma.ti,kf.	13
32	gamimmune.ti,kf.	0
33	gammagard.ti,kf.	12
34	gammonativ.ti,kf.	0
35	gamunex.ti,kf.	5
36	globulin n.ti,kf.	3
37	iveegam.ti,kf.	0
38	privigen.ti,kf.	17
39	sandoglobulin.ti,kf.	16
40	venimmune.ti,kf.	0
41	venoglobulin.ti,kf.	2
42	venoglobulin.ti,kf.	2
43	HyQvia.ti,kf.	1
44	Octagam.ti,kf.	11
45	Hizentra.ti,kf.	19
46	Gamunex-C.ti,kf.	1
47	Gammaked.ti,kf.	0
48	or/29-47	96
49	9 or 14 or 22 or 27 or 28 or 48	32634



50	limit 49 to yr="2008-current"	13119
51	Economics/	27028
52	exp "Costs and Cost Analysis"/	224438
53	Value of Life/ec	247
54	pharmacoeconomi*.ti,ab,kw.	3766
55	(economic adj1 evaluati*).ti,ab,kw.	10753
56	budget*.ti,ab,kw.	27240
57	cost-effectiveness.ti,ab,kw.	55165
58	cost-utility.ti,ab,kw.	4280
59	cost-mini*.ti,ab,kw.	1476
60	cost-benefit*.ti,ab,kw.	11107
61	letter.pt.	1026559
62	editorial.pt.	490082
63	historical article.pt.	351477
64	animals/ not humans/	4545726
65	51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60	304430
66	or/61-64	6341464
67	65 not 66	276776
68	50 and 67	197



1.5.2 EconLit (via Ovid)

Date	July 10, 2019
Database	Database: Econlit <1886 to June 17, 2019>
Search strategy	
1	immunoglobulin*.mp. [mp=heading words, abstract, title, country as subject] 5


1.5.3 CRD Databases – NHS EED; NHS HTA

Date	June, 2019
Database	CRD Databases – NHS EED; NHS HTA
Search strategy	
1	((Immunoglobulin):TI AND (cost)) and ((Economic evaluation:ZDT and Bibliographic:ZPS) OR (Economic evaluation:ZDT and Abstract:ZPS) OR Full publication record:ZDT) IN NHSEED, HTA FROM 2008 TO 2019 30




2 PRISMA'S PER INDICATION

Primary Immunodeficiency






Secondary immunodeficiency






Chronic Inflammatory demyelinating polyradiculoneuropathy (CIPD)






Streptococcal toxic shock syndrome




Kawasaki disease






Multifocal Motor Neuropathy






Idiopathic thrombocytopenic purpura






Guillain-Barre






Myasthenia Gravis






Dermatomyositis and polymyositis






Pemphigus (Immunobullous disease)






Solid Organ Transplantation






Fetomaternal thrombocytopenia (FMAIT)






Pure Red cell aplasia (Erythroblastopenia)





Post-transfusion Purpura





3 EXCLUSION LIST

3.1 Exclusion list of systematic reviews with reasons for exclusion

Author and year	Reference	Reasons for exclusion
PID		
Orange 2012	Orange, J. S., B. H. Belohradsky, M. Berger, M. Borte, J. Hagan, S. Jolles, R. L. Wasserman, J. S. Baggish, R. Saunders and B. Grimbacher (2012). "Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy." <i>Clinical & Experimental Immunology</i> 169 (2): 172-181	Quality (low)
Jones 2018	Jones, G. L., K. S. Vogt, D. Chambers, M. Clowes and A. Shrimpton (2018). "What is the burden of immunoglobulin replacement therapy in adult patients with primary immunodeficiencies? A systematic review." <i>Front. Immunol.</i> 9 (JUL)	Quality (low)
Song 2015	Song, J., L. Zhang, Y. Li, S. Quan, Y. Liang, L. Zeng and Y. Liu (2015). "20% subcutaneous immunoglobulin for patients with primary immunodeficiency diseases: A systematic review." <i>International Immunopharmacology</i> 25 (2): 457-464	Design (included only single arm studies on SCIG)
SID		
Compagno 2014	Compagno, N., G. Malipiero, F. Cinetto and C. Agostini (2014). "Immunoglobulin replacement therapy in secondary hypogammaglobulinemia." <i>Front. Immunol.</i> 5 (DEC)	Design (not systematic)
Lachance 2016	Lachance, S., A. L. Christofides, J. K. Lee, L. H. Sehn, B. C. Ritchie, C. Shustik, D. A. Stewart, C. L. Toze, E. Haddad and D. C. Vinh (2016). "A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia." <i>Curr. Oncol.</i> 23 (1): 42-51	Design (not systematic)
Raanani, Gafter-Gvili et al. 2009	Raanani, P., A. Gafter-Gvili, M. Paul, I. Ben-Bassat, L. Leibovici and O. Shpilberg (2009). "Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis." <i>Leukemia & Lymphoma</i> 50 (5): 764-772	Duplicate (referring to a SR already included)
CIDP		
Rajabally 2014	Rajabally, Y. A. (2014). "Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects." <i>Journal of Neurology, Neurosurgery & Psychiatry</i> 85 (6): 631-637	Design (not systematic)
Sala, Crave et al. 2018	Sala, T. P., J. C. Crave, M. Duracinsky, F. Lepira Bompeka, A. Tadmouri, O. Chassany and P. Cherin (2018). "Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases." <i>Autoimmunity Reviews</i> 17 (9): 873-881	Indication (results from studies on both MMN and CIDP pooled together)
Bright, Wilkinson et al. 2014	Bright, R. J., J. Wilkinson and B. J. Coventry (2014). "Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review." <i>BMC Neurology</i> 14 : 26	Quality (low)



Racosta, Sposato et al. 2017	Racosta, J. M., L. A. Sposato and K. Kimpinski (2017). "Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis." <i>Muscle & Nerve</i> 55 (6): 802-809	Quality – Mainly small observational studies and just one RCT. No subgroup analysis done on high vs low quality results, and no separate description or analysis on the RCT provided. A decision was made to exclude the Racosta's SR from our review and include instead the relevant RCT in our update of primary studies
-------------------------------------	--	---

STREPTOCOCCAL TOXIC SHOCK

Steer, Curtis et al. 2008	Steer, A. C., N. Curtis and J. R. Carapetis (2008). "Diagnosis and treatment of invasive group a streptococcal infections." <i>Expert Opin. Med. Diagn.</i> 2 (3): 289-301	Design (non systematic)
Low 2013	Low, D. E. (2013). "Toxic shock syndrome: major advances in pathogenesis, but not treatment." <i>Critical Care Clinics</i> 29 (3): 651-675	Design (non systematic)
Shalaby, Anandappa et al. 2014	Shalaby, T., S. Anandappa, N. J. Pocock, A. Keough and A. Turner (2014). "Lesson of the month 2: toxic shock syndrome." <i>Clinical Medicine</i> 14 (3): 316-318	Design (non systematic)
Parks, Barrett et al. 2015	Parks, T., L. Barrett and N. Jones (2015). "Invasive streptococcal disease: a review for clinicians." <i>British Medical Bulletin</i> 115 (1): 77-89	Design (non systematic)
Shah, Vakil et al. 2015	Shah, P. J., N. Vakil and A. Kabakov (2015). "Role of intravenous immune globulin in streptococcal toxic shock syndrome and Clostridium difficile infection." <i>Am J Health Syst Pharm</i> 72 (12): 1013-1019	Design (non systematic)

KAWASAKI

Wooditch and Aronoff 2005	Wooditch, A. C. and S. C. Aronoff (2005). "Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children." <i>Pediatrics</i> 116 (4): 989-995	Focus (addition of corticosteroids to IVIg)
Chen and Du 2016	Chen, Y. and J. Du (2016). "On a meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease." <i>Cardiol. Young</i> 26 (5): 1037	Focus (addition of corticosteroids to IVIg)
Yang, Lin et al. 2018	Yang, T. J., M. T. Lin, C. Y. Lu, J. M. Chen, P. I. Lee, L. M. Huang, M. H. Wu and L. Y. Chang (2018). "The prevention of coronary arterial abnormalities in Kawasaki disease: A meta-analysis of the corticosteroid effectiveness." <i>Journal of Microbiology, Immunology & Infection</i> 51 (3): 321-331	Focus (addition of corticosteroids to IVIg)
Baumer, Love et al. 2006	Baumer, J. H., S. Love, A. Gupta, L. Haines, I. K. Maconochie and J. S. Dua (2006). "Salicylate for the treatment of Kawasaki disease in children." (4)	Focus (addition of aspirin to IVIg)



Zheng, Yue et al. 2019	Zheng, X., P. Yue, L. Liu, C. Tang, F. Ma, Y. Zhang, C. Wang, H. Duan, K. Zhou, Y. Hua, G. Wu and Y. Li (2019). "Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: Current evidence based on a meta-analysis." <i>PLoS ONE</i> 14 (5)	Focus (addition of aspirin to IVIg)
Lo and Newburger 2018	Lo, M. S. and J. W. Newburger (2018). "Role of intravenous immunoglobulin in the treatment of Kawasaki disease." <i>International Journal of Rheumatic Diseases</i> 21 (1): 64-69	Design
Guo, Huang et al. 2015	Guo, X., Y. Huang, H. Jin and J. Du (2015). "Re-treatment for intravenous immunoglobulin-resistant Kawasaki disease." <i>Cardiol. Young</i> 25 (6): 1229	Publication type
Xue, Wu et al. 2017	Xue, L. J., R. Wu, G. L. Du, Y. Xu, K. Y. Yuan, Z. C. Feng, Y. L. Pan and G. Y. Hu (2017). "Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis." <i>Clinical Reviews in Allergy & Immunology</i> 52 (3): 389-400	Time of publication (less recent and same studies than other already included study)
MMN		
Sala, Crave et al. 2018	Sala, T. P., J. C. Crave, M. Duracinsky, F. Lepira Bompeka, A. Tadmouri, O. Chassany and P. Cherin (2018). "Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases." <i>Autoimmunity Reviews</i> 17 (9): 873-881	Indication (results from studies on both MMN and CIDP pooled together)
Racosta, Sposato et al. 2017	Racosta, J. M., L. A. Sposato and K. Kimpinski (2017). "Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis." <i>Muscle & Nerve</i> 55 (6): 802-809	Quality – Mainly small observational studies and just one RCT. No subgroup analysis done on high vs low quality results, and no separate description or analysis on the RCT provided. A decision was made to exclude the Racosta's SR from our review and include instead the relevant RCT in our update of primary studies
Rajabally 2014,	Rajabally, Y. A. (2014). "Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects." <i>Journal of Neurology, Neurosurgery & Psychiatry</i> 85 (6): 631-637	Intervention
Umapathi, Hughes et al. 2015,	Umapathi, T., R. A. Hughes, E. Nobile-Orazio and J. M. Leger (2015). "Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy." <i>Cochrane Database of Systematic Reviews</i> (3): CD003217	Intervention
MacIsaac, Siddiqui et al. 2018	MacIsaac, J., R. Siddiqui, E. Jamula, N. Li, S. Baker, K. E. Webert, D. Evanovitch, N. M. Heddle and D. M. Arnold (2018). "Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin." <i>Transfusion</i> 58 (11): 2729-2735	Intervention



Choquet-Hebbinkuyts, David et al. 2016	Choquet-Hebbinkuyts, E., F. David, J. Alba, P. Berard-Neyret and D. Merger (2016). "Analysis of unlabeled uses of intravenous immunoglobulin in university hospital." <i>J. Pharm. Clin.</i> 35 (2): 79-86	Research question/focus
Lunn and Nobile-Orazio 2016	Lunn, M. P. T. and E. Nobile-Orazio (2016). "Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies." (10)	Research question/focus
Mahdi-Rogers, Brassington et al. 2017	Mahdi-Rogers, M., R. Brassington, A. A. Gunn, P. A. van Doorn and R. A. C. Hughes (2017). "Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy." (5)	Research question/focus
Iro, Martin et al. 2017	Iro, M. A., N. G. Martin, M. Absoud and A. J. Pollard (2017). "Intravenous immunoglobulin for the treatment of childhood encephalitis." (10)	Indication
ITP		
Khan, Mydra et al. 2017	Khan, A. M., H. Mydra and A. Nevarez (2017). "Clinical practice updates in the management of immune thrombocytopenia." <i>P T</i> 42 (12): 756-763	Design
Rodriguez and Wagner-Weiner 2017	Rodriguez, M. M. and L. Wagner-Weiner (2017). "Intravenous Immunoglobulin in Pediatric Rheumatology: When to Use It and What Is the Evidence." <i>Pediatric Annals</i> 46 (1): e19-e24	Design
MacIsaac, Siddiqui et al. 2018	MacIsaac, J., R. Siddiqui, E. Jamula, N. Li, S. Baker, K. E. Webert, D. Evanovitch, N. M. Heddle and D. M. Arnold (2018). "Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin." <i>Transfusion</i> 58 (11): 2729-2735	Research question/focus
Li, Yilidaer et al. 2014	Li, Z., A. Yilidaer, X. G. Zhang and Y. Halida (2014). "Effectiveness and safety of middle and low-dose gamma globulin for severe idiopathic thrombocytopenic purpura: A systematic review." <i>Chin. J. Evid.-Based Med.</i> 14 (3): 312-319	No full copy of article could be found
GBS		
Wang, McQuilten et al. 2015	Wang, J., Z. K. McQuilten, E. M. Wood and C. Aubron (2015). "Intravenous immunoglobulin in critically ill adults: When and what is the evidence?" <i>Journal of Critical Care</i> 30 (3): 652.e659-616	Design
MacIsaac, Siddiqui et al. 2018	MacIsaac, J., R. Siddiqui, E. Jamula, N. Li, S. Baker, K. E. Webert, D. Evanovitch, N. M. Heddle and D. M. Arnold (2018). "Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin." <i>Transfusion</i> 58 (11): 2729-2735	Indication
Vitality 2015	Vitaliti, G., Tabatabaie, O., Matin, N., Ledda, C., Pavone, P., Lubrano, R., Serra, A., Di Mauro, P., Cocuzza, S., Falsaperla, R. (2015). "The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data". <i>Hum Vaccin Immunother.</i> 2015;11(12):2749-63	Quality (low)
MG		



Gogou, Papadopoulou-Alataki et al. 2017	Gogou, M., E. Papadopoulou-Alataki, M. Spilioti, S. Alataki and A. Evangelou (2017). "Clinical Applications of Intravenous Immunoglobulins in Child Neurology." <i>Current Pharmaceutical Biotechnology</i> 18 (8): 628-637	Quality (low)
--	--	---------------

DERMATOMYOSITIS AND POLYMYOSITIS

Anh-Tu Hoa and Hudson 2017	Anh-Tu Hoa, S. and M. Hudson (2017). "Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies." <i>Seminars in Arthritis & Rheumatism</i> 46 (4): 488-508	Quality (Low- only one database explored)
Gordon, Winer et al. 2012	Gordon, P. A., J. B. Winer, J. E. Hoogendoijk and E. H. Choy (2012). "Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis." <i>Cochrane Database of Systematic Reviews</i> (8): CD003643	Time of publication (published before the SRs already included in our review)
Wang, Shu et al. 2012	Wang, D. X., X. M. Shu, X. L. Tian, F. Chen, N. Zu, L. Ma and G. C. Wang (2012). "Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review." <i>Clinical Rheumatology</i> 31 (5): 801-806	Time of publication (published before the SRs already included in our review)

PEMPHIGUS IMMUNOBULLOUS DISEASE

Frew, Martin et al. 2011	Frew, J. W., L. K. Martin and D. F. Murrell (2011). "Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus." <i>Dermatol Clin</i> 29 (4): 599-606	Quality (low)
Joly and Sin 2011	Joly, P. and C. Sin (2011). "[Pemphigus: a review]." <i>Ann Dermatol Venereol</i> 138 (3): 182-200	Quality (low)
Zhao and Murrell 2015	Zhao, C. Y. and D. F. Murrell (2015). "Pemphigus vulgaris: an evidence-based treatment update." <i>Drugs</i> 75 (3): 271-284	Quality (low)
Cholera and Chainani-Wu 2016	Cholera, M. and N. Chainani-Wu (2016). "Management of Pemphigus Vulgaris." <i>Adv Ther</i> 33 (6): 910-958	Quality (low)
Gurcan, 2010	Gurcan HM, Jeph S, Ahmed RA (2010). "Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety." <i>Am J Clin Dermatol.</i> 11 (5):315-26.	Quality (low)
van Beek, 2019	van Beek, N., D. Zillikens and E. Schmidt (2019). "[Therapy of pemphigus]." <i>Hautarzt</i> 70 (4): 243-253	Quality (low)



3.2 Exclusion list of primary studies (RCTs) with reasons for exclusion

Author and year	Reference	Reasons for exclusion
PID		
Wasserman 2012	Wasserman, R. L., J. A. Church, M. Stein, J. Moy, M. White, S. Strausbaugh, H. Schroeder, M. Ballow, J. Harris, I. Melamed, D. Elkayam, W. Lumry, D. Suez and S. M. Rehman (2012). "Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency." <i>Journal of Clinical Immunology</i> 32 (4): 663-669	Design (single arm study on IVIg)
Krivan 2017	Krivan, G., L. Chernyshova, L. Kostyuchenko, A. Lange, Z. Nyul, B. Derfalvi, J. Musial, A. Bellon, M. Kappler, A. Sadoun and E. Bernatowska (2017). "A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IgYmune, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency." <i>Journal of Clinical Immunology</i> 37 (6): 539-547	Design (single arm study on IVIg)
Hagan 2010	Hagan, J. B., M. B. Fasano, S. Spector, R. L. Wasserman, I. Melamed, M. A. Rojavin, O. Zenker and J. S. Orange (2010). "Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency." <i>Journal of Clinical Immunology</i> 30 (5): 734-745	Design (single arm study on SCIG)
Krivan 2015	Krivan, G., C. Konigs, E. Bernatowska, A. Salama, A. Wartenberg-Demand, C. Sonnenburg and R. Linde (2015). "An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease." <i>Vox Sanguinis</i> 109 (3): 248-256	Intervention (administration methods e.g. escalating infusion rates)
SID		
Matutes 2010	Matutes, E. (2010); "Management of infectious complications in chronic lymphocytic leukemia" <i>European journal of Clinical and Medical Oncology - Volume 2, Issue 1</i>	Design (narrative review)
Spadaro 2016	Spadaro, G.; Pecoraro, A.; De Renzo, A.; Della Pepa, R.; Genovese, A.; (2016). "Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia". <i>Clin Immunol</i> 166 : 103-4	Publication type (letter to the editor)
Sarmiento 2016	Sarmiento, E.; Diez, P.; Arraya, M.; Jaramillo, M.; Calahorra, L.; Fernandez-Yanez, J.; Palomo, J.; Sousa, I.; Hortal, J.; Barrio, J.; Alonso, R.; Munoz, P.; Navarro, J.; Vicario, J.; Fernandez-Cruz, E.; Carbone, J.(2016). "Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial". <i>Transpl Infect Dis.</i> 18 (6): 832-843	Design (cohort)
Kröger 2016	Kröger, N. (2016). "Prevention of chronic graft-versus-host disease and the unique role of anti-human t-lymphocyte immune globulin." <i>Eur. Oncol. Haematol.</i> 12 (2): 93-95	Intervention (hyper immune Ig)
CIDP		



Nobile-Orazio 2012	Nobile-Orazio, E., D. Cocito, S. Jann, A. Uncini, E. Beghi, P. Messina, G. Antonini, R. Fazio, F. Gallia, A. Schenone and et al. (2012). "Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial." <i>The lancet. Neurology</i> 11 (6): 493-502	Time of publication (published before the SRs already included in our review)
Jakobsen, Markvardsen et al. 2012	Jakobsen, J., L. Markvardsen, T. Harbo, S. Sindrup, H. Andersen, I. Christiansen, N. Olsen and L. Lassen (2012). "A randomised, double-blinded, placebo controlled trial of the effect of subcutaneous immunoglobulin on muscular performance in chronic inflammatory demyelinating polyneuropathy." <i>Neurology</i> 78 (1 Meeting Abstract)	Publication abstract type (conference)
Nobile-Orazio, Cocito et al. 2013	Nobile-Orazio, E., D. Cocito, S. Jann, A. Uncini, P. Messina and G. Antonini (2013). "Frequency and time to relapse after therapy discontinuation in cipd patients treated for six months with ivig or iv methylprednisolone (imc study follow-up)." <i>Journal of the peripheral nervous system : JPNS</i> 18 (2 Suppl): S80-81	Publication abstract type (conference)
Camdessanche, Ferraud et al. 2014	Camdessanche, J. P., K. Ferraud, E. Lagrange, K. Viala, V. Chan, N. G. Renouil, S. L. Leonard, A. Echaniz-Laguna, G. Besson, F. Bouhour and et al. (2014). "Multicentre, randomised, open-label trial to compare efficacy and tolerance of prednisone and IVIg in patients with cipd on a one year follow up." <i>Neurology</i> 82 (10 SUPPL. 1)	Publication abstract type (conference)
Van Schaik 2016	Van Schaik IN, Bril V, Van Geloven N, Hartung HP, Lewis RA, Sobue G, (2016). "Randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of two different doses of IGPRO20 (subcutaneous immunoglobulin) for the treatment of CIDP-IGG dependency and restabilization phase". <i>Journal of neuromuscular diseases</i> .S61-S2.	Publication abstract type (conference)
Markvardsen, Sindrup et al. 2016	Markvardsen, L., S. Sindrup, I. Christiansen, J. Jakobsen and H. Andersen (2016). "Subcutaneous versus intravenous immunoglobulin in drug-naive patients with chronic inflammatory demyelinating polyneuropathy (CIDP); a randomized, single-blind, cross-over trial." <i>Inflammatory neuropathy consortium of the peripheral nerve society meeting programme</i> : 82, Abstract no PO81.26	Publication abstract type (conference)
Kuitwaard, Vrancken A 2016	Kuitwaard, K.; Vrancken, A.; Brusse, E.; Eftimov, F.; Notermans, N.; van der Kooi, A. (2016). "Dose response trial of IV immunoglobulin in CIDP (drip study)". <i>Inflammatory neuropathy consortium of the peripheral nerve society meeting programme - Volume 0, Issue 0</i> , pp. 86, Abstract no PO1.34	Publication type (protocol)
Sabet, Mielke et al. 2018	Sabet, A., O. Mielke, I. N. Van Schaik, J. M. Leger, V. Bril, N. Van Gloven, H. P. Hartung, R. A. Lewis, G. Sobue, J. P. Lawo and et al. (2018). "Efficacy and safety of intravenous immunoglobulin (IVIG) IGPRO10 in chronic inflammatory demyelinating polyneuropathy (CIDP)." <i>Journal of neurology, neurosurgery and psychiatry</i> 89 (6): e19-	Publication abstract type (Conference)
Cornblath 2018	Cornblath, D. R.; Hartung, H. P.; Katzberg, H. D.; Merkies, I. S. J.; van Doorn, P. A.; (2018) "A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol" <i>J Peripher Nerv Syst</i> 23 (2) pp. 108-114	Publication type (protocol)

Etimov 2015	Etimov, F.; Adrichem, M. E.; de Haan, R. J.; Dijkgraaf, M. G. W.; Merkies, I. S. J.; Vrancken, A. F. J.(2015) "Intravenous immunoglobulin overtreatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, randomized controlled non-inferiority trial (ioc trial)". <i>Journal of the peripheral nervous system</i> 20(2) pp. 135	Publication type (protocol)
Kuitwaard 2018	Kuitwaard K, Fokkink WR, Brusse E, Vrancken A, Etimov F, Notermans NC, (2018). "Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study)". <i>Journal of the Peripheral Nervous System</i> 23:5–10	Publication type (protocol)
Markvardsen, Harbo et al. 2014	Markvardsen LH, Harbo T, Sindrup SH, Christiansen I, Andersen H, Jakobsen J, (2014). "Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy." <i>Eur J Neurol.</i> 21(12):1465-70.	Design (follow-up study)
Chin, Deng et al. 2015	Chin, R. L., C. Deng, V. Bril, H. P. Hartung, I. S. Merkies, P. D. Donofrio, P. A. Van Doorn, M. C. Dalakas and N. Latov (2015). "Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse." <i>Muscle & Nerve</i> 52(4): 498-502	Design (follow-up study)
Nobile-Orazio, Cocito et al. 2015	Nobile-Orazio, E., D. Cocito, S. Jann, A. Uncini, P. Messina, G. Antonini, R. Fazio, F. Gallia, A. Schenone, A. Francia and et al. (2015). "Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP." <i>Journal of neurology, neurosurgery and psychiatry</i> 86(7): 729-734	Design (follow-up study)
Merkies, van Schaik et al. 2019	Merkies ISJ, van Schaik IN, Leger JM, Bril V, van Geloven N, Hartung HP (2019). "Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies." <i>Journal of the Peripheral Nervous System.</i> 24 (1):48-55.	Design (follow-up study)
Berger, Harbo et al. 2018	Berger M, Harbo T, Cornblath DR, Mielke O. (2018). "IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG." <i>Immunotherapy.</i> 10 (11):919-33.	Publication type (a rewrite of the already included PATH study)
Merkies, 2017	Merkies ISJ, Lawo JP, Edelman JM, De Bleecker JL, Sommer C, Robberecht W, et al (2017). "Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial." <i>Journal of the Peripheral Nervous System.</i> 22 (2):149-52.	Publication type (letter to the editor)
Markvardsen and Harbo 2017	Markvardsen LH, Harbo T. (2017). "Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs." <i>J Neurol Sci.</i> ; 378:19-25.	Design (narrative review)
Kuitwaard, 2017	Kuitwaard K, Fokkink WR, Brusse E, Vrancken A, Etimov F, Notermans NC, (2017). "Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy". <i>Journal of the Peripheral Nervous System.</i> 22(4):425-32.	Design (narrative review)
Sommer, England et al. 2015	Sommer, C., J. England, J. Jakobsen, R. Reeve, M. S. Oh and L. Y. Ngo (2015). "A phase III study to evaluate the efficacy, safety, and tolerability of recombinant human hyaluronidase (rhuh20)-facilitated subcutaneous (sc) infusion of immunoglobulin (ig) (ighy) for the treatment of chronic inflammatory	Design



demyelinating polyradiculoneuropathy (cidp)." *Journal of the peripheral nervous system : JPNS* **20**(2): 235

Kuwabara, Mori et al. 2017	Kuwabara, S., M. Mori, S. Misawa, M. Suzuki, K. Nishiyama, T. Mutoh, S. Doi, N. Kokubun, M. Kamijo, H. Yoshikawa, K. Abe, Y. Nishida, K. Okada, K. Sekiguchi, K. Sakamoto, S. Kusunoki, G. Sobue, R. Kaji and I. C. S. G. Glovenin (2017). "Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial." <i>Journal of Neurology, Neurosurgery & Psychiatry</i> 88 (10): 832-838	Design
Mielke, Bril 2019	Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP (2019). Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. <i>J Peripher Nerv Syst.</i> 24 (1):72-9.	Design (non randomised)

KAWASAKI

Liang, Lee et al. 2004	Liang, C. M., P. C. Lee, B. Hwang, J. H. Lu, P. Y. Wang, C. H. Lien and C. C. L. Meng (2004). "Comparison of different types and regimens of intravenous immune globulin (IVIG) in patients with Kawasaki disease." <i>Acta Cardiol. Sin.</i> 20 (1): 15-20	Time of publication (published before the SRs already included in our review)
Sakata, Hamaoka et al. 2007	Sakata, K., K. Hamaoka, S. Ozawa, A. Niboshi, T. Yoshihara, T. Nishiki, Y. Nakagawa, K. Kazuta, Y. Morimoto, Y. Kamiya and et al. (2007). "A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease." <i>European journal of pediatrics</i> 166 (6): 565-571	Time of publication (published before the SRs already included in our review)
Youn, Kim et al. 2016	Youn, Y., J. Kim, Y. M. Hong and S. Sohn (2016). "Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin." <i>Pediatric Infectious Disease Journal</i> 35 (4): 457-459	Time of publication (published before the SRs already included in our review)
He, Niu et al. 2016	He, L., C. W. Niu, F. Liu, G. Y. Huang, L. Wu, M. R. Huang, M. Huang, C. Chu, X. C. Liang, S. N. Sun and et al. (2016). "A prospective randomised study of intravenous immunoglobulin treatment regimens in acute kawasaki disease." <i>Journal of the hong kong college of cardiology</i> 24 (1): 49-	Publication type
He, Liu et al. 2017	He, L., F. Liu and G. Huang (2017). "Multi centeral study on IVIG treatment to Kawasaki disease." <i>Cardiology in the young</i> 27 (4): S472-	Publication type
Espinoza 2007	Espinoza, L. R. (2007). "Intravenous pulsed corticosteroid therapy for primary treatment of Kawasaki disease." <i>Curr. Rheumatol. Rep.</i> 9 (4): 301-303	Intervention
Gelmont, Thomas et al. 2015	Gelmont, D., R. G. Thomas, J. A. Dyck-Jones, S. Fritsch, P. Aisen, N. Relkin, B. McCoy, H. Leibl, W. Engl, V. Empson and et al. (2015). "Safety of intravenous immunoglobulin 10% (KIOVIG) therapy in patients with autoimmune and Alzheimer's disease." <i>Schweizer archiv fur neurologie und psychiatrie</i> 166 : 44-	Population

MMN



Hughes 2008	Hughes, R. (2008). "The role of IVIg in autoimmune neuropathies: the latest evidence." <i>Journal of Neurology</i> 255 Suppl 3 : 7-11	Study design
Kaji 2008	Kaji, R. (2008). "Diagnosis and treatment of multifocal motor neuropathy." <i>Curr. Treat. Options Neurol.</i> 10 (2): 103-107	Study design
Ruzhansky Brannagan 2013	Ruzhansky, K. and I. T. H. Brannagan (2013). "Intravenous immunoglobulin for treatment of neuromuscular disease." <i>Neurol. Clin. Pract.</i> 3 (5): 440-445	Study design
Leger, Hughes et al. 2015	Leger, J. M., R. Hughes, I. S. J. Merkies, E. Nobile-Orazio, W. Malyszczak and S. Puget (2015). "A european, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus KiovigR in patients with multifocal motor neuropathy." <i>Journal of the peripheral nervous system. Conference: 2015 peripheral nerve society biennial meeting. Canada</i> 20 (2): 181	Study design
Nobile-Orazio, Gallia et al. 2017	Nobile-Orazio, E., F. Gallia, F. Terenghi and M. Bianco (2017). "Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan." <i>Expert Review of Neurotherapeutics</i> 17 (8): 755-765	Study design
Kuwabara, Misawa et al. 2018	Kuwabara, S., S. Misawa, M. Mori, Y. Iwai, K. Ochi, H. Suzuki, H. Nodera, A. Tamaoka, M. Iijima, T. Toda, H. Yoshikawa, T. Kanda, K. Sakamoto, S. Kusunoki, G. Sobue, R. Kaji and I. M. M. N. S. G. Glovenin (2018). "Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multi-center, open-label, 52-week phase 3 trial." <i>Journal of the Peripheral Nervous System</i> 23 (2): 115-119	Study design
Remanan, Pavlakis et al. 2017	Remanan, R., P. Pavlakis, M. Shahbazi and D. Lange (2017). "A treatment classifier for long-term follow-up of intravenous immunoglobulin therapy response." <i>Neurology Conference: 69th American Academy of Neurology Annual Meeting, AAN 2017. United States</i> . 88(16 Supplement 1)	Research question/focus
Radziwill, Botez et al. 2009	Radziwill, A. J., S. A. Botez, J. Novy and T. Kuntzer (2009). "Interferon beta-1a as adjunctive treatment for multifocal motor neuropathy: an open label trial." <i>Journal of the Peripheral Nervous System</i> 14 (3): 201-202	Publication type
Hahn, Beydoun et al. 2012	Hahn, A. F., S. R. Beydoun, V. Lawson, M. Oh, V. G. Empson and D. Gelmont (2012). "A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN)." <i>Journal of the peripheral nervous system : JPNS</i> 17 (2): 243-244	Publication type
ITP		
Farahmandinia, Naderi et al. 2010	Farahmandinia, Z., A. Naderi, F. Sabzevari and S. Parvaresh (2010). "Comparison of intravenous immunoglobulin (IVIG) and intravenous anti-D for treatment of acute idiopathic thrombocytopenic purpura." <i>Int. J. Hematol. Oncol. Stem Cell Res.</i> 4 (4): 10-13	Time of publication (already included in one of the SRs retained)



Papagianni, Economou et al. 2011	Papagianni, A., M. Economou, A. Tragiannidis, E. Karatza, I. Tsatra, N. Gombakis, F. Athanassiadou-Piperopoulou and M. Athanasiou-Metaxa (2011). "Standard-dose intravenous anti-D immunoglobulin versus intravenous immunoglobulin in the treatment of newly diagnosed childhood primary immune thrombocytopenia." <i>Journal of Pediatric Hematology/Oncology</i> 33 (4): 265-269	Time of publication (already included in one of the SRs retained)
Alioglu, Ercan et al. 2013	Alioglu, B., S. Ercan, A. E. Tapci, T. Zengin, E. Yazarli and Y. Dallar (2013). "A comparison of intravenous immunoglobulin (2 g/kg totally) and single doses of anti-D immunoglobulin at 50 mug/kg, 75 mug/kg in newly diagnosed children with idiopathic thrombocytopenic purpura: Ankara hospital experience." <i>Blood Coagulation & Fibrinolysis</i> 24 (5): 505-509	Time of publication (already included in one of the SRs retained)
Celik, Bulbul et al. 2013	Celik, M., A. Bulbul, G. Aydogan, D. Tugcu, E. Can, S. Uslu and M. Dursun (2013). "Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura." <i>Journal of Thrombosis & Thrombolysis</i> 35 (2): 228-233	Time of publication (already included in one of the SRs retained)
Eghbali, Azadmanesh et al. 2016	Eghbali, A., P. Azadmanesh, B. Bagheri, H. Taherahmadi and B. Sadeghi Sedeh (2016). "Comparison between IV immune globulin (IVIG) and anti-D globulin for treatment of immune thrombocytopenia: a randomized open-label study." <i>Fundamental & Clinical Pharmacology</i> 30 (4): 385-389	Time of publication (already included in one of the SRs retained)
Blackhouse, Xie et al. 2012	Blackhouse, G., F. Xie, M. A. Levine, K. Campbell, N. Assasi, K. Gaebel, D. O'Reilly, J. Tarride and R. Goeree (2012). "Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura." <i>Journal of Population Therapeutics & Clinical Pharmacology</i> 19 (2): e166-178	Research question/focus
Heitink-Polle, Uiterwaal et al. 2016	Heitink-Polle, K. M. J., C. Uiterwaal, L. Porcelijn, R. Y. J. Tamminga, F. J. Smiers, N. L. Van Woerden, J. Wesseling, A. G. Laarhoven, M. De Haas and M. C. A. Bruin (2016). "Treatment with intravenous immunoglobulin does not prevent chronic immune thrombocytopenia in children: results of a randomized controlled trial." <i>Blood</i> 128 (22)	Publication type
Despotovic and Bussel 2018	Despotovic, J. M. and J. B. Bussel (2018). "IVIg and FcgRIIb in kids with ITP: Individualizing therapy." <i>Blood</i> 132 (9): 877-878	Publication type
GBS		
Bidabadi 2015	Bidabadi, E. (2015). "Comparison of intravenous immunoglobulin (IVIG) with plasmapheresis for treatment of pediatric Guillain-Barre syndrome." <i>Journal of the neurological sciences</i> 357 (Suppl 1): e194, Abstract no 601 WFN115-1021	Publication type
Davidson, Halstead et al. 2017	Davidson, A. I., S. K. Halstead, J. A. Goodfellow, G. Chavada, A. Mallik, J. Overell, M. P. Lunn, A. McConnachie, P. van Doorn and H. J. Willison (2017). "Inhibition of complement in Guillain-Barre syndrome: the ICA-GBS study." <i>Journal of the Peripheral Nervous System</i> 22 (1): 4-12	Design
Keller, Quast et al. 2019	Keller, C. W., I. Quast, M. C. Dalakas and J. D. Lunemann (2019). "IVIG efficacy in CIDP patients is not associated with terminal complement inhibition." <i>Journal of Neuroimmunology</i> 330 : 23-27	Research/focus

**MG**

Gajdos, Chevret et al. 2008	Gajdos, P., S. Chevret and K. Toyka (2008). "Intravenous immunoglobulin for myasthenia gravis." <i>Cochrane database of systematic reviews (Online)</i> (1)	Duplicate
Gamez 2014	Gamez, J. (2014). "Intravenous immunoglobulin for preparing myasthenia gravis patients for thymectomy and other surgical procedures preventing myasthenic crisis." <i>Clinical & Experimental Immunology</i> 178 Suppl 1: 134-135	Publication type (protocol)
Dimachkie, Levine et al. 2016	Dimachkie, M. M., T. Levine, J. Trivedi, V. Bril, N. J. Silvestri, D. Saperstein, S. Nations, H. Katzberg, G. I. Wolfe, M. Glenn and et al. (2016). "Open label Study of Subcutaneous Immunoglobulin (SC Ig) in myasthenia gravis: study design and progress update." <i>Journal of clinical neuromuscular disease. Conference: 38th annual carrell-krusen neuromuscular symposium, CK 2016. United states</i> 17(3): 177-178	Design (and publication type)
Furlan, Barth et al. 2015	Furlan, J. C., D. Barth, C. Barnett and V. Bril (2015). "Cost-minimization analysis comparing intravenous immunoglobulin (IVIg) with plasma exchange (PLEX) in the management of patients with myasthenia gravis: different perspectives for different payers." <i>Canadian journal of neurological sciences</i> 42(Suppl S1): S18	Design (economic evaluation already included in our economic review chapter)
Bril, Barnett-Tapia et al. 2012	Bril, V., C. Barnett-Tapia, D. Barth and H. D. Katzberg (2012). "IVIG and PLEX in the treatment of myasthenia gravis." <i>Annals of the New York Academy of Sciences</i> 1275: 1-6	Outcomes
Grifols Therapeutics LLC 9 May 2019	Grifols Therapeutics LLC (2019). "Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis"	Publication type (non published results)

DERMATOMYOSITIS AND POLYMYOSITIS

Anh-Tu Hoa and Hudson 2017	Anh-Tu Hoa, S. and M. Hudson (2017). "Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies." <i>Seminars in Arthritis & Rheumatism</i> 46(4): 488-508	Design (Review)
Griger, Nagy-Vincze et al. 2017	Griger, Z., M. Nagy-Vincze and K. Danko (2017). "Pharmacological management of dermatomyositis." <i>Expert Review of Clinical Pharmacology</i> 10(10): 1109-1118	Design (review and expert opinion)
Vacchi 2017	C Vacchi, M Sebastiani, A Manfredi, G Cassone, F Campomori, C Ferri (2017). "Cost analysis related to subcutaneous immunoglobulins in patients with inflammatory myopathies and immune-mediated chronic neuropathies. results of an open label study" <i>Annals of the rheumatic diseases. Conference: annual european congress of rheumatology, EULAR 2017.</i>	Publication type (abstract)

SOLID ORGAN TRANSPANTATION (antibody rejection)

Wan, Ying et al 2018	Wan, S. S., T. D. Ying, K. Wyburn, D. M. Roberts, M. Wyld and S. J. Chadban (2018). "The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis." <i>Transplantation</i> 102(4): 557-568	Design (Systematic review already included)
-----------------------------	--	---



Moreso 2018	Moreso, F.; Crespo, M.; Ruiz, J. C.; Torres, A.; Gutierrez-Dalmau, A.; Osuna, A.; Perelló, M.; Pascual, J.; Torres, I. B.; Redondo-Pachón, D.; Rodrigo, E.; Lopez-Hoyos, M.; Seron, D. (2018) "Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial" <i>American Journal of Transplantation</i> 18 (4), pp. 927-935	Time of publication (already included in one of the SRs retained)
--------------------	--	---

FETOMATERNAL TROMBOCYTOPENIA

Lakkaraja, Berkowitz 2016	Lakkaraja, M., R. L. Berkowitz, C. A. Vinograd, K. C. Manotas, J. C. Jin, P. Ferd, J. Gabor, M. Wissert, J. G. McFarland and J. B. Bussel (2016). "Omission of fetal sampling in treatment of subsequent pregnancies in fetal-neonatal alloimmune thrombocytopenia." <i>American Journal of Obstetrics & Gynecology</i> 215 (4): 471.e471-479	Design (nonrandomised, follow-up study)
Paridaans, Kamphuis et al. 2015	Paridaans, N. P., M. M. Kamphuis, A. Taune Wikman, E. Tiblad, E. S. Van den Akker, E. Lopriore, D. Challis, M. Westgren and D. Oepkes (2015). "Low-Dose versus Standard-Dose Intravenous Immunoglobulin to Prevent Fetal Intracranial Hemorrhage in Fetal and Neonatal Alloimmune Thrombocytopenia: A Randomized Trial." <i>Fetal Diagnosis & Therapy</i> 38 (2): 147-153	Time of publication (already included in one of the SRs retained) RCT already included in the SR